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Interactions between various hypothalamic peptides and
monoamines in the control of the release of luteinizing hormone (LH)
and prolactin (PRL) have been investigated in the rat. Attention
was focussed on serotonin (5-HT), dopamine (DA),
thyrotropin-releasing hormone (TRH), vasopressin (VP) and oxytocin
(OT).
The release of 3h~DA from the median eminence (ME) in vitro
was studied with a view towards developing this system to
investigate interactions between monoaminergic transmitters and
hypothalamic peptides. Electrical stimulation released ^h-DA
from the ME in a Na+ and Ca^"1" dependent manner, and neither
basal nor stimulated release was changed significantly during
different phases of the oestrous cycle, or by DA agonists or
antagonists, luteinizing hormone releasing hormone (LHRH), TRH or
PRL. Nomifensine, a DA uptake blocker, caused a significant
increase in the electrically-stimulated but not basal release of
^H-DA. It did not prove possible to adapt this system for the
investigation of 5-HT function and so all further studies were
carried out in vivo.
The 5-HT reuptake blockers, alaproclate and zimelidine, were
investigated to determine their effects on the steroid-induced
surges of LH and PRL in the pro-oestrous female rat and in a number
of experimental models. Alaproclate, but not zimelidine, caused
changes in the peripheral concentrations of LH and PRL, and the
direction of change was dependent upon the steroid status of the
animal. These changes may have been due to changes in central 5-HT
transmission since there was a significant decrease in the ratio of
5-hydroxyindoleacetic acid (5-HIAA) to 5-HT in the posterior
hypothalamus and raphe nuclei in those animal models which had shown
changes in LH and PRL. The spontaneous, pro-oestrous PRL surge was
abolished by injection of the 5-HT synthesis inhibitor,
parachlorophenylalanine (PCPA), and was delayed but not abolished by
the injection of a specific antiserum to TRH, a putative
PRL-releasing factor. The action of PCPA was possibly due to a
reduction in the plasma concentration of oestradiol-17e.
Vasopressin and oxytocin were present in hypophysial portal
plasma at concentrations significantly higher (~ 20-50 fold) than
those in peripheral plasma. In Brattleboro rats, VP was
undetectable in both portal and peripheral plasma. Several
experiments showed that VP and OT in portal blood was derived from
nerve terminals in the ME. However, hypothalamic stimulation with
a stimulus that significantly increased the release of LHRH did not
increase the release of VP and OT which was also unaffected by
alaproclate, PCPA or experimental manipulation of the plasma
glucocorticoid concentrations. A likely explanation for this
result is that under the experimental conditions used here, the
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It has been known for many years that reproductive function can
be modified by exteroceptive factors such as light, temperature and
tactile stimuli (Marshall, 1936, 1942). Since these factors exert
their actions through the nervous system, a functional link between
the nervous and endocrine systems has been proposed to be involved
in the control of reproductive function. The pituitary gland has
been shown to be essential for reproductive function since reflex
ovulation in the rabbit was inhibited after removal of the pituitary
gland (Fee and Parkes, 1929) and in the rat, mammary involution
occurred after removal of the gland (Jacobsohn and Westmann,
1946). In addition, extracts of anterior pituitary gland (PD)*
stimulated ovulation in rabbits (Bellerby, 1929a, b). It had been
demonstrated that the reflex ovulation occurring in rabbits in
response to coitus involved both neural (Marshall and Verney, 1936)
and humoural factors (Friedman, 1929) but the connection between the
two types of stimuli was unknown. These and many other studies
(Harris, 1948, 1955) led to the concept of the existence of a neural
link between the pituitary gland and the central nervous system
(CNS) controlling the release of hormones from the gland. The
nature of this link became an area of intensive study and eventually
the neurohumoural hypothesis was proposed.
*The definition of pituitary structure used in this thesis is
that proposed by Wislocki and King (1936) of anterior pituitary
gland = pars distal is (PD), and posterior pituitary gland = pars
nervosa (PN) and pars intermedia (PI).
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1.1 Development of the neurohumoural hypothesis
It had been demonstrated many times that the posterior lobe of
the pituitary gland was densely innervated (Cajal, 1894; Fisher,
Ingram and Ranson, 1938) and that from its embryological origins the
pars nervosa (PN) could be classified as a neural structure.
However, the existence of a prominent innervation of the anterior
lobe of the pituitary gland was in dispute (Harris, 1948) and
although the anterior lobe is in close proximity to the posterior
lobe, its embryological origins are from non-neural tissue
(Hanstrom, 1966). There were reports of sympathetic and
parasympathetic innervation of the anterior lobe (Dandy, 1913;
Pines, 1925; Chorobski and Penfield, 1932; Cobb and Finesinger,
1932; Hair, 1938; Zacharias, 1941) but experiments designed to
determine the role of these systems in the control of reproductive
function yielded negative results. Rabbits still exhibited reflex
ovulation in response to coitus after sympathectomy (Haterius,
1933a; Brooks, 1935) and stimulation of the cervical sympathetic
nerves failed to produce ovulation in the same species (Haterius,
1933b; Friedgood and Cannon, 1936; Markee, Sawyer and Hollinshead,
1946). Similar results were obtained after destruction of the
presumed parasympathetic innervation of the PD (Hair and Mezen,
1939; Vogt, 1942). Later work demonstrated that 'nerve fibres' in
the PD revealed by histological staining were probably reticular
fibres (Wingstrand, 1951) and Rasmussen (1938) and Green (1951)
concluded that the PD was either not innervated or innervated so
sparsely as to make it very unlikely that nerve fibres were the
major secretory route for active substances to pass from the CNS to
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the PD.
Despite these observations, there were still indications of a
neural link between the CNS and the activity of the PD. Ovulation
could be induced in the rabbit and in the rat by the application of
an electrical stimulus to the head (Harris, 1936; Marshall and
Verney, 1936) an effect later localized to the hypothalamus (Harris,
1937; Haterius and Derbyshire, 1937). There was some dispute
concerning the effect of electrical stimulation of the pituitary
gland. Although direct electrical stimulation of the PD could
induce ovulation in the anaesthetized rabbit (Harris, 1937; Markee
et al., 1946), remote control stimulation of the PD in the conscious
rabbit had no effect on ovulation (Harris, 1948). The differences
between these results could have been due to differences in
magnitude of the applied stimuli, since the stimuli applied in the
earlier studies were likely to be much greater than those applied in
the later study of Harris (1948). There is also a possibility,
however remote, that the gross stimulation (Harris, 1937; Markee et
al., 1946) led to changes in the electrical excitability of the
cells of the PD (Poulsen and Williams, 1976; Taraskevich and
Douglas, 1977) and consequently to changes in hormone release.
Due to the relative paucity of nerve fibres in the PD, a few
authors had tentatively suggested the existence of a humoural link
between the PD and the hypothalamus that might be important in the
control of the activity of the PD (Friedgood, 1936; Harris, 1937;
Hinsey, 1937; Brooks, 1938; Taubenhaus and Soskin, 1941). The
necessary anatomical connection for a direct humoural link between
the hypothalamus and the pituitary gland was first described by Popa
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and Fielding (1930, 1933) and confirmed by Wislocki and King
(1936). Although both groups of investigators described a system
of portal vessels in the pituitary stalk, consisting of a large
number of fine vessels in the hypothalamus that united into large
trunks in the pituitary stalk before breaking up into a second set
of capillaries in the pituitary gland, they differed in their
interpretations of the direction of blood flow within the vessels.
While Popa and Fielding (1930, 1933) believed that the direction of
flow was probably from the pituitary gland towards the hypothalamus,
Wislocki and King (1936) thought that blood flowed in the opposite
direction, from hypothalamus to pituitary gland. This difference
of interpretation persisted until flow through these vessels was
observed in the living animal. Blood flow in this system in the
anaesthetized toad was demonstrated to be from the hypothalamus to
the pituitary gland (Houssay, Biasotti and Sammartino, 1935). These
observations were later confirmed in the rat (Green and Harris,
1949). Despite these findings, there continue to be disputes
concerning the direction of blood flow in these hypophysial portal
vessels. There have been many claims of evidence consistent with
the existence of flow of blood from the anterior pituitary gland to
the hypothalamus (Tdrdk, 1962; Ambach, Palkovits and Szentagothai
1976; Oliver, Mical and Porter, 1977; Bergland and Page, 1978)
perhaps by way of the posterior pituitary gland (Bergland and Page,
1979). However, a recent study of blood flow in the ME and
pituitary gland in the anaesthetized pig demonstrat ed that there
was no evidence for blood flow from the pituitary gland to the ME
although there was evidence for intra-pituitary blood flow from the
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PN to the PD (Page, 1983).
Experiments designed to sever any link, whether humoural or
neural, between the pituitary gland and the hypothalamus yielded
contradictory results concerning the degree of control exerted by
the hypothalamus over the activity of the PD (Richter, 1933;
Dempsey and Uotila, 1940; Dempsey and Searles, 1943; Jacobsohn and
Westmann, 1945). Although this may have been due to incomplete
sectioning of the pituitary stalk, allowing the persistent
expression of a neural or a humoural control, the inconsistencies
were probably due to differing degrees of regeneration of the
hypophysial portal vessels after stalk section (Harris, 1950, 1955;
Harris and Jacobsohn, 1952; Nikitovitch-Winer and Everett, 1958)
leading to differing degrees of reconnect!'on of the hypothalamus and
the pituitary gland. Difficulties of interpretation in these
experiments also arose due to the probable release of hormones from
the degenerating gland which undergoes necrosis after stalk section
(Daniel and Pritchard, 1956). This phenomenon is well-documented
for hormones of the PN: after stalk section or lesion of the
supraopticohypophysial tract (SOHT) (Chapter 8), urine output occurs
in three different phases, a rapid increase for 1-2 days followed by
a decrease for the next few days and then a permanent phase of
polyuria after 5-8 days (Fisher et al., 1938); the phase of
decreased urine production does not occur if the PN is removed at
the time of cutting the pituitary stalk (O'Connor, 1952).
Transplantation of endocrine organs is a classical procedure in
the study of endocrine function which revealed much information
concerning the mechanisms of control of these organs (e.g. Marshall
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and Jolly, 1907; Manley and Marine, 1916; Moore, 1926; Wyman and
Turn Suden, 1937). This was also to prove true of studies on the
mechanisms of control of the transplanted pituitary gland.
Although the vascular link to the PD from the hypothalamus had
been demonstrated to be important for the maintenance of functional
activity of the PO, it was not until studies were carried out on the
transplanted pituitary gland that the importance of the physical
contact between the pituitary gland and the hypothalamus was
realized. When the PD was transplanted to other areas in
hypophysectomized animals, such as into the ocular chamber (Westmann
and Jacobsohn, 1940), under the kidney capsule (Nikitovitch-Winer
and Everett, 1958) or below the temporal lobe (Harris and Jacobsohn,
1952), although the tissue was well vascularized, there was almost
no resumption of functional activity of the PD. However, Everett
(1954) found a marked luteotrophic response in the ovaries of
hypophysectomized animals implanted with PD tissue under the kidney
capsule. This was the first demonstration that the 'luteotrophic
factor' of the PD, now recognized as prolactin, was secreted at a
greater rate after removal of the PD from the influence of the
hypothalamus. The lack of complete functional activity of the
transplanted pituitary glands in spite of good vascularization was
in marked contrast to the maintenance of activity observed in
studies concerning the transplantation of peripheral endocrine
organs (Marshall and Jolly, 1907; Manley and Marine, 1916; Moore,
1926; Wyman and Turn Suden, 1937). Full functional activity of the
PD only returned when pituitary tissue was transplanted immediately
below the cut pituitary stalk of hypophysectomized animals, where it
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could become vascularized by the hypophysial portal vessels of the
ME (Harris and Jacobsohn, 1952). These observations indicated
therefore that it was the vascular link between the hypothalamus and
the pituitary gland that was of critical importance in the control
of the functional activity of the gland. The importance of the
vascular link was confirmed by Benoit and Assenmacher (1953) in
their studies on birds. The PD and PN of the pituitary gland in
birds are separated by a thick connective septum, which enables
sectioning of either the nerve fibres or of the hypophysial portal
vessels in the pituitary stalk, a procedure not possible in most
mammals due to the close anatomical association of these
structures. Benoit and Assenmacher (1953) demonstrated that
reproductive function was maintained after sectioning of the nerve
fibres of the pituitary stalk but not after sectioning of the
hypophysial portal vessels, and they therefore concluded that the
vascular link was of vital importance in the control of PO function.
Once the neurohumoural hypothesis of control of the function of
the PD had been established there still remained the question as to
the mechanism of control. Early ideas such as control being exerted
by means of nervous regulation to change blood flow to the PD or by
some 'filtering' mechanism for hormones from peripheral endocrine
organs, leading to differences in feedback and so to differences in
the release of PD hormones, received little support. The currently
accepted view of the means of regulation of anterior pituitary
function is embodied in the releasing-factor concept.
1.2. The releasing factor concept
The releasing factor concept has been reviewed in detail (e.g.
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Harris, 1955, 1972; Schally, Arimura and Kastin, 1973; Fink,
1976). Empirical studies into the nature of the humoural
substances that might act as releasing-factors investigated those
substances that were known to act as transmitter agents in the
peripheral nervous system. The demonstration by Taubenhaus and
Soskin (1941) that pseudopregnancy could be induced in rats by
application of a mixture of acetylcholine (ACh) and prostygmine
suggested that there was perhaps an acetylcholine-like humoural
transmission between the hypothalamus and the pituitary gland.
However, later work by Feldberg and Vogt (1954) showed that there
was very little choline-acetyltransferase activity in an area of
brain containing the ME and so rendered the idea of an ACh-link
unlikely. Markee, Sawyer and Hollinshead (1948) reported that an
injection of adrenaline (ADR) into the pituitary gland could
stimulate ovulation in the rabbit and that the reflex ovulation that
occurs in this species after coitus could be blocked by the
administration of a sympatholytic drug within one minute of
copulation. These results received support from the demonstration
of the presence of high concentrations of NA and ADR in the
hypothalamus (Vogt, 1954). However, these results were criticized
because of the high concentrations of ADR that were required to be
effective (Harris, 1955), the possible non-specific actions of the
sympatholytic drugs used (Nickerson, 1949), and the fact that
studies by Donovan and Harris (1956) suggested that the ovulation
induced by the injection of ADR into the pituitary gland could have
been due to the low pH of the injection fluid rather than the ADR.
More recent data has demonstrated that a direct action of these
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neurotransmitter agents on anterior pituitary function is unlikely
in the majority of cases (Weiner and Ganong, 1978; Kordon
Enjalbert, Hery, Joseph-Bravo, Rotsztejn, and Ruberg, 1980; Meites
and Sonntag, 1981) and that the action is of an indirect nature
through the releasing hormones of the hypothalamus.
The observation that ACTH and vasopressin (VP) are frequently
released together after physiological stimuli suggested that
neurohypophysial hormones might be involved in the release of ACTH,
and by extension in the release of other anterior pituitary
hormones (McCann and Brobeck, 1954; Mirsky, Stein and Paulisch,
1954). However, studies by other workers demonstrated the presence
of a releasing factor for ACTH in hypothalamic extracts and extracts
of PN, that was not VP or oxytocin (0T), and that was active both in
vivo and in vitro (Guillemin and Rosenberg, 1955; Saffran, Schally
and Benfrey, 1955; Guillemin, Dear, Nicholas and Lipscomb, 1959;
Schally and Guillemin, 1959) (see Chapter 8 for a detailed
discussion of the status of VP as a CRF). With the realization
that there was a distinct CRF present in hypothalamic tissue which
did not appear to be related to known neural transmitters or
neurohypophysial hormones, it was logical to search for other
hypothalamic factors, similarly unrelated to known substances, that
might regulate the secretion of PD hormones.
A broad review of the control of the release of hormones from
the PD by releasing factors is beyond the scope of this thesis and
therefore details are only discussed for LH and PRL. Several recent
reviews have been published concerning the control of hormones of
the PD by releasing factors (McCann, 1980, 1982; Vale, Rivier and
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Brown, 1980; Meites and Sonntag, 1981; Yasuda, Greer and Aizawa,
1982).
1.2.1 Luteinizing hormone-releasing hormone
Luteinizing hormone-releasing activity was demonstrated in
ME/hypothalamic extracts by a number of workers in the early sixties
using various in vivo methods. Ovulation in the rabbit and in the
pentobarbital-blocked rat could be stimulated by intrapituitary
injections of ME extracts (Nikitovitch-Winer, 1962; Campbell, Feuer
and Harris, 1964). Injections of extracts from other brain areas
or of a number of other active substances were ineffective.
Injections of the extract were ineffective when injected into other
areas of the pituitary gland. McCann, Taleisnik and Friedman
(1960) demonstrated the LH-releasing activity of a hypothalamic
extract, using the ovarian ascorbic acid depletion bioassay method
of Parlow (1958). Subsequently it was shown that the extract could
stimulate the release of LH from pituitary glands incubated in vitro
(Schally and Bowers, 1964). If this factor with LH-releasing
activity was active in vivo it was presumed that it must be
released into the hypophysial portal vessels and so capable of being
measured in portal blood. This was demonstrated initially by
bioassay (Fink, Nallar and Worthington, 1967; Fink and Harris,
1970) and later by radioimmunoassay (Fink and Jamieson, 1976;
Eskay, Mical and Porter, 1977). Although LH-releasing activity in
hypothalamic tissue had been demonstrated in 1960, it was a decade
before the releasing factor was isolated and characterized from
porcine and ovine hypothalami (Matsuo, Baba, Nair, Arimura and
Schally, 1971; Burgus, Butcher, Amoss, Ling, Monabian, Rivier,
Fellows, Blackwell, Vale and Guillemin, 1972). The synthetic
decapeptide LHRH (pyro) Glu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-
Gly-NH^ stimulates LH and FSH release both in vitro and in vivo.
1.2.2 Prolactin-inhibiting factors and prolactin-releasing factors.
Unlike LH, the control of the release of PRL from the PD in the
mammal is predominantly inhibitory (Everett, 1954; McCann, Dhariwal
and Porter, 1968; Meites and Nicoll, 196(b). The secretion of PRL
from the PD in vitro (Meites, Kahn and Nicoll, 1967) is increased
compared with secretion in vivo whereas secretion of other hormones
is decreased, similarly when the PD is transplanted to sites distant
from the ME, PRL secretion increases (Everett, 1954; McNeilly,
Sharpe, Davidson and Fraser, 1978). The first observations of the
presence of prolactin-inhibitory factor (PIF) activity in
hypothalamic extracts were made in in vitro systems (Talwalker,
Ratner and Meites, 1963; Kragt and Meites, 1967). The identity of
PIF has been difficult to elucidate since it did not have the
properties of a peptide, unlike other identified releasing factors
(McCann and Porter, 1969). A role for the catecholamines in the
regulation of the release of PRL was suggested by Kanematsu,
Hi 11iard and Sawyer (1963) when they observed the induction of
pseudopregnancy in rabbits after the administration of reserpine.
However, it was not until the anatomical observations of Hokfelt and
Fuxe (1967), showing DA-containing nerve terminals in the ME
adjacent to the portal blood vessels, that a direct action of the
monoamines on the release of PRL from the PD could be proposed.
Further evidence for a possible direct action came from the
demonstration by Van Maanen and Smelik (1968) of the induction of
pseudopregnancy in the rat after local depletion of monoamines in
the ME. Direct inhibition of the release of PRL by DA in vitro was
demonstrated a few years later (Birge, Jacobs, Hammer and Daughaday,
1970; MacLeod, Fontham and Lehmeyer, 1970) and a significant
proportion of PIF activity in hypothalamic extracts was identified
as DA (Shaar and Clemens, 1974). It has now been shown that the
concentration of DA in hypophysial portal blood is sufficient to
inhibit the release of PRL from the PD in vivo (Ben-Jonathan,
Oliver, Weiner, Mical and Porter, 1977; Gibbs and Neill, 1978;
Plotsky, Gibbs and Nei11, 1978). However, unlike the relative
certainty concerning the role of LHRH, there is growing scepticism
as to the identity of DA as the sole PIF (Leong, Frawley and Neill,
1983). Additional PIFs have been proposed such as GABA (Schally,
Redding, Arimura, Dupont and Linthicum, 1977; Enjalbert, Ruberg,
Arancibia, Fiore, Priam and Kordon, 1979; Racagni, Apud, Locatelli,
Cocchi, Nistico, di Giorgio and Muller, 1979), catecholoestrogens
(Linton, White, de Tineo and Jeffcoate, 1981) and
histidyl-proline-diketopiperazine (a metabolite of TRH, itself
proposed as a prolactin-releasing factor (PRF) (Tashjian, Barowsky
and Jensen, 1971; Enjalbert, Ruberg, Arancibia, Priam and Kordon,
1979).
That PRL may also be under a degree of stimulatory control is
suggested by a number of observations. Abrupt increases in PRL
secretion are known to follow ether stimuli, anaesthesia or suckling
(Terkel, Blake and Sawyer, 1972) which cannot be solely accounted
for by decreased DA transmission (Plotsky and Neill, 1982).
Extracts of hypothalamus induced lactation in oestrogen-primed rats
(Meites, Talwalker and Nicoll, 1960) and injections of sodium
pentobarbital only raised plasma PRL for 30 min, after which PRL was
depressed, implying initial blockade of an inhibitory control and
subsequent blockade of a stimulatory control (Wuttke and Meites,
1970). Prolactin releasing activity has also been identified in
hypothalamic extracts tested in vitro (Nicoll, Fiordino, McKennee
and Parsons, 1970; Arimura and Schally, 1977). The identity of a
possible PRF is far from being elucidated with numerous substances
being put forward for this role. In a recent review, Leong et al
(1983) listed at least sixteen substances that have been reported to
exhibit PRF activity, of which 5-HT (Wehrenberg, Nicol, Frantz and
Ferin, 1980) TRH (Tashjian et al., 1971) LHRH (Denef, 1981) VP
(Shin, 1982) OT (Forsling, Reinhard and Himmler, 1974; Lumpkin,
Samson and McCann, 1983) and oestradiol (Zyzek, Dufy-Barbe, Dufy and
Vincent, 1981) are of particular relevance to this thesis.
1.3 Neuroanatomical considerations
There is a vast amount of confusing evidence concerning the role
of the hypothalamus in the control of the release of LH and PRL
(Fink and Geffen, 1978; Weiner and Ganong, 1978; Barraclough and
Wise, 1982). Before discussion of the aspects of this control as
relevant to this thesis, a brief outline will be given of the neural
pathways involved in the studies reported here.
As discussed in section 1.2.2, numerous substances have been
proposed as PIFs and PRFs but the delineation of their distribution
within the CNS is outwith the scope of this thesis. Therefore, only
the distribution of those substances investigated in this thesis as
possible PRFs and PIFs is considered.
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1.3.1 Serotonin
The distribution of 5-HT in the CNS, and particularly in the
hypothalamus, has been extensively studied by Descarries and Beaudet
(1978) and by Parent, Descarries and Beaudet (1981) using
autoradiographic techniques and by Steinbusch (1981) and Steinbusch
and Nieuwenhuys (1981) using immunohistochemical techniques. The
advantages and disadvantages of both detection techniques have been
reviewed by Consolazione and Cuello (1982).
Most of the 5-HT in the brain originates from cell bodies in the
raphe nuclei of the midbrain (Parent et al., 1981; Steinbusch,
1981). Projections from these nuclei extend widely throughout the
brain and there is a dense 5-HT innervation within the hypothalamus
(Descarries and Beaudet, 1978, Kent and Sladek, 1978). The
concentration of 5-HT is highest in the arcuate (ARC) and
suprachiasmatic nuclei (SCN) although all nuclei in the hypothalamus
appear to contain some 5-HT (Saavedra, Palkovits, Brownstein and
Axelrod, 1974). Recent work by Van de Kar and Lorens (1979) has
suggested that the hypothalamus may be differentially innervated
from the raphe nuclei, with the medial raphe (MR) nucleus supplying
the anterior hypothalamus (AH) and the medial preoptic area (MPOA),
and both the MR and dorsal raphe (DR) nuclei supplying the
antero-1ateral hypothalamus and the ARC. There is evidence for the
existence of an intrahypothalamic 5-HT system since 20-30% of the
total content of 5-HT was still present in the hypothalamus after
electrolytic lesions of the DR nuclei and after deafferentation of
the medio-basal hypothalamus (MBH) (Palkovits, Saavedra, Jacobowitz,
Kizer, Zaborsky and Brownstein, 1977; Palkovits, Brownstein, Kizer,
-15-
Saavedra and Kopin, 1979). Cell bodies containing 5-HT have been
demonstrated in hypothalamic nuclei by autoradiographic (Beaudet and
Descarries, 1979) but not by immunohistochemical techniques
(Steinbusch, 1981; Consolazione and Cuello, 1982).
Serotonin-containing fibres and terminals are present in the ME
(Baumgarten and Lachenmayer, 1974; Calas, Alonso, Arnauld and
Vincent, 1974), and although it has been stated that there are no
5-HT-containing fibres in the PD (Steinbusch and Nieuwenhuys, 1982),
a brief report by Westlund and Chi1ds(1982) of the results of an
immunocytochemical study, claims to demonstrate the presence of
fine, varicose fibres containing 5-HT that extend over the surface
of the PD and penetrate the first 2-3 layers of cells. However,
the authors state that the origin of these proposed fibres is
unknown, and the fact that the reaction product for 5-HT is situated
alongside the blood vessels of the PD may cast some doubt as to a
possible central neural origin of the 5-HT.
1.3.2 Dopamine
The detailed anatomy of the DA systems of the brain has been
reviewed by Moore and Bloom (1978) and, therefore, only those areas
of DA innervation directly relevant to this thesis will be
discussed. Two hypothalamic systems are of relevance, the
tuberohypophysial system and the incertohypothalamic system.
The cell bodies of the tuberohypophysial system are located in
the ARC and periventricular areas of the hypothalamus (Bjorklund,
Falck, Nobin and Stenevi, 1973) and projections pass ventrally to
terminate in the PN (Smith and Fink, 1972), the PI (Bjorklund,
Moore, Nobin and Stenevi, 1973) and the ME and pituitary stalk
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(Bj&rklund, Falck et al., 1973).
The cell bodies of the incertohypothalamic system are located in
the posterior hypothalamus and zona incerta and in the
periventricular nucleus (Lindvall, Bjorklund, Moore and Stenevi,
1974; Bjorklund, Lindvall and Nobin, 1975). This system supplies
its surrounding areas with a network of short, diffuse fibres
(Bjorklund et al., 1975).
1.3.3 Noradrenaline
The cell bodies of the NA systems in the brain are situated,
like those of the 5-HT systems ,in the brain stem (Moore and Bloom,
1979). The hypothalamus receives a rich, though diffuse NA
innervation with the highest concentrations of NA being present in
the retrochiasmatic area and the paraventricular (PVN) and
dorsomedial nuclei. The majority of the hypothalamic nuclei
receive innervation from NA cell bodies in the lateral tegmentum
(Lindvall and Bjftrklund, 1978). Exceptions to this are the
supra-optic (SON), the dorsomedial, the PVN and the periventricular
nuclei, which also receive projections from the locus coeruleus
(Jones and Moore, 1977). The ME also contains some NA terminals
from projections outwith the MBH, as shown by the presence of
dopamine-e-hydroxylase in the ME (Fuxe et al., 1978) and its
dramatic reduction after deafferentation of the MBH (Palkovits,
1979).
1.3.4 Luteinizing hormone-releasing hormone
There is a dense plexus of LHRH terminals in the external layer
of the ME, particularly in the lateral regions (Selmanoff, 1981).
There is also a significant LHRH terminal field in the organum
vasculosum lamina terminal is (OVLT) (Fuxe et al., 1978). A recent
report has demonstrated the presence of widely-dispersed LHRH fibres
in the rat CNS (Witkin, Paden and Silverman, 1982). It has proved
difficult to determine the location of LHRH-containing cell bodies
in the rat CNS, although several studies have now demonstrated the
presence of these cell bodies within the MPOA and the SCN (Barry,
Dubois and Poulain, 1973; Setalo, Vigh, Schally, Arimura and
Flerko, 1976; Kawano and Daikoku, 1981). The presence of
LHRH-containing cell bodies within the MBH remains controversial
although, as for 5-HT, the demonstration that 20-30% of the total
LHRH content is still present in the MBH after deafferentation,
indicates that there may be some intrinsic hypothalamic LHRH
neurons. Although the majority of investigators have not been able
to demonstrate LHRH-containing cell bodies in the MBH, a recent
report (Kelly, Ronnekleiv and Eskay, 1982) demonstrated the presence
of LHRH-containing cell bodies in the MBH and particularly in the
ARC.
The LHRH terminals in the EL of the ME appear to be from cell
bodies in the AH but projections to the lateral and medial regions
of the ME follow different courses. The lateral regions of the ME
receive projections from the septal and lateral POA which run
laterally and then converge onto the ME. The medial region of the
ME receives projections from the SCN and from near the optic chiasm
which run ventrally and caudally before reaching the ME (Kawano and




Thyrotrophin-releasing hormone has been implicated in the
control of PRL secretion (Chapter 7) and, therefore, a brief outline
of its distribution is given here.
Thyrotrophin-releasing hormone is widely distributed in the CNS
(Brownstein, Palkovits, Saavedra, Bassiri and Utiger, 1974; Winokur
and Utiger, 1974; Hokfelt, Fuxe, Johansson, Jeffcoate and White,
1975) but little is known of TRH pathways in the brain. The
presence of TRH has been demonstrated in the hypothalamus in the
dorsomedial and ventromedial areas and in the perifornical area.
The external layer of the ME also exhibits a significant amount of
TRH (Fuxe et al., 1978; Renaud, 1981). In common with LHRH and
5-HT, although the TRH content of the MBH was decreased after
deafferentation (Palkovits, 1979) the concentration remaining was
high enough to allow the proposal of the existence of an
intrahypothalamic TRH system. Recently, cell bodies containing TRH
have been demonstrated in the PVN (Jackson, 1983).
1.3.6 Vasopressin and oxytocin
A detailed description of the distribution and function of VP
and OT in the PN system, consisting of the magnocellular neurons of
the SON and PVN, their axons in the SOHT and their terminals in the
PN (Scharrer and Scharrer, 1954; Sloper, 1966; Lederis, 1974) are
not directly relevant to the studies reported in this thesis and
attention will be focussed on the system of VP and OT with terminals
in the EL of the ME (Silverman and Zimmerman, 1983).
The existence of a projection to the EL of the ME from the PVN
and/or SON has been proposed for some years on the basis of the
-19-
results of Gomori staining. Gomori-positive material was described
in the EL of the ME in a number of vertebrates, including the rat
(Dierickx and Van den Abeele, 1959; Oksche, Laws, Kamemoto and
Farner, 1959; Rinne, 1960) and this material seemed to subserve
different functions from the hormones of the PN, since it was
unaffected by experimental manipulations that caused changes in the
Gomori-positive material of the PN. However, extracts of ME shared
many of the physiological characteristics of extracts of PN (Ishii,
Hirano and Kobayashi, 1962). It was thought that the material
might be involved in the release of ACTH since the size of
neurosecretory granules within Gomori-positive fibres in the EL of
the ME was increased after adrenalectomy (Wittkowski and Bock, 1972)
and the increase could be inhibited by the administration of
glucocorticoids (Brinkmann and Bock, 1973). It was subsequently
demonstrated using immunohistochemical techniques that the
neurosecretory material was composed of VP and OT and associated
neurophysins (Zimmermann, Hsu, Robinson, Carmel, Frantz and
Tannenbaum, 1973; Dierickx, Vandesande and De Mey, 1976). Lesion
studies and the application of retrograde tracers to the ME have
demonstrated that the cells of origin of this system differ from
those of the PN system and that they are located in the PVN rather
than in the SON (Vandesande, Dierickx and De Mey, 1977; Wiegand and
Price, 1980). There is electrophysiological evidence that suggests
that some cell bodies in the PVN may send axon branches to both the
PN and the EL of the ME (Pittman, Blume and Renaud, 1978).
The PVN is a compex nucleus composed of distinct magnocel1ular
and parvocel1ular divisions. The magnocellular components form
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three dense clusters of neurons, termed the anterior, medial and
posterior divisions, which are embedded in a matrix of five
parvocellular divisions, the periventricular, anterior, medial,
dorsal and lateral parts (Fig. 1-1). These divisions give rise to
a number of different efferent projections (Fig. 1-1) (Swanson and
Sawchenko, 1983). The projection to the EL of the ME arises from
the periventricular, medial and anterior parts of the parvocel1ular
division of the PVN, areas that have few projections to the PN
(Wiegand and Price, 1980; Swanson and Sawchenko, 1983).
Vasopressin and oxytocin are not uniformly distributed in the PVN:
OT-containing cells are found mainly in the anterior and medial
magnocellular divisions of the nucleus, whereas VP-containing cells
are found mainly in the dorsal and lateral parts of the posterior
magnocellular division (Swanson and Sawchenko, 1983).
The relationship of the VP and OT system in the EL of the ME to
other VP and OT-containing neurons in the CNS is described in detail
by Silverman and Zimmerman (1983) and Swanson and Sawchenko (1983).
1.3.7 Possible structural interactions between the dopaminergic and
luteinizing hormone-releasing hormone systems
The close anatomical relationship of many identified nerve
terminals, particularly in the ME, has led to suggestions that
monoamines and peptides may interact by way of axo-axonic or
axo-dendritic contacts. Terminals containing LHRH and OA are in
7
close proximity in the ME (Kizer, Arimura, Schally and Brownstein,
1975; Ajika, 1979; Selmanoff, 1981) and it has been claimed that
these terminals are in direct contact with each other (Ajika,
1979). However, there is no ultrastructural evidence for the
FIGURE 1 1 Diagrammatic representation of the major subdivisionsand projections of the paraventricular nucleus (hatchedareas = magnocellular parts), pv = periventricular part,ap = anterior parvocellular part, dp = dorsal
parvocellular part, mp = medial parvocel1ular part, lp =lateral parvocellular part, am = anterior magnocellularpart, mm = medial magnocellular part, pm = posteriormagnocellular part.
PN = projection to pars nervosa
ME = projection to median eminence
ANS = projection to autonomic nervous system.
From Swanson and Sawchenko (1983).
(
existence of axo-axonic synapses in the ME of the rat. (The only
published report of the presence of axo-axonic synapses in the ME is
concerned with the turtle (Tsuneki, 1976)). The density of LHRH
terminals is highest in the lateral regions of the ME (Selmanoff,
1981) and the concentration of DA seems to be higher in the lateral
than in the medial region of the ME (L'bfstrom, Jonsson and Fuxe,
1976). However, a recent report (Reymond, Speciale and Porter,
1983) suggests that this may not be a significant correlation since
the concentration of DA in hypophysial portal vessels in the lateral
region of the pituitary stalk was lower than the concentration in
hypophysial portal blood in the medial region of the pituitary stalk.
1.4 Control of the release of luteinizing hormone
The secretion of LH from the PD is directly controlled by the
release of LHRH from the hypothalamus. The release of LHRH is
itself controlled by monoaminergic systems in the CNS whose activity
is modified by gonadal steroids. These various aspects of the
control of the release of LH have been extensively reviewed: LHRH
involvement by Fink (1979a), McCann (1982), and Sarkar (1983);
monoaminergic involvement by Fink and Geffen (1978), Weiner and
Ganong (1978), Krulich (1979), Sawyer (1979), Kordon et al., (1980),
Barraclough and Wise (1982), Meites and Sonntag (1982); steroid
modulation by McCann (1974), Fink (1979a, b) and Goodman and Knobil
(1980). As shown by the number of recent reviews cited, this is an
enormous field of research and, therefore, only those aspects of
control directly relevant to the studies reported in this thesis
will be discussed.
While acknowledging that the degree of control at each of these
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levels may differ between species, particularly in the primate
(Knobil, 1974; Goodman and Knobil, 1980), the examples cited are
concerned primarily with studies in the rat.
1.4.1 Dopaminergic involvement in the release of luteinizing hormone
Current evidence for a role of DA in the control of LH release
is confusing and conflicting due to the presence of multiple DA
pathways and receptors that may be involved in the basal and phasic
release of LH (1.3.2.; Sarkar and Fink, 1981).
Much work has been published by Fuxe and his co-workers (e.g.
Hokfelt and Fuxe, 1972) on immunohistochemical observations of
changes in activity of DA neurons during different endocrine
states. They claim the existence of an inhibitory DA system
modifying the release of LH. However, as with all histochemical
observations it is difficult to correlate observed changes with
peripheral events since so many other parameters may be changing
besides those that are of immediate interest. For example, the
correlation claimed by Fuxe et al. (1976) between the increased DA
turnover and the inhibition of LH release after oestradiol treatment
of castrated animals may well be invalid since the oestradiol
treatment also induces changes in PRL release that may cause changes
in DA turnover (Gudelsky, Simpkins, Mueller, Meites and Moore, 1976).
These interpretations are also not in agreement with a
suggestion in the literature that steroid treatment may change the
DA influence on LH from an inhibition to a stimulation (Weiner and
Ganong, 1978). It has been shown that apomorphine causes a
decrease in the release of LH in ovariectomized rats (Beck and
Wuttke, 1977) whereas, DA causes an increase in the release of LH in
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ovariectomized rats that have been treated with oestrogen and
progesterone (Vijayan and McCann, 1978). However, these results
may also indicate that in addition, DA has different effects at
different sites since an i.p. injection of apomorphine caused a
decrease in the release of LH in the ovariectomized rat (Beck and
Wuttke, 1977) but an i.e.v. injection of apomorphine had no effect
(Vijayan and McCann, 1978).
There are 3 possible sites of action at which DA may affect the
release of LH: either directly at the gonadotrophs of the PD, or
through interactions with LHRH terminals in the ME (1.3.6), or
through neurons in the hypothalamus. Schneider and McCann (1969)
were unable to show that DA released LH directly from the PD
but it has been reported that DA can cause an increase in the
release of LHRH from hypothalamic/ME tissue in vitro (Schneider and
McCann, 1969; Bennett, Edwardson, Holland, Jeffcoate and White,
1975) in particular from the rostral palisade region of the ME
(Rotsztejn, Charli, Pattou and Kordon, 1977), an area that receives
a dense LHRH-innervation (1.3.4). Dopamine can both stimulate and
inhibit neurons in the hypothalamus (Moss, Kelly and Riskind, 1975).
1.4.2 Serotonergic involvement in the release of luteinizing hormone
A «
The role of 5-HT in the control of the release of LH from the PD
is equally as controversial as the role of DA. Indeed, the
difficulty of assigning a role to 5-HT in this system is compounded
by the involvement of this transmitter in the maintenance of many
hormonal circadian rhythms (Moore, 1978; Kordon, Hery, Szafaraczyk
Ixart and Assenmacher, 1980). The function of 5-HT appears to be
essentially permissive or 'neuromodulatory' and therefore its
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effects are dependent on the overall hormonal and metabolic status
of the animal.
As for DA, the effect of 5-HT on the release of LH appears to be
inhibitory in the ovariectomized animal but stimulatory in the
presence of gonadal steroids, particularly progesterone (Walker,
1983; Walker and Wilson, 1983). An i.e.v. injection of 5-HT
caused a decrease in LH release in the ovariectomized rat (Schneider
and McCann, 1970) but blockade of 5-HT synthesis inhibited the LH
surge in the pro-oestrous rat (Coen and Mackinnon, 1980) and in the
ovariectomized rat treated with oestrogen and progesterone (Hery,
Laplante and Kordon, 1976).
It has recently been suggested that these similar results seen
after either an augmentation or a depletion of 5-HT in the CNS may
be due to a disruption of the circadian rhythm of 5-HT activity
present in the brain (Hery, Rouer and Glowinski, 1972; Hiller and
Redfern, 1976; Meyer and Quay, 1976; Hery, Faudon, Dusticier and
Hery, 1982). Walker (1983), has proposed that "if drugs abolish
the rhythm (of 5-HT) and thus the facilitatory signal (for LH
release) then it becomes physiologically irrelevant whether the
compounds stimulate or retard 5-HT synthesis"; that is, it is the
abolition of rhythmic changes in the activity of 5-HT systems that
is important and not whether there is an increase or decrease in the
absolute concentration of 5-HT.
The possible sites of action of 5-HT to alter the release of LH
from the PD are discussed in detail in section 4.1.1.
1.4.3 Noradrenergic involvement
There is general agreement that NA stimulates the release of LH
under many conditions (Fink and Geffen, 1978; Weiner and Ganong,
1978; Barraclough and Wise, 1982). The contribution of ADR to the
control of the release of LH is as yet, undefined; however, ADR and
phenylethanolamine N-methyl transferase are present in the
hypothalamus (Moore and Bloom, 1979) and ADR has been found in
hypophysial portal blood at concentrations higher than those present
in peripheral blood (Johnston, Gibbs and Negro-Vilar, 1983).
Adrenaline has been reported to be involved in the LH surge of the
ovariectomized rat treated with oestrogen (Coen, Coombs, Wilson,
Clement and Mackinnon, 1983).
1.4.4 The role of gonadal steroids in the control of the release of
luteinizing hormone.
The negative feedback effects of gonadal steroids have been
reviewed in detail by McCann (1974). Positive feedback effects of
gonadal steroids have been considered in depth by Fink (1979a,b).
Possible sites of action of gonadal steroids within the CNS have
been reviewed by Goodman and Knobil (1981).
The release of LH under basal and 'surge' conditions is
controlled by two different systems. Deafferentation of the MBH
leads to a loss of ovulation without any marked disruption of
follicular development (Halasz, 1969) indicating that the 'tonic'
release of LH is controlled from within the MBH while the LH surge
is generated by systems outwith the MBH. Attention has focussed on
the POA and SCN, both of which contain LHRH cell bodies (1.3.4).
Early studies in the rat demonstrated that stimulation of the POA
could cause ovulation (e.g. Everett, 1965) and an increase in the
release of LH (e.g. Cramer and Barraclough, 1971). There is now
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general agreement that the neural signal for the release of LHRH in
the rat is generated in the POA (e.g. Fink, 1979a; Goodman and
Knobil, 1981). It is generally presumed that the POA-LHRH neurons
act by way of their projections to the ME. However, studies which
showed that lesions of the OVLT blocked the LH surge in
ovariectomized rats treated with oestrogen and progesterone, make it
impossible to exclude the physiological significance for the LH
surge of the POA projections to the OVLT (Samson and McCann, 1976;
Wiegand, Terasawa and Bridson, 1978). In the rhesus monkey the
relative importance of the POA and the SON for the generation of the
LH surge is still a matter of debate (Norman, Resko and Spies,
1976; Plant, Moosy, Hess, Nakai, McCormack and Knobil, 1979).
In addition to disagreement over the importance of various
neural structures in the generation of the surge of LH, the sites at
which gonadal steroids exert their feedback effects is also a matter
of dispute.
Since Bogdanove (1963) conclusively demonstrated that oestrogen
had a direct effect in the pituitary gland to prevent the appearance
of castration cells in the pituitaries of castrates (which are
caused by increased synthesis and release of gonadotroph!ns)
argument has continued regarding the relative importance of the
hypothalamus compared with the pituitary gland as a site for the
feedback actions, whether stimulatory or inhibitory, of gonadal
steroids on the release of LH.
The inhibitory effect of oestrogen on the basal release of LH is
probably exerted both at the pituitary (Bogdanove, Nolin and
Campbell, 1975) and at the hypothalamic levels since the
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concentration of LHRH in hypophysial portal plasma is increased
after ovariectomy (Sarkar and Fink, 1980). The site of the
inhibitory action of progesterone on the tonic release of LH has
received little attention although a site within the MBH may be
important, since progesterone still exerted an inhibitory feedback
after deafferentation of the MBH (Blake, 1977).
A dual level of control is also apparent for the stimulatory
effects of oestrogen on the release of LH. Oestrogen increases the
responsiveness of the pituitary gland to LHRH (Henderson, Baker and
Fink, 1977a) and facilitates the self-priming effect of LHRH (Aiyer,
Chiappa and Fink, 1974). In addition, oestrogen caused an increase
in the amount of LHRH released into hypophysial portal blood
following electrical stimulation of the POA (Sherwood, Chiappa and
Fink, 1976) and an increase in the concentration of LHRH in
hypophysial portal blood in the ovariectomized rat (Sarkar and Fink,
1979). The stimulatory effects of progesterone on the release of
LH are thought to be restricted to the pituitary gland.
Progesterone treatment of the ovariectomized rat, primed with
oestrogen, causes an increase in the responsiveness of the pituitary
gland to LHRH (Aiyer and Fink, 1974) but does not cause an increase
in the release of LHRH (Sarkar and Fink, 1979). However, there is
increasing evidence that progesterone may also have stimulatory
effects in the hypothalamus. Levine and Ramirez (1980) have
demonstrated that progesterone administration to ovariectomized
rats, primed with oestrogen, caused an increase in the release of
LHRH from the ME in vivo in rats bearing a push-pull cannula in the
ME. This study can be subjected to a number of criticisms.
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Firstly, the tip of the push-pull cannula was situated in the third
ventricle and not directly in the ME and, therefore, LHRH could have
been released into the CSF of the ventricle from sources other than
the hypothalamus, such as the OVLT. Secondly, the lower limit of
sensitivity of the LHRH RIA used was 0.8pg/tube and it was claimed
that the significant increases of LHRH were from l.Opg/ml to
3.0pg/ml. While this may be claimed to be an increase of over 100%
in the amount of LHRH released, as these values are so close to the
lower limit of sensitivity of the RIA, the results must be
interpreted with a great deal of caution. A more recent report by
Drouva, Laplante and Kordon (1983) has demonstrated that
progesterone treatment in vivo of ovariectomized rats primed with
oestrogen can enhance the K+-induced release of LHRH from MBH
tissue from these animals in vitro.
There is evidence that progesterone acting in the hypothalamus
may inhibit the stimulatory action of oestrogen under some
circumstances (Banks and Freeman, 1980). Progesterone can decrease
the release of LHRH induced by treatment of ovariectomized rats with
oestradiol benzoate (0B)(Sarkar and Fink, 1979) and can reduce the
LHRH output in response to stimulation of the POA (Sherwood et a!.,
1976). These results are consistent with the observation that
progesterone tends to inhibit the firing of hypothalamic neurons
(Moss, 1976).
To summarize, oestrogen appears to both directly stimulate and
inhibit the release of LH from the PD although there must be
additional actions in the CNS to account for the release of LH
during the LH surge. Similarly, progesterone also appears to have
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both stimulatory and inhibitory actions on the PD and may also have
mixed actions in the hypothalamus.
1.4.4.1 The pro-oestrous female
The spontaneous surge of LH occurring on the afternoon of
pro-oestrus in the female rat, is dependent upon the increased
secretion of oestrogen by the ovary (Ferin, Tempone, Zimmering and
Van de Wiele, 1969). The increased concentration of oestrogen
permits the expression of a neural signal for the release of LH
(Everett and Sawyer, 1950) in the form of an increased release of
LHRH from the hypothalamus. The responsiveness of the pituitary
gland to LHRH, increased due to the action of oestrogen, is further
increased by the self-priming effect of LHRH. The increasing
peripheral concentration of LH causes increased secretion of ovarian
progesterone, which causes further increases in responsiveness to
LHRH. This amplifying cascade of events leads to the massive LH
surge (Fink, 1979a, b). Termination of the surge is probably due
to a decrease in the concentration of LHRH in hypophysial portal
plasma (Blake, 1977) which may be due to an inhibitory effect of
progesterone (Freeman, Dupke and Croteau, 1976; Rahe, Owens,
Newton, Fleeger and Harms, 1979; Orouva et al., 1983).
The different roles of gonadal steroids in the control of LH
release have been determined by studies on ovariectomized rats
treated with various combinations of steroids at different times
after ovariectomy (Fink, 1979b).
1.4.4.2 The short-term ovariectomized rat treated with oestrogen
and progesterone.
In this model, designed to mimic the changes occurring in
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steroid concentrations in the intact animal, rats are ovariectomized
and given an injection of OB on dioestrus followed by an injection
of progesterone (P) on the next day, presumptive pro-oestrus (Kalra,
Fawcett, Krulich and McCann, 1973; Mann and Barraclough, 1973;
Aiyer and Fink, 1974; Tapper, Grieg and Brown-Grant, 1974). There
is a surge of LH in peripheral plasma approximately 5h after the
injection of P. It has been shown that the injection of OB in this
model caused the concentration of LHRH in hypophysial portal plasma
to increase above concentrations seen at dioestrus (Sarkar and Fink,
1979). However, although the subsequent injection of P caused an
increase in the pituitary responsiveness to LHRH and a surge of LH
(Fink and Henderson, 1977) P had either no or an inhibitory effect
(depending on dose) on the stimulatory effect of OB on the release
of LHRH (Sarkar and Fink, 1979). These apparently contradictory
effects of P are consistent with a proposed stimulatory site of
action of the steroid at the pituitary gland (Martin, Tyrey, Everett
and Fellows, 1974; Fink and Henderson, 1977) and an inhibitory site
of action within the CNS, either at the hypothalamus or POA
(Schuiling, van Dieten and van Rees, 1974; McLean, Chang and
Nikitovitch-Winer, 1975; Blake, 1977).
1.4.4.3 The long-term ovariectomized rat treated with oestrogen and
progesterone
The concentration of LH in peripheral plasma in the long-term
ovariectomized rat is increased due to the removal of the negative
feedback effects of gonadal steroids (McCann, 1974). This increase
is inhibited by the administration of oestrogen (Blake, Norman and
Sawyer, 1974) but an LH surge can be induced by an injection of P
72h after an injection of OB (Caligaris, Astrada and Taleisnik,
1968; Brown-Grant, 1974). Contrary to expectation, Sarkar and Fink
(1980) were not able to demonstrate an increase in the release of
LHRH into hypophysial portal blood in this model. Although a
blocking effect of anaesthesia and surgical trauma might be
involved, it is conceivable that the surge of LH in this model is
due primarily to a massive increase in pituitary responsiveness
(approximately three times greater than that seen at 1700h on
pro-oestrus (Aiyer, Sood and Brown-Grant, 1976; Sarkar and Fink,
1980). Although LHRH release does not need to be increased, some
LHRH release is required for the occurrence of the LH surge since
the stimulatory effect of P is blocked by an injection of sodium
pentobarbitone (Brown-Grant, 1974) or by administration of an
anti-LHRH serum (Lu and Yen, 1980).
1.4.4.4 The long-term ovariectomized rat exposed to a constantly
elevated concentration of oestrogen.
Continuous exposure of long-term ovariectomized rats to elevated
peripheral concentrations of oestrogen results in a diurnal rhythm
of LH, with a peak in the late afternoon in rats maintained under a
summer lighting schedule (Caligaris, Astrada and Taleisnik, 1971;
Henderson, Baker and Fink, 1977b). The afternoon surge of LH would
appear to be generated by increases both in the secretion of LHRH
(Sarkar and Fink, 1980) and in pituitary responsiveness (Henderson
et al., 1977a).
1.4.5 Interactions between gonadal steroids and monoamine systems
involved in the release of luteinizing hormone.
Numerous aspects of the interactions occurring between gonadal
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steroids and the transmitter systems involved in the release of LH
have been reviewed by McEwen (1979) and McEwen and Parsons (1982).
Steroids may affect the activity of monoamine systems either by
changes in the electrical activity of neurons, or changes in the
turnover of monoamines, perhaps as a result of changes in enzyme
activity, or by changes in number or affinity of neurotransmitter
receptors. Many examples of each of these effects are cited by
McEwen and Parsons (1982). Of particular relevance to this thesis
are reports of i) changes in the turnover of DA after oestrogen or
after oestrogen and P treatment (Eikenburg, Ravitz, Gudelsky and
Moore, 1977; L'ofstrom, Eneroth, Gustafsson and Skett, 1977; Ranee,
Wise and Barraclough, 1981; Ranee, Wise, Selmanoff and Barraclough,
1981) and of the turnover of 5-HT after oestrogen and P treatment
(Ladisch, 1974; Everitt, Fuxe, Hokfelt and Jonsson, 1975) and ii)
a reported biphasic effect of oestrogen on 5-HT receptors, with
oestrogen causing an acute decrease in the number of 5-HT receptors,
followed by an increase in receptor number 48-72h later (Biegnon and
McEwen, 1982).
Many experimental changes in transmitter function reported to be
due to oestrogen, may be changes secondary to an increase in the
release of hormones from the PD, for example, oestrogen causes the
release of PRL from the PD (Chen and Meites, 1970; Haug and
Gautvik, 1975) and there are well-documented effects of PRL on the
turnover of DA (see 3.1 and 3.4).
1.5 Control of the release of prolactin
The physiological conditions under which PRL is released have
been reviewed by Meites, Lu, Wuttke, Welsch, Nagasawa and Quadri
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(1972) and by Nei 11 (1974). This discussion is concerned with the
control mechanisms for PRL release.
The release of PRL in the mammal is under the inhibitory
influence of the hypothalamus (1.2.2). For many years, it was
assumed that changes in PRL secretion could be accounted for solely
by changes in PIF activity, mediated by feedback effects of PRL
itself. In the absence of the production of any obvious
target-tissue hormones, the degree of control was thought to be much
less complex than that of other hormones of the PD, for example, of
LH. However, a recent review by Leong et al. (1983) demonstrates
that this view has been too simple and that, in addition to control
of PRL secretion through changes in PIF activity, recognition must
be made of the contribution of PRFs and of PRL responsiveness
factors controlling the responsiveness of the PD to PRFs and PIFs.
1.5.1 Inhibitory control of the release of prolactin
Since the statement of Meites et al. in 1972 that "the direct
effects of catecholamines (dopamine) on pituitary prolactin release
observed in vitro are mainly of pharmacological significance" it is
now recognised that these effects are indeed of physiological
significance and that DA is one of the major PIFs secreted by the
mammalian hypothalamus. The large body of work in support of this
fact has been reviewed by MacLeod (1975), Ben-Jonathan (1980) and
Neill (1980). Briefly, DA is found in hypophysial portal plasma
(Plotsky, Gibbs and Nei11, 1980) at concentrations greater than in
peripheral plasma, that are high enough to inhibit the release of
PRL (Gibbs and Nei11, 1978). The release of PRL is inhibited by a
direct action of DA (Shaar and Clemens, 1974; Takahara, Arimura and
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Schally, 1974) on DA receptors on the pituitary lactotrophs
(Goldsmith, Cronin and Weiner, 1979).
However, it seems increasingly likely that hypothalamic DA is
not the sole physiological PIF. For example, the concentration of
PRL in peripheral plasma in male rats is low (Neill, 1972) but the
responsiveness of pituitary cells from male rats to DA is lower than
in cells from female rats (Leong et a!., 1983) and the concentration
of DA in hypophysial portal plasma is lower in male than in female
rats (Gudelsky and Porter, 1981). Therefore, it would appear that
the existence of an additional PIF must be invoked, since PRL
release is low but the DA system is not particularly active.
Possible PIFs have been discussed in 1.2.2.
Ben-Jonathan (1980) proposed that DA may be the sole PIF but
that in addition to DA released by the hypothalamus some DA may
reach the PD from extrahypothalamic sources. In particular, it was
suggested that DA may be released from the PN into the portal
vessels, a suggestion that is supported by observations of blood
flow from the PN to the PD (Bergland and Page, 1979) and of the
presence of a rich network of capillaries between the two lobes
(Page, 1983). The concentration of DA in the PN is similar to that
in the hypothalamus (Saavedra, Palkovits, Kizer, Brownstein and
Zivin, 1975), and the release of PRL was inhibited by an acidic
extract of the PN (Hoefer, Arbogast and Ben-Jonathan, 1979).
Removal of the PN has been demonstrated to cause an increase in the
concentration of PRL in peripheral plasma (Oliver, Mical and Porter,
1977) but this increase has since been found to be transient
(Froehlich and Ben-Jonathan, 1983).
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1.5.2 The role of serotonin in the release of prolactin
The prevailing view in the literature is that 5-HT stimulates
the phasic release of PRL and may also stimulate tonic release
(Weiner and Ganong, 1978; Krulich, 1979; Kordon et al., 1981;
Meites and Sonntag, 1981).
The concentration of PRL in peripheral plasma is increased after
a systemic injection of 5-HTP, the immediate precursor of 5-HT (Lu
and Meites, 1973; Chen and Meites, 1975) an effect which is
potentiated by administration of an inhibitor of 5-HT reuptake
(Krulich, 1975; Clemens, Cerimele and Sawyer, 1977). Blockade of
5-HT synthesis causes an inhibition of steroid-induced or
suckling-induced surges of PRL (Caligaris and Taleisnik, 1974;
Kordon, Blake, Terkel and Sawyer, 1974) an effect which could be
overcome by treatment with 5-HTP (Kordon et al., 1974).
Serotonin does not appear to have a direct effect on the
pituitary gland to release PRL (Birge, Jacobs, Hammer and Daughaday,
1970) but has its action at the level of the hypothalamus. There
are two possible mechanisms by which 5-HT could cause an increase in
the release of PRL, i) by inhibiting the secretion of a PIF, or
ii) by stimulating the release of a PRF. There is little evidence
that interactions between DA and 5-HT contribute to an increase in
the release of PRL (Krulich, Coppings, Giachetti, McCann and
Mayfield, 1980; Pilotte and Porter, 1981), however, since DA is
probably not the only PIF, there is a possibility of interaction
with other as yet unidentified PIFs. It seems more likely that
5-HT stimulates the release of a PRF (Clemens, Roush and Fuller,
1978; Garthwaite and Hagen, 1979) that may be VIP (Garthwaite,
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Martinson and Hagen, 1983; Shimatsu, Kato, Matsushita, Katakami,
Ohta, Yanaihara and Imura, 1983).
Pharmacological evidence presented as indicating a stimulatory
effect of 5-HT on the release of PRL must be interpreted with some
care, since many of the drugs used in pharmacological studies of the
role of 5-HT have mixed actions (Douglas, 1975). For example, the
effect of methysergide to decrease the release of PRL has been
variously ascribed to its 5-HT antagonist properties (Gallo, Rabii
and Moberg, 1975), its DA antagonist properties (Lamberts and
MacLeod, 1978) and to its DA agonist properties (Krulich et al.,
1980).
As with LH, the involvement of 5-HT in the phasic release of PRL
is difficult to assess due to its important role in the maintenance
of neural rhythms (1.4.2). It must be borne in mind that a
facilitatory effect of 5-HT on rhythmic hormonal surges does not
necessarily preclude inhibitory effects of the transmitter on
minute-to-minute release of hormones.
1.5.3 The role of noradrenaline in the release of prolactin
There is some dispute concerning the effect of NA on the release
of PRL (Fink and Geffen, 1978; Weiner and Ganong, 1978).
Noradrenaline may be involved in the release of PRL induced by
oestrogen (Subramanian and Gala, 1976; Carr, Conway and Voogt,
1977; Langelier and McCann, 1977) but does not seem to be involved
in basal PRL secretion (Weiner, 1975). As discussed in 1.4.3,
effects assumed to be due to NA activity might also be mediated by
ADR, but any involvement of ADR in the release of PRL does not
appear to have been investigated.
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1.5.4 The role of gonadal steroids in the release of prolactin
The role of gonadal steroids in the release of PRL appears to
differ from their role in the release of LH. Whereas gonadal
steroids essentially modulate the release of LH as induced by LHRH
their role in the release of PRL is more direct. Oestrogen
directly stimulates the release of PRL from the PD (Chen and Meites,'
1970) but probably also causes changes in responsiveness of
pituitary lactotrophs to PIFs and PRFs (Raymond, 8eaulieu, Labrie
and Boissier, 1978). Progesterone alone seems to have no direct
effect on the release of PRL (Nicoll and Meites, 1964) but can
partially counteract the stimulatory effect of oestrogen (Chen and
Meites, 1970).
1.5.4.1 The release of prolactin in the pro-oestrous rat
At approximately the same time as the LH surge on the afternoon
of pro-oestrus there is a massive surge of PRL (Niswender, Chen,
Midgley, Meites and Ellis, 1969; Amenomori, Chen and Meites,
1970). The increase in the release of PRL is dependent upon the
increasing plasma concentration of oestrogen since administration of
an anti-LH serum on dioestrus or of an anti-oestrogen serum on
pro-oestrus abolished the surge of PRL (Neill, Freeman and Tillson,
1971; Freeman, Reichert and Neill, 1972) and both of these
inhibitory effects could be overcome by the administration of
exogenous oestrogen.
In addition to the direct effect of oestrogen to release PRL
from the PD (Chen and Meites, 1970) there are also changes in the
PRL responsiveness of the PD that may be mediated by oestrogen. De
Lean, Garon, Kelly and Labrie (1977) reported that the amount of PRL
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released in response to TRH was much higher at pro-oestrus than at
other stages of the oestrous cycle but that the increased
responsiveness was not due to a self-priming effect of TRH, a
proposed PRF. Pickering and Fink (1977) have also reported that a
self-priming effect of a PRF was not present since repeated exposure
of pituitary glands in short-term incubation to a hypothalamic
extract had no effect on the PRL response. Further work has
demonstrated a complex series of interactions between oestrogen and
proposed PIFs and PRFs to increase the secretion of PRL by the PD:
pre-incubation with oestrogen of pituitary cells in culture caused a
decreased responsiveness to DA in addition to an increased
responsiveness to TRH (Raymond et a!., 1978). Low concentrations
of TRH in combination with oestrogen pre-treatment caused a
significant increase in the release of PRL in the presence of
inhibitory concentrations of DA. Thyrotrophin-releasing hormone
alone caused no stimulated release of PRL in the presence of DA.
However, it has also been demonstrated that there are interactions
between DA and TRH to alter PRL responsiveness in the absence of
oestrogen; a brief decrease in the concentration of DA before the
addition of TRH causes a greater stimulation of PRL release than the
sum of each treatment applied alone (Fagin and Nei11, 1981). A
detailed discussion of the role of TRH as a PRF is given in
Chapter 7.
The surge of PRL occurring on the afternoon of pro-oestrus is
often regarded as a singular phenomenon occurring on only one day of
the oestrous cycle, but there is ample evidence to suggest that as
for the LH surge, the PRL surge is due to an amplification by
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oestrogen of a circadian rhythm generated by a daily neural
signal. There is a diurnal release of PRL in male rats (Dunn,
Arimura and Scheving, 1972; Mattheij and Swarts, 1978) and in
intact and ovariectomized female rats (Koch, Chow and Meites, 1971;
Lawson and Gala, 1974) and a pro-oestrous-1ike surge of PRL can be
induced in ovariectomized rats by injection of OB or OB followed by
P (Caligaris, Astrada and Taleisnik, 1974). The pro-oestrous PRL
surge can be blocked by sodium pentobarbital (Wuttke and Meites,
1970) and nicotine (Blake, Norman, Scaramuzzi and Sawyer, 1973)
demonstrating that a neural signal is required for manifestation of
the surge. The neural signal may be generated in the anterior
hypothalamus since the oestrogen-induced PRL surge in the
ovariectomized rat was blocked by a retrochiasmatic cut (Neill,
1972; Caligaris and Taleisnik, 1977). Dunn, Johnson, Castro and
Swenson (1980) have demonstrated a loss of PRL surges in
pro-oestrous rats after placement of a lesion in the SCN, an area
thought to be important in the maintenance of many other circadian
rhythms (Brown-Grant and Raisman, 1977; Szafarczyk et a!., 1979).
Although the surges of LH and PRL occur at approximately the
same time during the oestrous cycle, there are differences in the
neural mechanisms involved. Exposure to constant light blocks the
oestrogen-induced surge of LH in the ovariectomized rat but the
surge of PRL although diminished, is still present (Mann, Cost,
Jacobson and Macfarland, 1977; Pieper and Gala, 1979) and the dose
of oestrogen required to induce a surge of PRL in the ovariectomized
rat is much lower than that required to induce a surge of LH
(Caligaris et al., 1971; Caligaris et al., 1974).
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1.5.4.2 The release of prolactin in various endocrine models
Although it is known that surges of PRL can be induced by
steroid treatment of ovariectomized rats, in which the concentration
of PRL in peripheral plasma is decreased due to the loss of
stimulatory effects of oestrogen, the mechanisms by which steroids
induce this surge have been less widely investigated than those
which induce the LH surge. Almost nothing is known of the sites at
which steroids act to induce the PRL surge although both central and
pituitary sites are likely to be involved (1.5.3.1). There is some
suggestion that oestrogen may act at a site in the AH to induce a
PRL surge but that progesterone has an action outwith this area
(Kawakami and Arita, 1981). In the majority of cases, the two
models most frequently studied, the long-term ovariectomized rat
treated with oestrogen and progesterone or exposed to a continuously
elevated concentration of oestrogen, have been used as tools to
investigate neurotransmitter involvement in the release of PRL, with
little investigation being carried out as to the mechanisms of
generation of the PRL surge.
1.5.4.3. Neurohypophysial hormones and the release of prolactin
The observation by Benson and Folley (1956) that injections of
OT, like PRL, could retard mammary involution in postpartum
lactating rats after the removal of a litter, led them to suggest
that OT might be capable of causing the release of PRL. However,
the mechanisms by which this effect is induced by the two hormones
differ markedly (Meites and Nicol 1, 1966) and therefore the idea
received little support.
More recent work has shown that VP and OT can stimulate the
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release of PRL from the PD (Forsling, Reinhard and Himmler 1974;
Vaughan, Blask and Johnson, 1979; Shin, 1982; Lumpkin, Samson and
McCann, 1983) although there have also been some negative reports
(Hoefer et a!., 1979; Ben-Jonathan, 1980). (A detailed discussion
of the possible role of VP as a CRF is given in Chapter 8).
1.6 Aims of this thesis
The main hypothesis tested in this thesis was that central 5-HT
systems affect the release of certain pituitary and hypothalamic
hormones. An in vitro preparation was first investigated with the
intention of developing a method for investigating 5-HT uptake and
release by ME slices. However, while the system yielded data on
the uptake and release of DA, it proved difficult to adapt the
system for 5-HT. Therefore, attention was focussed on in vivo
studies. The 5-HT systems were manipulated by the use of the 5-HT
reuptake blockers, alaproclate and zimelidine, and an inhibitor of
5-HT synthesis, parachlorophenylalanine. The pituitary hormones
studied were LH and PRL and their release was examined under
'physiological' conditions as well as in several well-defined animal
preparations designed to investigate the effect of different steroid
hormone regimes on the function of the hypothalamic-pituitary-LH and
-PRL systems. Vasopressin and oxytocin were the hypothalamic
hormones studied, not with respect to their release from the PN, but
rather with respect to their release into hypophysial portal
blood. The release of the two peptides was studied under 'basal'
conditions in normal and Brattleboro rats and also after





Animals used in these studies were adult male and female Wistar
cobs (caesarean-originated barrier-sustained) supplied by Charles
River UK Ltd. (Margate, Kent), and male homozygous and heterozygous
Brattleboro rats obtained from Charing Cross Hospital Medical
School. Animals were housed in groups of four (unless they were
cannulated intra-atrially, when they were housed singly) under
controlled lighting (lights on 0500-1900h) and temperature (22°C).
Access to food (Diet 41B; Oxoid, Basingstoke) and tap water was
freely available. All animals that had been subjected to surgery
and maintained for more than 48 hours had access to drinking water
which was supplemented with aureomycin (50mg/litre)
(chlortetracycline hydrochloride; Cynamid G.B. Ltd., Gosport).
Long-term adrenalectomized animals received 0.9% saline supplemented
with glucose (250mg/1itre) and aureomycin instead of tap water.
2.2 SURGICAL AND EXPERIMENTAL PROCEDURES
2.2.1 Anaesthetics
Four anaesthetics were used:-
i) Anaesthetic ether - purchased from Macfarlane Smith Ltd.,
Edinburgh. Anaesthesia was induced by placing the animal in a
sealed box containing a cotton wool pad saturated with ether. Time
to anaesthesia was usually less than 2 minutes.
ii) Ethyl carbamate - (Urethane; BDH, Poole). A 10% w/v in 0.9%
saline solution was used at a dose of 10m1/kg body weight (b.w.) and
injected intraperitoneal^ (i.p.)
iii) Halothane - (Fluothane; ICI Pharmaceuticals, Cheshire).
Animals were placed in a sealed box through which a 5% halothane/air
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mixture was circulated by a vaporizer. After induction, anaesthesia
was maintained with a 1.5% halothane/air mixture administered
through a face mask,
iv) Avertin - (tribromoethanol; Winthrop, Surrey). Stored as 1
gm/ml stock in amylene hydrate, was prepared for injection by
dilution in absolute ethanol (1:4) and then diluted with saline
(1:10), and administered i.p. at a dose of 0.25 gm/kg b.w.
2.2.2 Steroids for Injection
Dexamethasone (9a-fluoro-16a-methyl prednisolone; Sigma, Poole,
Dorset) was stored as a stock solution of 0.9 mg/ml in ethanol and
diluted 1:10 with 0.9% saline before i.p. injection.
Oestradiol benzoate (0B) and progesterone (P) (Paines and Byrne
Ltd., Greenford, Middlesex) were supplied in ethyl oleate and
diluted to working concentrations with arachis oil (Hopkins and
Williams, Romford, Essex). Steroids were injected subcutaneously
(s.c.) while the animals were lightly restrained.
2.2.3 Drugs Acting on Serotonergic Systems
Parachlorophenylalanine and 5-hydroxytryptophan (PCPA and 5-HTP;
Sigma, Poole, Dorset) and 2-(4-chlorophenyl )-l,l dimethylethyl
2-aminopropionate, (alaproclate) and (z)-l-(4-bromophenyl)-l-
(3-pyridyl)-3-dimethylaminopropene dihydrochloride hydrate,
(zimelidine) (Astra Pharmaceuticals, Sodertalje, Sweden)were
dissolved in 0.9% saline immediately before use and administered
intravenously (i.v.) or i.p. (See appendix I for chemical structures
of alaproclate and zimelidine).
2.2.4 Median Eminence Dissection
Rats were decapitated and brains removed and placed ventral side
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uppermost on an ice-cold microscope slide. A few drops of ice-cold
Krebs-Heinsleit (K-H) buffer (see appendix II) were placed on the
median eminence-pituitary stalk region and all further dissection
carried out under a binocular operating microscope (Zeiss,
Switzerland) according to the method of Cuello, Horn, Mackay and
Iversen (1973). The cut pituitary stalk was held with fine forceps
and the borders of the median eminence (ME) (defined by the presence
of capillary loops) cut to a depth of 0.2-0.3mm with iridectomy
scissors. Tissue weight was 0.2-0.3mg. Dissected ME tissue was
floated free of the forceps in 1ml of ice-cold K-H buffer.
2.2.5 Hypothalamus and Raphe Dissection
Rats were decapitated and brains rapidly removed and placed on
ice, ventral side uppermost. Before dissection of the hypothalamus,
the optic nerves were grasped with fine forceps and removed at the
level of the optic chiasm. A block of tissue about 2mm deep,
extending rostro-caudally from the pre-optic area to just caudal to
the mammillary bodies and laterally 1mm on either side of the ME,
was dissected out. The block was cut at the optic chiasm into two
pieces, designated posterior and anterior hypothalamus and weighing
16-20mg and 5-8mg, respectively.
The brain was further sectioned between the cerebellum and the
superior colliculus, leaving a block of tissue containing the raphe
nuclei. Tissue in this block lying 1.0mm laterally to the aqueduct
was retained as a representative sample of raphe nuclei. Tissue
weights were 15-20mg.
2.2.6 Pro-oestrous Animals
Animals in pro-oestrous were defined as those with a vaginal
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smear showing a large majority of nucleated epithelial cells. Only
animals showing at least two consecutive, regular 4 day oestrous
cycles were used. Oestrous cycles were determined by inspection of
daily vaginal smears obtained by lavage between 0900-1100h and a
regular pattern was defined as:
metoestrus - smear shows a mixture of cells, predominantly leucocytes
with a few epithelial and cornified cells,
dioestrus - smear shows only leucocytes
pro-oestrus - smear shows clumps of nucleated epithelial cells
(clumps visible to the naked eye),
oestrus - smear shows cornified epithelial cells.
2.2.7 Ovariectomy
Bilateral ovariectomy was carried out on dioestrus between
0630-0900h under ether or halothane anaesthesia. The posterior
flank was shaved and a small (1.5cm) incision made in the skin and
abdominal wall. The ovary and distal end of the uterus were drawn
out of the wound and the ovary and oviduct excised. A silk ligature
was tied round the end of the uterus to prevent haemorrhage as these
animals were also implanted with an intra-atrial cannula containing
heparin during the same operative period. Incisions in the
abdominal wall and skin were sutured and animals left to recover for
24h before use.
Long-term Ovariectomy
Bilateral ovariectomy was carried out as for short-term




Animals were adrenalectomized in 2 stages; the second adrenal
gland was removed 7 days after removal of the first gland. This was
found to give a better survival rate than immediate bilateral
adrenalectomy.
On day 1 animals were anaesthetized with Avertin and an incision
made along the right costal margin. The right kidney was exposed
and the adrenal gland excized. Any bleeding was stopped by gentle
pressure with a piece of cotton wool and once bleeding had ceased
the incision was sutured. On day 8, animals were again
anaesthetized and the left adrenal removed as for the right adrenal,
noting hypertrophy of the more recently removed gland. The incision
was sutured and animals left to recover for the requisite
post-operative period.
Some groups of animals were sham-adrenalectomized, during which
incisions were made along the costal margins and were then sutured.
2.2.9 Blood Sampling from Conscious Animals
Sequential blood samples were withdrawn from conscious animals
by means of a cannula implanted long-term into the right atrium.
The cannulae consisted of an i.v. portion of Silastic tubing
(0.5mm i.d., 0.93mm o.d. Dow-Corning cat. no. 602-135; Macarthy's
Surgical Ltd., Dagenham, Essex) (3.2cm for 200-250g rat) connected
to a piece of Tygon tubing (0.5mm i.d. 2.25mm o.d.; Technicon Inst.
Co. Ltd., Basingstoke, Hampshire) by a connecting pin (0.6cm long)
made from a 23 gauge stainless steel needle. Heparinized saline
(250 IU/ml) was introduced into the cannula immediately before use
with a 1ml syringe attached to the Tygon tubing.
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Animals were anaesthetized with Halothane and placed in a supine
position. A longitudinal incision, approximately 2.0cm long was
made over the right external jugular vein, about 1.0cm above the
clavicle. Tissue was gently retracted to reveal the underlying
vein. Three silk ligatures were placed underneath the vein and the
most anterior tied immediately. Gentle traction was applied to this
ligature and a small incision made in the external surface of the
vein, above the level of the 2 posterior ligatures, with iridectomy
scissors. The i.v. portion of the cannula was then introduced into
the vein and the 2 posterior ligatures tied firmly round the
connecting pin. The anterior ligature was tied round the Tygon
tubing to hold the cannula in close contact with the vein. After
checking the patency of the cannula, the 1ml syringe was removed and
replaced with a stainless steel dental plug. A small ventral
incision was made between the scapulae and the cannula brought out
through this with the aid of a stainless steel trochar. After
suturing the ventral incision, the patency of the cannula was again
checked, the Tygon tubing was trimmed to a length of 4cm and the
dental plug was replaced. Animals were kept in individual cages
until used.
Blood samples were taken using an extension cannula, consisting
of a length of Tygon tubing (30-35cm) filled with heparinized saline
with a 1ml syringe at one end and a connecting pin at the other.
The dental plug was removed from the indwelling cannula and the
extension cannula attached with the connecting pin. Heparinized
saline remaining in the indwelling cannula was withdrawn into the
1ml syringe. When blood appeared within 1cm of the syringe needle,
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the syringe was replaced with an empty heparinized syringe and blood
was withdrawn. Blood volume was maintained by replacing blood
withdrawn with 0.9% saline of equal volume.
When blood samples were taken frequently, the cannula extension
was left in place and the free end brought through onto the roof of
the cage, allowing the animal to move freely. When less frequent
sampling was required, the cannula extension was removed after each
sample and was replaced by the dental plug.
2.2.10 Treatment of Blood Samples
Blood was collected with heparinized syringes into small plastic
tubes (LP2; Luckham Ltd., Sussex) kept on ice. Samples were
centrifuged at 2500g for 15 min at 4°C and plasma removed with a
Pasteur pipette into plastic storage tubes (PT-0944; Luckham Ltd,
Sussex) kept at -25°C until assayed.
2.2.11 Long-term Electrode Implantation and Electrical Stimulation
Electrodes were made and implanted according to the method of
Jamieson and Fink (1976), using co-ordinates described by de Groot
(1959) (for details see particular experiments).
A 13mm piece of platinum wire (0.125mm diameter) was insulated
with glass tubing to within 0.3mm of the tip and soldered to a
length of copper wire. The whole assembly was mounted in a Teflon
jig and fixed in place with acrylic cement (Simplex; Dental Fillings
Ltd., London). Both single and bipolar electrodes were used:
bipolar electrode tips were separated by 1.0mm for stimulation of
the paraventricular nucleus (PVN) and suprachiasmatic nucleus (SON).
Male animals (180-200g) were anaesthetized with Avertin and
placed in a stereotactic frame in which the incisor bar was 5mm
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higher than the ear bars. A midline incision was made in the scalp
and the cranial periosteum removed to reveal the frontal and
parietal bones. Using a bench dental drill (John Quayle Dental
Manufacturing Co. Ltd., Sussex) a hole was drilled in the frontal
bones, taking care to avoid damage to the superior sagittal sinus.
Bone fragments were removed to reveal the dura mater. Bleeding was
controlled with gentle pressure on cotton wool saturated with 0.9%
saline. Three screws (diameter 3mm) were inserted into the skull
near the margins of the drilled hole. Electrodes were implanted
with the aid of a triplanar micromanipulator at co-ordinates
appropriate for each experiment. The electrode assembly was secured
to the skull using dental cement and the scalp was sutured.
Animals were used 7-10 days after implantation. Electrical
stimuli were applied using a constant current generator
(Digitimer-Neurolog; Welwyn Garden City) based on parameters used
by Jamieson and Fink (1976). The parameters of the stimulus, which
consisted of accurately balanced biphasic square waves, were,
frequency 50Hz, pulse width 1 msec and amplitude of 1mA, in trains
of 30 sec on and 30 sec off. Stimuli were monitored on a calibrated
oscilloscope and applied for a period of 30 minutes.
At the end of each experiment, animals were decapitated and the
heads placed in 10% phosphate-buffered formalin for at least 7
days. Dental cement was dissolved with chloroform and the screws
and electrode assembly gently removed. The brain was then removed
from the skull and stored in 10% formalin. Serial 40ym frozen
sections of the brain were prepared and stained with luxol fast blue




Electrothermal lesions were made using an a.c. current of 3-5mA
at a frequency of lOOKHz for 15 sec with a lesion maker (Grass; West
Germany). Animals were anaesthetized with Avertin and prepared as
for long-term electrode implantation (2.2.11).
A unipolar glass-insulated platinum electrode was lowered to the
required co-ordinates (see particular experiments for details) and
an indifferent electrode inserted into the rectum and a lesion made
as stated above. The scalp was sutured and animals left to recover
for 7-10 days before use.
2.2.13 Intracerebroventricular Cannulation and Collection of
Gerebrospinal Fluid
Intracerebroventricular (i.e.v.) cannulae consisted of a
27 gauge needle (11.5mm long) fixed in a metal block, with patency
maintained by a wire stilet protruding 0.3mm below the tip of the
needle.
Animals were anaesthetized with Avertin and prepared as for
electrode implantation substituting the i.e.v. cannula for the
electrode. Co-ordinates for implantation into the third ventricle
were, lateral 0.0 mm, anterior +5.8 mm and ventral +2.0 mm according
to de Groot (1959). The cannula was secured to the skull using
dental cement, the scalp sutured and a perspex cap screwed over the
top of the cannula and stilet. Animals were left to recover for
7-10 days before CSF was sampled.
On the day of sampling, animals were anaesthetized with urethane
and placed on an operating board. The protective perspex cap was
removed and the top of the cannula and stilet visualized under a
binocular dissecting microscope. When the stilet was removed, CSF
welled-up spontaneously to the top of the cannula. A piece of
Silastic tubing was attached and CSF flowed passively from the
cannula into the tubing. Occasionally, gentle suction was applied
with a 1ml syringe to enhance flow. Collection continued for Ih.
Samples were stored at -25°C until assayed.
2.2.14 Collection of Pituitary Stalk Blood
Hypophysial portal blood was collected according to the method
of Worthington, (1966) as used in this laboratory by Fink and
Jamieson, (1974) with a few minor modifications.
The animal was anaesthetized with urethane and immobilized
supine on an operating board. General anaesthesia was supplemented
with xylocaine (1%) (Astra Pharmaceuticals; Sweden) injected into
the skin and muscle of the lower jaw. A midline incision was made
in the skin of the lower jaw, extending caudally from the lower lip
for 3-4cm. Skin and subcutaneous tissue were gently retracted to
expose the muscles overlying the trachea. A 1cm longitudinal
midline incision was made in these to expose the trachea. A silk
thread was passed beneath the trachea and a small transverse
incision (rostral to the thread) was made allowing the insertion of
a 1.5cm piece of polythene tubing rostral to the bronchi. The
tubing was then secured with the thread. Gentle traction was
applied to the tongue by means of a long silk Guy suture passed
through the tip. Ligatures were placed round each mandibular ramus,
taking care to avoid damage to the tongue. Traction was applied to
the jaw with these ligatures and the lower jaw and floor of the
mouth divided with a midline incision. The incision was extended
through the muscles of the floor of the mouth parallel to each side
of the mandible, and the fauces were cut, resulting in mobilization
of the tongue. Using the Guy suture already in place, the tongue
was gently retracted to reveal the soft palate and epiglottis, and
fixed over the chest under gentle traction. Haemorrhage was
controlled with sterilised cellulose gauze (Ethicon; Edinburgh).
All further manipulations were performed under a binocular operating
microscope.
The soft palate was incised longitudinally along the midline
with an iris electrocautery from the posterior edge of the hard
palate to 1mm anterior to the epiglottis, and laterally to the
pterygoid processes of the sphenoid bone, (in preparations involving
removal of the pituitary gland, the incision was extended caudally
to the epiglottis). This incision exposed the mucosa overlying the
basosphenoid which was then removed with cotton wool.
Using a dental drill, a hole was drilled in the outer table of
the basosphenoid bone from the occipi to-sphenoid suture to the
basosphenoido-presphenoid suture anteriorly. Throughout the
drilling procedure, the hole formed was packed with bone wax,
particularly in the area of the transverse venous sinus. The
exposed inner table was then gently eburnated until it yielded to
gentle pressure from either a drill or a pair of fine forceps. The
thin layer of bone remaining was removed with a pair of watchmaker
forceps, revealing the dura mater overlying the ME and pituitary
gland. A piece of razor blade held in a pin chuck was used to make
a "V"-shaped cut in the dura. The base of the "V" was over the
pituitary gland and the apex was just rostral to the portal
vessels. Cerebrospinal fluid appearing at this stage was removed
with a small piece of cotton wool. The flap of cut dura (with cut
arachnoid attached) was retracted caudally, thus exposing the
median eminence and pituitary gland.
Animals which were to be sampled with the pituitary gland in
situ were then injected with 2500IU heparin into the external
jugular vein. Using iridectomy scissors the pituitary stalk was cut
transversely at its junction with the pituitary gland. Blood was
allowed to flow into the drilled trough and collected using a glass
Pasteur pipette; fluid collected during the first 5 minutes after
cutting was discarded to allow removal of any tissue debris, bone
wax or cotton wool fibres. Collection was continued into ice-cooled
plastic tubes.
The procedure differed slightly in animals used with the
pituitary gland removed. After exposure of the ME and pituitary
gland, the pituitary stalk was cut and the pituitary gland was
removed by suction. Suction was maintained for a few minutes to
reduce haemorrhage and prevent formation of a blood clot. After
haemorrhage into the pituitary fossa had ceased (about 5 min), 2500
IU of heparin were injected into the external jugular vein. To
recommence bleeding from the pituitary stalk, the free end of the
stalk was either gently massaged with watchmakers forceps or the
stalk was again cut close to the site of the initial transection.
Blood was collected as in animals with the pituitary gland in situ,
discarding fluid collected during the first 5 min and taking great
care not to touch the pituitary fossa. Peripheral blood samples
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were routinely taken from the external jugular vein at the beginning
and end of the procedure. Plasma was stored at -25°C until assayed.
2.2.15 Median Eminence Stimulation
Animals were prepared as for collection of pituitary stalk blood
until the ME and pituitary gland had been exposed. A unipolar
electrode (2.2.11) was then lowered into position on the ME with the
aid of a dissecting microscope and a micromanipulator. The
electrode was placed on the ME over the long portal vessels, about
1mm rostral to their junction with the pituitary gland. (In those
experiments involving animals with the pituitary gland removed, the
electrode was positioned before the removal of the gland.) The
portal vessels were cut and blood collection carried out as before.
Electrical stimulation was applied only during the second half-hour
collection of blood, using parameters described in section 2.2.13.
2.3 RADIOIMMUNOASSAY
The principle of radioimmunoassay (RIA) is the competition
between labelled and unlabelled antigen for a limited number of
molecules of specific antibody. The amount of labelled antigen that
is bound to antibody decreases as the concentration of unlabelled
antigen is increased, and by comparing the degree of inhibition with
the inhibition produced by a set of known standards, an estimate of
the unknown concentration of antigen can be made.
Numerous reviews on the subject of RIA have been published
(Midgeley, Niswender and Rebar, 1969; Kirkham and Hunter, 1971;
Rodbard, 1971; Abraham, 1974; Ekins, 1974; Yalow, 1980), therefore
only the methods used in this thesis to measure hormones in rat
plasma will be discussed.
-55-
Rat-prolactin (PRL), ovine-luteinizing hormone (LH), rat thyroid
stimulating hormone (TSH) and rat luteinizing hormone releasing
19 C 1 ?C
hormone (LHRH) were labelled with I (Na I; Amersham
International, Bucks.) using modifications of the chloramine-T
method of Greenwood, Hunter and Glover (1963). 'Free' hormone was
separated from antibody-bound ('bound') hormone by the double
antibody technique of Utiger, Parker and Daughaday (1962).
0estradiol-17e was measured in rat plasma using an RIA modified
from that used by Dick, Culbert, Wells, Gilbert and Davidson
(1978). Samples were incubated with H-oestradiol and 'free'
hormone separated from 'bound' hormone using dextran coated charcoal.
Oxytocin was measured in rat plasma using a modification of the
method described by Robinson (1980). Oxytocin was iodinated using
the iodogen procedure as described by Salacinski, Hope, McLean,
Clement-Jones, Sykes, Price and Lowry (1979). Free hormone was
separated from bound hormone by the addition of absolute ethanol.
Vasopressin in rat plasma was measured using an antiserum raised
by Mohring and Mohring (1975) and described by North,' La Rochelle,
Haldar, Sawyer and Valtin (1978), using the same assay conditions as
for OT.
The assays of VP and OT were carried out in the laboratories of
Dr. I.C.A.F. Robinson, (Department of Endocrine Physiology, National
Institute for Medical Research, Mill Hill, London).
The inter-assay and intra-assay variability for each hormone
were monitored by including a 'high pool' sample and a 'low pool'
sample in duplicate within each assay, and repeating estimations of
these same samples in successive assays. Assay quality was also
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monitored by recording 'total counts' (total labelled hormone), and
'blanks' (no specific antibody) and 'total bound' (no unlabelled
hormone) as a percentage of the total counts. The equivalent
concentrations of the 20%, 50% and 80% B/Bo were also recorded for
each assay.
Standards were assayed in triplicate and samples in duplicate
for all assays except OT and VP where standards were assayed in
duplicate and samples were assayed singly.
Details of stock solutions used and methods for radioisotope
labelling for all hormones studied are given in Appendices 111—VI.
All samples and standards were aliquoted into LP3 tubes (Luckham
Ltd., Dagenham, Essex) using Gilson pipettman automatic pipettes
(Scotlab Instrument Sales Ltd.; Carluke, Scotland). All assay
reagents were dispensed using a Micromedic 25006 automatic dispenser
(Micromedic-Systems; Horsham, PA, U.S.A.).
The 'bound' hormone was counted using an automatic Gamma Counter
(Berthold Mag 310; Scotlab Instrument Sales Ltd., Carluke, Scotland)
and the concentration of hormones was obtained by linear regression
of the standard curves of logit B/Bo on the ordinate against log
concentration on the abcissa, (B/Bo = counts per minute (cpm) of
standard or sample - background cpm/cpm of total bound - background
cpm^ logit B/Bo — In (B/Bo/(1-B/Bo)). The lower limit of
sensitivity of the assay was determined as being the cpm - 2 x
standard deviation of the total bound tubes (Rodbard, 1971).
2.3.1 Radioimmunoassay of prolactin
The concentration of PRL in rat plasma samples was measured
using double antibody RIA kits supplied by the National Institute of
*
B = cpm of standard or sample — background cpm
Bo = cpm of total bound — background cpm
Arthritis, Diabetes, Digestive and Kidney Diseases (NIADDK;
Baltimore, U.S.A.)* The assay has been described by Pickering
(1978) and is briefly outlined in Appendix (III). Reference
standards were prepared from rat-PRL-RP-1 (NIADDK) (range 0.5-64
ng/ml) and rat-PRL-I-S (NIADDK) was used for iodination. The
hormone-specific antibody was anti-rat-PRL-55 (NIADDK) used at a
1
final dilution of 1:20,000. After incubation of I-PRL with
anti-PRL serum and samples/standards, the 'bound' hormone was
separated from the 'free' hormone using anti-rabbit gamma globulin
(ARGG) supplied by the Scottish Antibody Production Unit (SAPU) (Law
Hospital, Carluke, Lanarkshire), at a final dilution of 1:100.
A representative standard curve and quality control data for the
assay are shown in Figures 2-1 and 2-2, respectively. Using a high
and a low pool sample, the inter- and intra-assay coefficients of
variation were found to be 10% and 7% respectively. The lower
limits of sensitivity ranged from 20-27ng/ml for 20yl samples of
plasma.
2.3.2 Radioimmunoassay of luteinizing hormone
The ovine-ovine RIA developed by Niswender, Midgley, Monroe and
Reichert (1968) was used to measure the concentration of LH in rat
plasma. The protocol used in this thesis has been described by
Aiyer (1974) and Aiyer and Fink (1974) and is outlined in
Appendix (III). Ovine-LH (LER-1056-C2) provided by Dr. L.E.
Reichert Jr. (NIADDK) was used for iodination and ovine-LH
(NIH-LH-S18) was used to prepare the standards (range
0-25—16ng/ml). The specific antibody, antiovine-LH (GDN 15) was
provided by Dr. G.D. Niswender (NIADDK) and was used at a final
' 1 1 —r-—i 1
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FIGURE 2-1 Standard curve of a representative assay for prolactin






















dilution of 1:240,000. After incubation of I LH with anti-LH
serum and samples/standards, the 'bound' hormone was separated from
the 'free' hormone using ARGG (SAPU) at a final dilution of 1:100.
A representative standard curve and quality control data for the
assay are shown in Figure 2-3 and Figure 2-4, respectively. The
inter- and intra-assay coefficients of variation were 10% and 9%
respectively. The lower limits of sensitivity ranged from
1.0-1.5ng/ml for 20yl samples of plasma.
2.3.3 Radioimmunoassay of luteinizing hormone releasing hormone
The concentration of LHRH in rat hypophysial plasma was measured
using the double-antibody RIA developed by Nett, Akbar, Niswender,
Hedlund and White (1973). The protocol used in this thesis has been
described by Jamieson (1974), Fink and Jamieson (1976) and Chiappa
(1976) and is outlined in Appendix (IV). Synthetic LHRH (ICI
Pharmaceuticals, Macclesfield) was used both to prepare standards
(7.8-500pg/ml) and for iodination. The specific antibody
(R-42-anti-GnRH) was provided by Dr. G.D. Niswender (NIADDK) and was
used at a final dilution of 1:32,000. The antibody recognized the
whole LHRH molecule and did not cross-react with LHRH analogues or
fragments (Nett et al, 1973) or various pituitary hormones and
peptides (Nett et al, 1973; Chiappa, 1976; Jamieson and Fink,
1976). After incubation of ^1 LHRH with anti-LHRH serum and
samples/standards, the 'bound' hormone was separated from the 'free'
hormone using ARGG (SAPU) at a final dilution of 1:100.
Since only one LHRH RIA was carried out, the standard curve is
shown in Figure 2-5. In this case, intra-assay variation only was
determined and found to be 10%. The lower limits of sensitivity
~3)0-14 0-37 r~1-0 2-72 7-39 10
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FIGURE 2-3 Standard curve of a representative assay for luteinizing






























FIGURE2-4Qualitycontroldatafoeightlut nizinghorm e(LH) assays.
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FIGURE 2-5 Standard curve of the assay for luteinizing hormone-
releasing-hormone (LHRH). Each point represents the mean
of three replicates.
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ranged from 10—12pg/ml for lOOyl samples of hypophysial portal
piasma.
2.3.4 Radioimmunoassay of oxytocin
The RIA developed by Robinson (1980) was used to measure the
concentration of OT in rat plasma. This assay has been described in
detail by Robinson (1980) and the protocol used in this thesis is
outlined in Appendix (V). Reference standards (range 1—250pg) were
prepared from the IVth International Standard for oxytocin (National
Institute for Biological Standards and Controls: Hampstead, England)
(NIBSC) and OT (440 IU/mg) (a gift from Dr. H. Vilhardt, Ferring AB,
Malmo, Sweden) was used for iodination. The specific antibody, R^
was raised in rabbits, against OT conjugated with porcine
thyroglobulin, by Dr. I.C.A.F. Robinson (full details in Robinson,
1980) and was used at a final dilution of 1:225,000. The antibody
showed < 0.004% cross reactivity with arginine-VP. After incubation
125
of I OT with anti-OT serum and samples/standards, the 'bound'
hormone was separated from the 'free' hormone by the rapid addition
of absolute ethanol.
A representative standard curve is shown in Figure 2-6. The
inter- and intra-assay coefficients of variation were 7% and 12%
respectively. The lower limit of sensitivity ranged from 2-5pg/tube
for 50y 1 samples of plasma.
2.3.5 Radioimmunoassay of vasopressin
The concentration of VP in rat plasma was measured using an
assay described in detail by Mohring and Mohring (1975) and North et
al (1978). The protocol used in this thesis is outlined in
Appendix (V). Dilutions of the 1st International Standard for VP
10 10-0 100-0
Oxytocin conc.pg/tube
FIGURE 2-6 Standard curve of a representative assay for oxytocin.
Each point represents the mean of duplicates.
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(NIBSC) were used as working standards (range 1—250pg) and synthetic
VP (400IU/mg) (Batch no. 770110, Ferring; Sweden) was used for
iodination. The specific antibody, Erwin 74 was raised in rabbits
to arginine-VP conjugated with porcine gamma globulin and donated by
Dr. J. Mohring (Mohring and Mohring, 1975). Used at a final
dilution of 1:5,000, it showed < 0.01% cross reactivity with 0T.
125
After incubation of I VP with anti-VP serum and
standards/samples, the 'bound' hormone was separated from the 'free'
hormone by the rapid addition of absolute ethanol. A representative
standard curve is shown in Figure 2-7. The inter- and intra-assay
coefficients of variation were 6% and 12% respectively and the lower
limit of sensitivity ranged from l-3pg/tube for 25pl samples of
piasma.
2.4 HIGH PRESSURE LIQUID CHROMATOGRAPHY
2.4.1 Introduction
High pressure liquid chromatography (HPLC) with electrochemical
detection (LCED) was used to measure the concentrations of catechol¬
amines and indoleamines in brain extracts. This technique is highly
selective and sensitive and is more rapid and inexpensive than the
previously used radioenzymatic method (Coyle and Henry, 1973;
Saavedra, Brownstein and Axelrod, 1973), and it also allows
simultaneous measurement of several amines and their metabolites
with minimal sample preparation. The detailed theory of
electrochemical reactions and continuous flow voltammetry have been
described by Adams (1969) and Weber and Purdy (1978). Therefore,
only the principles relevant to the measurement of catechol- and
indoleamines in this thesis are described.
The basis of HPLC-LCED is the ability of compounds, after having
95—
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FIGURE 2-7 Standard curve of a representative assay for
vasopressin. Each point represents the mean of
duplicates.
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been separated on a chromatographic column, to undergo redox
reactions in such a way as to accommodate either loss or gain of one
or more electrons within certain limits of electrical potential.
These limits are fixed by the composition of the electrolyte
solution in which the compound is dispersed and the material of
which the detector electrode is composed. Almost all catechol- and
indoleamines are oxidised between the potential limits of +0.5 and
+0.7 volts (with reference to an Ag/AgCl reference electrode).
Typical oxidative reactions for a catecholamine and an indoleamine
are shown in Figure 2-8. Electrons are lost to the detector
electrode and the current which is derived is proportional to the
concentration of the amine present in the sample. This generated
current is then converted to a proportional voltage and displayed on
a suitable recorder.
2.4.2 Materials and Methods
2.4.2.1 Instrumentation
The system used in these studies is shown schematically in
Figure 2-9. All equipment was purchased from Scotlab Instrument
Sales Ltd. unless otherwise stated.
The mobile phase (2.4.2.2) was pumped through the system at a
rate of lml/min using an Altex 110A pump. Standards and samples
were loaded onto the columns through a Rheodyne 7125 injection
valve, fitted with a 20ul injection loop, using an SGE 25pl
syringe. The main analytical column was protected from
deterioration by first passing samples through a pre-column
consisting of a 10cm x 0.4cm stainless steel tube packed with either
Ultrasphere ODS (column purchased pre-packed) or Spherisorb 5ym ODS
a)
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FIGURE 2-9 Diagrammatic representation of the HPLC-LCED system.
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(column packed in the laboratory with a Magnus slurry packer at a
pressure of 4000psi). (These 2 different types of pre-column were
interchanged freely as no difference was found in their
performance.) The analytical column consisted of a 25cm x 0.46cm
stainless steel tube, purchased pre-packed with Ultrasphere ODS (5ym
silica particles coated with hydrocarbon chains, 18 CH^ groups in
length). Compounds were detected by a Bioanalytical System (BAS
Inc., Indiana, U.S.A.)LC—17 glassy carbon 'transducer cell
(Fig. 2-10). The cell consisted of a plexiglass block divided in
half by a 0.2mm polytetrafluoroethylene (teflon) gasket. A flow
cell with a volume of < lyl, containing the glassy carbon working
electrode, was formed by a slit (1.6cm x 0.5cm) cut in the gasket.
A potential of + 0.7 volt was maintained across the cell (with
reference to an Ag/AgCl reference electrode) by a BAS-LC4A
controller which also amplified and converted the signal from the
working electrode to a voltage for display on a Tarkan 600 chart
recorder set at a range of 1 volt for a full-scale chart deflection.
2.4.2.2 Mobile phase
An aqueous mobile phase (buffer) was used, consisting of 0.1 M
sodium acetate, 0.1M citric acid, 5% (v/v) methanol, 2% (v/v)
tetrahydrofuran (THF) and 100mg/l sodium octanesulphonic acid (Mayer
and Shoup, 1983), brought to pH 4.9-5.1 with sodium hydroxide.
Distilled, deionized water and Analar grade reagents were used at
all times.
Buffer without THF was filtered under pressure through a 0.22ym
millipore filter and then degassed for 10 min. Tetrahydrof u ran
was added and the buffer and THF very gently mixed taking care not
2.5 cm






to introduce any air into the mixture.
2.4.2.3 Standards
Stock solutions (lOOyg free base/ml) of noradrenaline
hydrochloride (NA), dopamine hydrochloride (DA), dihydroxyphenyl
acetic acid (DOPAC), 5-hydroxytryptamine creatinine sulphate (5-HT),
5-hydroxyindoleacetic acid (5-HIAA) and of internal standard,
n-acetyldopamine hydrochloride (n-acDA), were prepared in 10~^M
cysteine and diluted daily before use in 0.2M perchloric acid
(HCIO^). Stock solutions were stable for up to 6 weeks when
stored in the dark at 4°C. The range of concentrations used
routinely was 50pg, lOOpg, 200pg and 2ng per 20yl injection but
standard curves were linear over the range of 20pg to 2ng (see Fig.
2-11). An internal standard of lng/20pl of n-acDA was included in
both the sample homogenization buffer and in the standard
solutions. Typical chromatograms for 2 different concentrations of
standards are shown in Figure 2-12.
The lower limit of sensitivity of this procedure was defined as
three times baseline 'noise' and was between 15-20pg per 20ul
injection for all compounds studied.
2.4.2.4 Extraction and preparation of samples
The amines present in brain samples were extracted by
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homogenization of tissue in 0.2M HCIO^ containing 10 M
cysteine as antioxidant, and lng/20ul of internal standard.
Homogenized tissue was centrifuged at 1000 x g for 5 min and the
supernatant then filtered through a 0.2um regenerated cellulose
filter using a BAS MF1 centrifugal microfilter. The filtered
supernatant was then kept on ice until injected directly into the
Cone, of compounds,pg/20jul
FIGURE 2-11 Standard curves for noradrenaline (NA), dopamine (OA),
dihydroxyphenylacetic acid (DOPAC), 5-hydroxytryptamine
(5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) using
peak height ratios=
Peak height of standard ('x' nq/20u1)
Peak height of internal standards (lng/20yl)
Retention time,mins.
FIGURE 2-12 Representative chromatograms for a) 2ng/20yl and b)
200pg/20y1 of noradrenaline (NA) dopamine (DA),
dihydroxyphenyl acetic acid (DOPAC), 5-hydroxytryptamine
(5-HT) and 5-hydroxyindoleacetic acid (5-HIAA) with the
addition of lng/20yl of n-acetyldopamine (IS - internal
standard) to each injection.
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HPLC-LCED system.
2.4.2.5 Calculation of results
Peak heights were measured from a point on the baseline from
which a perpendicular (relative to the direction of movement of the
recorder paper) could be drawn to the maximum point of the peak.
Since the same mass of internal standard (lng/20yl) had been
added to all standards and samples, the peak height ratio (PHR)
relative to the internal standard, for each concentration of
standard, was calculated, i.e.
Peak height of standard (1x' ng/20yl)/Peak height of internal
standard (lng/20yl)
Peak height ratios relative to an internal standard allowed for
correction of recovery and injection volume variation without
further calculation. A standard curve was constructed for each
compound using PHR against concentration. Typical examples are
shown in Figure 2-11. The mass of each different compound in each
sample was determined by linear regression from the relevant
standard curve using the PHR of each compound relative to the
internal standard in that sample.
CHAPTER 3




The secretion of hormones by the anterior pituitary gland is
largely controlled by hypothalamic releasing- and release-inhibiting
factors (Harris, 1955; Sawyer, 1959). Much attention has focussed
on the modulation of the release of PRL, which in the mammal appears
to be primarily under inhibitory control (Everett, 1954; Meites et
a!., 1972; Bishop, Krulich, Fawcett and McCann, 1971). The
identity of the prolactin-inhibitory factor (PIF) has been sought
for a number of years and the most likely candidate proposed, so
far, is DA (Macleod, 1976). Dramatic decreases in the secretion of
PRL are seen both in vivo and in vitro after treatment with DA
(Macleod, 1969; Birge et al., 1970; Blake, 1973; Mueller,
Simpkins, Meites and Moore, 1976) and there is anatomical and
neuroendocrine evidence to support the role of DA as a PIF under
some circumstances (Leong et al., 1983).
It has been demonstrated (Htfkfelt and Fuxe, 1967; Smith and
Fink, 1972) that fluorescence associated with DA terminals is
present in the ME adjacent to the hypophysial portal vasculature and
to other nerve terminals, the probable sites of hypophysiotrophic
hormone storage (Barnea, Ben-Jonathan, Colston, Johnston and Porter,
1976). This has been confirmed by electron microscopy (Cuello and
Iversen, 1973) and by radioenzymatic assay in combination with RIA
(Selmanoff, 1981). The cell bodies of these tuberoinfundibular DA
(TIDA) neurons are located mainly in the arcuate nucleus, with some
fibres arising in the periventricular area and the paraventricular
nucleus (Moore and Bloom, 1978; Renaud, 1981). There is some
dispute regarding possible sites of origin in the ventromedial
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nucleus and the preoptic area, as although projections from these
areas to the ME have been identified by retrograde tracing studies
they have not been shown to contain OA (Wiegand and Price, 1980).
All of the areas mentioned above have been shown to be involved in
the control of the release of anterior pituitary hormones (Joseph
and Knigge, 1978). Consistent with the view that DA is a PIF are
observations of changes in DA turnover that are associated with
changes in PRL concentration. The turnover of DA in TIDA neurons is
increased when plasma PRL concentrations are high (Hfikfelt and Fuxe,
1972; Gudelsky et a!., 1976; Eikenburg et al., 1977) and treatment
of animals with exogenous PRL results in increased DA turnover in
TIDA neurons (Annunziato and Moore, 1978). However, data from
turnover studies must be interpreted carefully due to several
assumptions which have to be made and which may not be valid
(Weiner, 1974), such as the existence of a direct relationship
between turnover and neuronal release of DA. The latter assumption
has been shown not to be valid for the method of measuring turnover
3 3
by estimating the conversion of H-tyrosine to H-DA (Roth,
Walters and Aghajanian, 1974). Further evidence that DA may
function physiologically as a PIF comes from measurements of DA in
hypophysial portal blood (Ben-Jonathan et al., 1977; Reymond et
al., 1983) and detection of specific DA receptors on cells from the
anterior pituitary gland (Goldsmith et al., 1979). The
concentration of DA in hypophysial portal plasma is sufficient to
inhibit PRL secretion in vivo (Gibbs and Neill, 1978) and the DA
receptors of the anterior pituitary exhibit supersensitivity after
withdrawal of hypothalamic hypophysiotrophic factors by destruction
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of the medial basal hypothalamus (MBH) (Cheung and Weiner, 1976).
The TIDA neuronal system appears to differ markedly from another
wel1-characterized central dopaminergic neuronal pathway, the
striato-nigral system (Annunziato, 1979). The well-documented
negative feedback effect of DA agonists on DA synthesis (Carlsson,
1975) appears to be absent in the TIDA neuron (Meltzer, Simonovic,
Fang, Piyakalamala and Young, 1978) and there are significant
differences in the kinetics of DA uptake and release in the two
systems (Demarest and Moore, 1979; Annunziato, Cerrito and Raiteri,
1980).
Much information concerning DA function in other brain areas has
been discovered using synaptosomal and brain slice preparations in
vitro (Snyder and Coyle, 1969; Bogdanski and Tissari, 1976;
Starke, Reinmann, Zumstein and Hertting, 1978; Aceves and Cuello,
1981). The TIDA system has not been extensively studied in vitro
and there are only a few reports of work on either ME synaptosomes
or slices of MBH (Annunziato et al., 1981; Foreman and Porter,
1981). The MBH is a complex structure (Bjorklund, Falck et al.,
1973; Kavanagh and Weisz, 1973) and the release of DA seen in vitro
(Perkins and Westfall, 1978; Foreman and Porter, 1980) is likely to
be due to the summation of stimulatory and inhibitory influences
present in the slice. The ME is a much simpler structure containing
mainly axons and terminals (Scott, Krobisch-Dud.ley, Gibbs and Brown,
1972), therefore, interpretation of neurotransmitter release from a
ME slice should be simpler than interpretation of release from a MBH
si ice.
Recently, it has been demonstrated that it is possible to
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electrically-induce the release of neurotransmitters from very small
pieces of brain tissue in vitro (Aceves and Cuello, 1981). This
technique was used in the studies reported here, to investigate the
3
release of H-DA from slices of rat ME in vitro. After initial
studies had been completed, further experiements were carried out to
determine:
3
(i) whether H-DA release was altered under different
physiological conditions
3
(ii) if H-DA release was affected by DA agents
(iii) whether there was any evidence for the presence of a
pre-synaptic DA receptor on the terminals of TIDA neurons.
3.2 MATERIALS AND METHODS
3.2.1 Animals
Animals used in these studies were male Wistar cobs, (200-350g)
and female Wistar cobs (200-250g) that had exhibited two consecutive
4 day oestrous cycles. Dissection of the ME was carried out as
described in section 2.2.5.
3.2.2 Buffers and compounds
—8
Krebs-Heinsleit buffer (Appendix II) containing 0.27 x 10 M
- -8
EDTA and 1.3 x 10 M ascorbic acid was freshly made up before each
superfusion. Luteinizing hormone-releasing hormone, TRH and PRL
were dissolved in distilled water and stored frozen at -20°C in
aliquots of lOmg/ml. Aliquots were thawed immediately before use
and then added to the K-H buffer. Peptides were protected from
C
degradation by the addition of 5 x 10 M bacitracin (Sigma) to the
K-H buffer. Nomifensine, apomorphine, haloperidol, chlorpromazine
—6
and domperidone were dissolved in distilled water containing 10" M
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ascorbic acid as antioxidant and stored in the dark at 4°C until
added to the K-H buffer. Stock solutions of drugs were not
retained for longer than 8h during any experiment. Drugs and
peptides were added to superfusion buffer after the initial control
stimuli and before the test stimuli.
3
3.2.3 Accumulation of H-dopamine
Six ME at a time were placed in 1ml of oxygenated K-H buffer at
37°C and preincubated for 5 min. Three ME were then removed from
this storage buffer and placed in another 1ml of buffer containing
3various concentrations of H-DA and incubated for a further
35 min. In those experiments designed to study the rate of H-DA
uptake, tissue was incubated under similar conditions for varying
lengths of time. Uptake was terminated by removing the tissue from
the incubation tube and plunging it into 1ml of ice-cold buffer.
Tissue was rinsed by transfer into another 1ml ice-cold buffer and
then removed and homogenized in 1.0ml of 0.1N HC1. A 250yl aliquot
was taken and mixed with 10ml of scintillation fluid (NE260, Nuclear
Enterprises Ltd.) in a plastic scintillation vial, and radioactivity
determined by liquid scintillation counting.
Vials were placed in the scintillation counter (Nuclear Chicago,
Mark II Liquid Scintillation System) to cool for lh before
counting. Counting efficiency was 37%.
3
3.2.4 Release of H-dopamine
Median eminence tissue was incubated for 20 min with 0.5 x
—fi ?
10 M H-DA in a final volume of 1ml of oxygenated K-H buffer at
37°C. Tissue was then placed in a small perspex chamber (3 ME per
chamber) in the superfusion apparatus (Fig. 3-1). Oxygenated
FIGURE3-1Schematicrepresentat onoftsup rfusisy temd tostudyhereleaseof^H-dopamin(^H-DA)fr medianeminencetissueinvitro
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K-H buffer at 37"C was passed through the system at a rate of
500nl/min using a peristaltic pump. A 40 min wash-out period was
3
allowed to remove non-specific binding of H-OA to the tissue
after which 1ml fractions were collected on ice for another 40-60
min.
Electrical field stimulation consisting of a train of
accurately-balanced biphasic square waves was applied using a
constant current generator (Neurolog system; Digitimer, Welwyn
Garden City). The stimuli were monitored with a calibrated
oscilloscope. Electrodes were silver plates embedded in perspex
plugs, linked to the stimulator by connecting clips attached to the
steel superfusion inlet and outflow (Fig. 3-1).
At the end of the superfusion, 250ul aliquots from each
collected fraction were taken and mixed with 10ml of scintillation
fluid and counted as before. Tissue was removed from the
superfusion chambers and homogenized in 1ml of 0.1N HC1 and a 250p1
aliquot counted as before for determination of the amount of
radioactivity left in the tissue.
Results were expressed as a fractional rate constant for basal
release and as a relative fractional rate constant (RFRC) for
stimulated release, defined as,
3fractional rate constant for H-OA release during stimulation
(2 fractions)
fractional rate constant for H-OA release immediately before
3




Data are presented as mean ± S.E.M. Significance of difference
between two means was determined by Students t-test. The
significance of differences between more than two means was
determined by analysis of variance and Duncan's multiple range test.
3.3 RESULTS
3
3.3.1 Accumulation of H-dopamine 0.s-,<\o~ufA
When ME tissue was incubated with^H-DA there was an
accumulation of radioactivity in the tissue. The accumulation was
rapid and time-dependent (Fig. 3-2) and could be inhibited by
incubation at 4°C (62% inhibition) or in the presence of 10~^M
ouabain (65% inhibition) (Fig. 3-2).
3
The specificity of uptake of the H-DA was tested by
incubating the tissue with various concentrations
(10~^M - 10"^ M) of unlabelled DA. Dopamine caused a
3
dose-dependent inhibition of H-DA accumulation in the tissue with
an ICLq of 0.5 x 10~Sl, (Fig 3-3).
Accumulation could also be inhibited by nomifensine, a specific
DA uptake inhibitor, in a dose-dependent manner.(Fig. 3-4).
33.3.2 Spontaneous release of H-dopamine
3
Spontaneous H-DA release decreased from an initially very
-3 1
high to a low basal rate (rate constant = 2-4 x 10 , min )
after 40 min (Fig. 3-5) Spontaneous release was higher in
2+ +
Ca -free and lower in Na -free buffer than in normal buffer
(Fig. 3-5).
Footnote
Median eminence tissue was examined histologically for the presence
of cell bodies. Haematoxylin and eosin staining revealed no
evidence for the presence of cell bodies.
FIGURE 3-2 Accumulation of ^H-dopamine (^H-DA) in median
eminence tissue after incubation with 0.5 x 10~6m^H-DA for different periods of time at 37"C, at 4°C
or in the presence of 10~^M ouabain in incubation
mediurn.





Inhibitionofspecific^H-dopam ne(^H-DA)u tak intomedianeminencetissuebyincreasi goncen rations ofDAaddedtincubationme ium.Eachp int representsthmea±S.E.M.for6experiments
1I]B-76-54 Nomifensineco e.(LogM)
FIGURE3-4Inhibitionofspecific^H-dopam e(^H-DA)uptake intomedianeminencetissuebyi creasingconc ntratio s ofnomifensineaddedtincubationme ium.Eachpo t representsthm an±S.E.M.for4experiments.
TIME.mins
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3.3.3 Electrically stimulated release of H-dopamine
3
Release of H-DA was raised significantly above basal rates by
applying an electrical stimulus. The increase in the rate of
H-OA release was dependent on the amplitude (Fig. 3-6) frequency
(Fig. 3-£) and duration (Fig. 3-7) of the stimulus. Electrically
3 2+
induced H-OA release was abolished in Ca -free buffer and
greatly reduced in Na+-free buffer (Fig. 3-9)
From these initial studies a submaximal stimulus of 6mA at 50 Hz
(f\^. 3—
applied for 15 sec^was chosen for all subsequent experiments.
3
3.3.4 Effect of dopaminergic agents on the release of H-dopamine
Dopaminergic agents (3.2.2) were added to the superfusion buffer
and the effect on spontaneous and electrically-induced release
tested. None of the agonists or antagonists tested had any
significant effect on spontaneous or induced release (Table 3-1 and
Fig. 3-10).
Nomifensine, a dopamine reuptake blocker, had no effect on the
3basal release of H-DA but caused a significant increase in the
electrically-induced release (Table 3-1 and Fig. 3-10). This effect
was still seen in the presence of apomorphine even although
apomorphine itself had no effect (Fig. 3-10).
3
3.3.5 The release of H-dopamine throughout the oestrous cycle
Figure 3-11 and Table 3-2 show that there were no significant
3differences between either electrically-induced or basal H-DA
release during the different stages of the oestrous cycle, and that
this release was also unaffected by the presence of TRH.
33.3.6 Effect of peptides on the release of H-dopamine
Figure 3-12 and Table 3-3 show that none of the three peptides
TIME.mins
FIGURE 3-6 Electrically-stimulated release of ^H-dopamine
(3h-DA) from superfused slices of median eminence:
the effect of increasing the amplitude of the applied
stimulus.
Tissue was pre-incubated with 0.5 x 10-^m 3h_qa for
20 min. After 40 min wash-out period, tissue was
stimulated at lOmin interval with biphasic square waves,
pulse width 2ms, duration 15s, frequency 50Hz and
increasing pulse amplitude.
•, normal K-H superfusion buffer
o,Ca2+-free K-H superfus ion buffer.
Each point represents the mean ± S.E.M. for 6
experiments.
Release is expressed as a fractional rate constant
FIGURE 3-7 Electrically-stimulated release of ^H-dopamine
(^H—DA) from superfused slices of median eminence:
the effect of increasing the duration of the applied
stimulus.
Tissue was pre-incubated with 0.5 x 10~®M ^h-DA for
20 min. After a 40 min wash-out period, tissue was
stimulated at 10 min intervals with biphasic square
waves, pulse width 2ms, amplitude 6mA, frequency 50Hz
and increasing duration of the applied stimulus.
•, normal K-H superfusion buffer
OjCa2+-free K-H. superfusion buffer
Each point represents the mean ± S.E.M. for 6
experiments.


















FIGURE 3-8 Electrically-stimulated release of ^H-dopamine
(3h-DA) from superfused slices of median eminence:
the effect of increasing the frequency of the applied
stimulus.
Tissue was pre-incubated with 0.5 x 10~^M with ^h-OA
for 20min. After a 40min wash-out period, tissue was
stimulated at 10 min intervals with biphasic square
waves, pulse width 2ms, amplitude 6mA, duration 15s and
increasing frequency of the applied stimulus.
•,normal K-H superfusion buffer
o,C&2+-free K-H superfusion buffer
Each point represents the mean ± S.E.M. for 6
experiments.
Release is expressed as a fractional rate constant.
 
FIGURE 3-9 The relative fractional rate constants (RFRC) for the
electrically-stimulated release of -^-dopamine
(^H-DA) from superfused slices of median eminence:
the effect of increasing amplitude, frequency and
duration of the applied stimulus (Data derived from
Figs. 3-6, 3-7 and 3-8). RFRC =
fractional rate constant for 3h~0A release during
stimulation (2 fractions)
fractional rate constant tor ^h-DA release immediately
before stimulation +
fractional rate constant for 3h-DA release immediately
after stimulation.
Mean ± S.E.M. of 6 experiments.
□ normal K-H superfusion buffer
K3Ca2+-free K-H superfusion buffer
0Na+-free superfusion buffer.
(Electrical stimuli of increasing duration (Fig. 3-9a)




The mean (± S.E.M.) basal release of 3H-dopamine (3H-DA)
(fractional rate constant x 10~3) from median eminence tissue
superfused with various dopaminergic drugs.
Initial basal release is the fractional rate constant of 3H-DA
release at the end of the initial 40 min wash-out period. Final
basal release is the fractional rate constant for 3H-DA release
after the additional 40 min superfusion in the presence of
dopaminergic drugs.
Group n Initial basal release Final basal release
(pre-drug) (post-drug)
No drug 8 4.60 ± 0.54 2.05 ± 0.27
Dopamine 10~^M 5 5.84 ± 1.46 4.24 ± 1.45
Apomorphine 10~3m 4 2.35 ± 0.27 1.57 ± 0.07
Chlorpromazine 10-5m 6 2.75 ± 0.36 1.56 ± 0.13
Haloperidol lO-^M 5 5.68 ± 0.60 2.48 i: 0.35
Domperidone 10~5m 5 4.30 ± 0.19 2.78 X. 0.19
Nomifensine 10-3M 6 3.06 ± 0.40 1.51 0,18
Drugs were tested at a range of concentrations from 10~9 - 10~3M.
Since there were no significant effects of any of the drugs at any
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Control, APO NOM DA
no drug 10"5M 10"SM 10"6M
Cone, drug in superfusion fluid
APO 10 s Ml
+ NOM10"sM
FIGURE 3-10 The effects of dopamine (DA), apomorphine (APO) and
nomifensine (NOM) on the electrically-stimulated release
of ^H-dopamine (^H-DA) from superfused slices of
median eminence. Data, expressed as mean ± S.E.M. of
relative fractional rate constant (RFRC). After
pre-incubation with ^h-DA, 0.5 x 10~®M,tissue was
superfused with K-H buffer containing dopaminergic
drugs, and electrical stimulation applied every 10 min,
(number of stimulated periods shown within each column).
* p < 0.01; level of significance of difference between
electrically-stimulated release of ^h-DA
in the absence of drugs compared with ^H-DA
release in the presence of NOM.
TABLE 3-2
The mean (± S.E.M.) basal release of 3H-dopamine (3H-DA)
(fractional rate constant x 10-3) from median eminence tissue
removed from rats at different stages of the oestrous cycle.
Initial basal release is the fractional rate constant of 3H-DA
release at the end of the initial 40 min wash-out period. Final
basal release is the fractional rate constant for 3H-DA release
after the additional 40 min superfusion period.
Group n Initial basal release Final basal release
Males 6 2.49 ± 0.56 0.88 ± 0.15
Dioestrus 6 2.60 ± 0.14 1.22 ± 0.06
Pro-oestrus (pm) 5 3.74 ± 0.29 1.69 ± 0.16
Oestrus 5 3.00 ± 0.46 1.24 ± 0.17
Pro-oestrus (am)
+ TRH 10-SM
5 3.04 ± 0.28 1.34 ± 0.13
Pro-oestrus (pm)
+ TRH 10-8M
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FIGURE 3-11 The electrically-stimulated release of ^H-dopamine
(3h~DA) from slices of median eminence throughout the
oestrus cycle. After pre-incubation with ^h-DA, 0.5
x 10~6m, tissue was superfused with K-H buffer and
electrical stimulation applied every 10 min. Data
expressed as mean ± S.E.M. of relative fractional rate
constant (RFRC), (number of stimulated periods shown
within each column).
TABLE 3-3
The mean (± S.E.M.) basal release of 8H-dopamine (^H—DA)
(fractional rate constant x 10-8) from median eminence tissue
superfused with prolactin (PRL), luteinizing hormone-releasing
hormone (LHRH) or thyrotrophin-releasing hormone (TRH).
Initial basal release is the fractional rate constant of 8H-DA
release at the end of the initial 40 min wash-out period. Final
basal release is the fractional rate constant for 8H-DA release
after the additional 40 min superfusion in the presence of PRL, LHRH
or TRH.
Group n Initial basal release Final basal release
(pre-peptide) (post-peptide)
No peptide 8 4.60 ± 0.54 2.05 ± 0.27
PRL 10-8M 8 2.96 ± 0.29 2.45 ± 0.36
PRL 10~7M 6 3.56 ± 0.49 1.52 ± 0.09
LHRH 10"9M 6 3.99 ± 0.77 1.52 ± 0.32
LHRH 10~8M 5 2.94 ± 0.29 1.43 ± 0.29
LHRH 10"7M 8 4.66 ± 0.57 1.72 ± 0.16
TRH 10~9M 4 3.57 ± 0.54 1.73 ± 0.18
TRH 10"8M 5 4.74 ± 1.28 1.89 ± 0.54





































Cone, peptide added to superfusion fluid
FIGURE 3-12 The effects of various peptides on the
electrically-stimulated release of ^H-dopamine
(^H-DA) from superfused slices of median eminence.
Data expressed as mean ± S.E.M. of relative fractional
rate constant (RFRC). After pre-incubation with
^H-DA, 0.5 x 10~6m, tissue was superfused with K-H
buffer containing peptides and bacitracin (peptidase
inhibitor) and electrical stimulation applied every 10
min, (number of stimulated periods shown within each
column).
tested, LHRH, TRH and PRL had any effect on the electrically-induced
3
or the basal release of H-OA.
3.4 DISCUSSION
The studies reported here show that the ME, a tissue containing
primarily nerve axons and terminals (Scott et al., 1972; Bjorklund,
3
Falck et al., 1973) can take-up and release exogenous H-DA under
in vitro conditions. While there are several reports in the
3
literature of H-DA uptake into and release from MBH slices and ME
synaptosomes in vitro (Perkins and Westfall, 1978; Annunziato et
al., 1981), the release has generally been induced by a medium
+
containing a high concentration of K . These studies report the
3
release of H-DA from the ME caused by the application of an
electrical stimulus.
3 + 2+
The uptake of H-DA was temperature, Na - and Ca -
dependent, indicating that the site of uptake was likely to be
neuronal (Orrego, 1979), and displayed character isties similar to
neurotransmitter uptake in other CNS regions in vitro (Bogdanski,
Blaszkowski and Tissari, 1970; Baldessarini and Vogt, 1971;
Geffen, Jessell, Cuello and Iversen, 1976; Aceves and Cuello,
1981). When incubations were carried out in the presence of
exogenous DA, uptake of H-DA was inhibited (Fig. 3-3). The
IC,-Q for inhibition of ^H-DA uptake by DA, 0.5 ± 0.2 x 10~Sl,
3
is in good agreement with the reported for H-DA uptake into
ME synaptosomes (1.8 ± 0.9 x 10~®M) (Annunziato et al., 1980) and
ME homogenates (1.5 ± 0.2 x 10~Sl) Demarest and Moore, 1979).
3
Uptake of H-DA was also significantly inhibited in the presence
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of nomifensine, a specific DA uptake blocker (Hunt, Kennengiesser
and Raynaud, 1974). These data indicate that the uptake of H-DA
into the ME is a specific process but is of low affinity unlike the
3
uptake of H-DA into striatal and cortical DA terminals which is a
high-affinity process (Snyder and Coyle, 1969). This conclusion is
supported by measurements of low concentrations of DOPAC in fluid
from superfused ME stimulated with high K+, relative to
concentrations of DOPAC in fluid from superfused and stimulated
striatal tissue (Kapoor, 1982) which was interpreted as lack of
uptake and subsequent degradation by MAO. The incubation medium
used in the present studies did not include any inhibitors of
catecholamine uptake into noradrenergic terminals as have been used
in other studies (e.g. Annunziato et a!., 1981), since it has been
3
shown that 78% of total H-DA taken up by a ME homogenate is taken
up specifically into DA terminals (Demarest and Moore, 1979).
3
Median eminence tissue pre-incubated with H-DA showed a
3
spontaneous release of H-DA consisting of an initial high rate of
release rapidly decreasing to a much slower sustained rate of
release (Fig. 3-5). The initial phase of the spontaneous release is
3
thought to represent release of extraneuronal H-DA present in the
ME tissue whereas the following slower phase is thought to represent
release from intraneuronal stores (Orrego, Jankelevich, Ceruti and
Ferrera, 1974). The slower phase of spontaneous release of H-DA
was increased in Ca -free medium and slightly decreased in
Na+-free medium (Fig. 3-5). The increase in spontaneous release
3 2+
of H-DA observed in Ca -free medium could be due to an
increase in intraneuronal Na+ (Keesey, Wallgren and Mcllwain,
2+
1975), which occurs when cells are placed in a Ca -free
+
environment, and this increase in Na concentration subsequently
causing increased release of transmitter (Schultz and Curran,
1970). The decrease in spontaneous release of H-DA observed in
Na+-free medium is more difficult to explain si nee.in a Na+-free
medium, the ratio of intra- and extracellular Na+ concentrations
is reversed, and an outward downhill gradient across the nerve
membrane is formed; according to the Na+-gradient hypothesis
(Crane, 1965), this should facilitate the release of a
neurotransmitter whose uptake depends on the normal Na+
3
gradient. In contrast to the present data on H-OA release from
3
ME slices, H-DA release from ME synaptosomes was increased in
Na+-free medium, (Annunziato et a!., 1981). This difference
between the slice and synaptosome preparations may indicate that the
3
spontaneous release of H-DA from ME slices in vitro is not a
carrier-mediated process but rather that the release is due to
non-specific changes in membrane permeability under in vitro
conditions. Further evidence for this possibility is the
observation that nomifensine (10-^ M) did not modify the
3
spontaneous release of H-DA from ME slices in vitro in the
3
present studies, or H-DA release from ME synaptosomes (Annunziato
et al., 1981), suggesting again that this spontaneous release is not
a carrier-mediated process.
It has been shown on numerous occasions that brain slices in
vitro can release endogenous and exogenous neurotransmitter in
response to electrical stimulation (Orrego et al., 1974; Saldate
and Orrego, 1975; Saldate and Orrego, 1977; Potaschner, 1978;
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Starke et al., 1978; Szerb, 1979; Arbilla, Kama! and Langer,
1980). Using a technique described by Aceves and Cuello (1981) the
studies reported in this chapter show that it was possible to elicit
3
the release of previously accumulated H-DA from ME slices in
vitro by the application of an electrical stimulus (Fig. 3-6,7,8).
+ 2+
This evoked release was Na - and Ca - dependent, important
criteria to be fulfilled before classifying such
depolarization-induced release as being from nerve terminals (see
Orrego, 1979). The release of H-DA increased proportionally in
response to increasing amplitude or fequency of the stimulus (Fig.
3-7,8) up to an amplitude of 10mA and a frequency of 100Hz. Stimuli
3
which were above 12mA or 100Hz caused a massive release of H-DA,
which was probably due to the high current intensities displacing
3
H-DA from sites other than those operating during the action
potential. This has been observed to occur in slices of neocortex
in vitro where low stimulation intensities caused release of a
neurotransmitter and high stimulation intensities caused a much
greater release of the neurotransmitter accompanied by the release
of a non-transmitter amino acid (Orrego et al., 1974).
Nomifensine, a compound proposed as a DA uptake blocker, caused
3
a significant increase in the release of H-DA caused by
electrical stimulation (Fig. 3-10). It has been proposed that the
apparent reuptake blocking action of nomifensine on DA is in fact
due to a DA-releasing action of this compound (Baumann and Maitre,
1976). This is not supported by the present studies, as nomifensine
3
had no effect on the spontaneous, unstimulated release of H-DA
(Table 3-1). These effects of nomifensine were also present during
K+ stimulation of endogenous DA release from ME slices
(Kapoor, 1982). The study of Kapoor (1982) also found that the
concentration of DOPAC in superfusion fluid from ME slices in vitro
was very low compared with the concentration in fluid from
superfused striatal slices. This again suggests the absence of a
high-affinity DA uptake mechanism in ME tissue.
3
Since the electrically-stimulated release of H-DA from ME
slices in vitro showed characteristics comparable to neuronal
release of neurotransmitters in vitro and since the release was
reproducible, it was decided that this was a suitable model for
investigation of TIDA function and further studies were carried out.
There is much evidence for the involvement of DA in the release
of LH and PRL from the anterior pituitary gland during the oestrous
cycle particularly during pro-oestrus, but, whereas there is some
evidence for a decrease in the action of DA to inhibit the release
of PRL during the pro-oestrous PRL surge, the question as to whether
DA stimulates or inhibits the pro-oestrous surge of LH is still
controversial (Fink and Geffen, 1978; Weiner and Ganong, 1978;
Barraclough and Wise, 1982; 1.4.1). Measurements of steady-state
DA concentrations in the ME during the oestrous cycle have yielded
little information, with some groups claiming increased DA
concentration (Crowley, Donohue and Jacobowitz, 1978) and others
claiming that DA concentrations do not change (Selmanoff,
Pramik-Holdway and Weiner, 1976; Demarest, Johnston and Moore,
1981). However, it has been argued that measurement of steady-state
concentrations of neurotransmitters gives no information on the
activity of the neuronal system (Weiner, 1974) and that before any
-78-
indication can be obtained as to neuronal function, turnover of
neurotransmitter and not steady-state concentration must be
measured. It has been shown histochemically (Ahren, Fuxe, Hamberger
and Hokfelt, 1971; Lofstrtim, 1977) and radioenzymatically (Demarest
et al., 1981, Ranee et al., 1981b) that the turnover of DA in TIDA
neurons is decreased on the afternoon of pro-oestrus. In support of
these studies, there have been reports of decreased concentrations
of DA in hypophysial portal blood on the afternoon of pro-oestrus
(Ben-Jonathan et al., 1977) and of changes in tyrosine-hydroxylase
(the rate-limiting enzyme in DA synthesis) activity during the
oestrous cycle (Carr and Vogt, 1980).
In the present studies no change was found in the spontaneous or
3
the electrically-induced release of H-DA from the ME in vitro at
any stage of the oestrous cycle (Table 3-3 and Fig. 3-11). This
result was unexpected, but could perhaps be due to the specific
3
activity of the H-DA released by the ME being too low to allow
detection of the small changes that might be expected to occur in
the activity of the TIDA neurons. It could also be argued that
3
the H-DA taken up and released by the ME in vitro does not mix
with the endogenous DA pool and so may not be under the same
control. This hypothesis is supported by the results of Kapoor
(1982) who found that endogenous DA released from the ME in vitro
was almost undetectable, using an LCED system with a detection
sensitivity of 50pg. These results appear to contradict those of
Ben-Jonathan et al. (1977) and Reymond et al. (1983) who found high
concentrations of DA in hypophysial portal blood in vivo, presumably
released from terminals of TIDA neurons. However, it may be that DA
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was arriving in portal blood from a source other than the TIDA
terminals (Ben-Jonathan, 1980) or that TIDA function was disrupted
by the anaesthesia and surgical preparation of the animals used in
the studies of Ben-Jonathan et al. (1977) and Reymond et al. (1983).
Changes in DA turnover in response to dopaminergic drugs have
been reported in other central dopaminergic systems both in vivo
(DiChiara, Porceddu, Vargui, Argiolas and Gessa, 1976) and in vitro
(Farnebo and Hamberger, 1971; Westfall, Benson, Giorguieff and
Glowinski, 1976). These changes have been claimed to be mediated in
part by a specific pre-synaptic dopaminergic 1autoreceptor1 (Nowycky
and Roth, 1978; Kebabian and Calne, 1981). Studies on DA turnover
in TIDA neurons in vivo (Gudelsky and Moore, 1977; Demarest and
3
Moore, 1979) and on H-DA release from ME synaptosomes in vitro
(Annunziato et al., 1981) have shown that these 1autoreceptors1 do
not appear to be present on the terminals of TIDA neurons. The
results of the present studies are consistent with this view as
there was no change in either the spontaneous or the
3
electrically-induced release of H-DA from ME slices in vitro when
either DA or DA agents were added to the superfusion medium (Table
3-1 and Fig. 3-10). It seems unlikely that there would be
1autoreceptors1 present on the terminals of TIDA neurons since they
do not abut onto a classical post-synaptic neuron and form a
synapse, but rather they presumably release their transmitter into
the hypophysial portal blood, which carries it to act some distance
away, in the anterior pituitary gland.
Although DA synthesis and release in TIDA neurons do not appear
to be regulated by autoreceptors or by a neuronal feedback loop,
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there is evidence for some feedback control by PRL. Animals
implanted with PRL-secreting tumours or given exogenous PRL show
increased DA turnover in TIDA neurons (Olson, Fuxe and Hokfelt,
1972; Gudelsky et al., 1976; Hfthn and Wuttke, 1978; Perkins,
Westfall, Paul, Macleod and Rogol, 1979) and PRL injected into the
lateral ventricle also causes increased DA turnover in these neurons
(Annunziato and Moore, 1978).
In experiments designed to investigate the possible roles of
oestrogen and haloperidol in TIDA neuronal regulation, it was
discovered that the stimulatory effects of these agents on DA
turnover were secondary to the increases in plasma PRL
concentrations caused by these agents since they were ineffective in
hypophysectomized animals (Eikenburg et al., .1977; Moore and
Demarest, 1982).
Prolactin has also been shown to release both endogenous and
3
H-DA from pieces of MBH in vitro (Perkins and Westfall, 1978;
Foreman and Porter, 1981).
In the present studies PRL was found to have no effect on either
3
the spontaneous or the electrically-induced release of H-DA from
the ME in vitro. This was unexpected, as two other studies had
shown that DA could be released from the MBH in response to PRL
(Perkins and Westfall, 1978; Foreman and Porter, 1981). However,
Kapoor (1982) did not find any significant effect of PRL on the
release of endogenous DA from the ME in vitro. It may be that the
increase in DA turnover caused by PRL is exerted through the cell
bodies of TIDA neurons in the arcuate nucleus rather than at the
nerve terminals. This is supported by reports that PRL can change
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the electrical activity in some hypothalamic neurons (Clemens,
Gallo, Whitmayer and Sawyer, 1971; Yamada, 1975) and that PRL in
CSF can change DA turnover in TIDA neurons (Annunziato and Moore,
1978). However, the lack of effect may also be due to the brief
duration of exposure of the tissue in the ME slice to PRL. The PRL
effect on DA turnover has been reported to have a latency of at
least 4h in vivo and to be dependent on de novo protein synthesis
(Johnston, Demarest and Moore, 1980).
The terminals of the TIDA system in the ME are found in close
association with terminals containing TRH (Kizer, Palkovits, Tappaz,
Kebabian and Brownstein, 1976; Agnati, Fuxe, Hokfelt, Goldstein and
Jeffcoate, 1977) and those containing LHRH (Ajika, 1979; Selmanoff,
1981). There is evidence that in some systems in the CNS putative
amine and peptide neurotransmitters may co-exist in the same neuron
(Burnstock, 1975; Chan-Palay, Jonsson and Palay, 1978; Hbkfelt,
Ljungdahl, Steinbusch, Verhofstad, Nilsson, Brodin, Pernow and
Goldstein, 1978), however it has been demonstrated that in the ME,
DA, LHRH and TRH are present in different terminals (Kizer, Arimura,
Schally and Brownstein, 1975). The interactions of central
monoamines and neuropeptides are likely to be very complex, whether
substances are present in the same terminal or not. An example of
this is shown in work by Rotzstejn, Drouva, Pattou and Kordon,
(1978) who reported that DA could induce the release of LHRH from
MBH tissue in vitro and that this DA-stimulated release, but not
basal release, was inhibited by met-enkephalin. Other reports show
the possibility of complex interactions between NA and somatostatin
(SS) and between melatonin, LHRH and DA. Gothert (1980) reported
-82-
3
that SS inhibited the release of H-NA from hypothalamic slices in
vitro and Epelbaum, Tapia-Arancibia and Kordon, (1981) subsequently
showed that NA could stimulate SS release from slices of POA but not
from MBH in vitro; melatonin has been reported to stimulate LHRH
release (Richardson, Prasad and Hollander, 1982) and inhibit H-DA
release (Zisapel, Egozi and Laudon, 1983) from the MBH in vitro.
While there are well-documented effects of DA on the release of both
LHRH and TRH (Maeda and Frohman, 1980; Negro-Vilar, 1982), there
are very few observations on reciprocal interactions between LHRH pr
TRH on the release of DA. These interactions might be expected on
consideration of the anatomical data discussed previously. There is
3
evidence that TRH can stimulate release of H-DA from bovine
retina (Reading, 1983) and from rat nucleus accumbens (Kerwin and
Pycock, 1979) in vitro, and a brief report (Bennett, Marsden,
Metcalf, Sharp and Tulloch, 1981) stated that endogenous DA could be
released from rat hypothalamus, nucleus accumbens and septum by
incubation with a long-acting TRH analogue, CG5309
(orotyl-histidyl-prolyl-amide). There are no reports of LHRH
affecting DA release.
In the present studies it was found that the addition of LHRH or
TRH to the superfusion medium had no effect on the spontaneous or on
3
the electrically-induced release of H-DA from ME slices in
vitro. This lack of effect may again be due to the fact that the ME
slice contains only axons and terminals and these peptides, if they
have any effect on TIDA function may do so at the level of the cell
body in the arcuate nucleus. However, it has been reported that
TI cell bodies in the arcuate nucleus are unresponsive to
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microiontophoretically applied LHRH and TRH (Moss et al., 1975;
Moss, 1977) in contrast to the inhibitory and stimulatory action of
these peptides on electrophysiological activity in other regions of
the CNS (Dyer and Dyball, 1974; Renaud, Martin and Brazeau, 1975).
In summary, although the ME has been shown to take-up and
3
release H-DA in vitro its usefulness as a model to study function
in the TIDA neuron seems limited. These limitations are perhaps
reflected in the paucity of literature concerning catecholamine
release from the ME in contrast to the increasing body of literature
dealing with the release of peptides from this tissue (e.g.
Rotsztejn et al., 1977; Beny and Baertschi, 1981; Negro-Vilar,
1982).
It had been hoped that this in vitro system could be adapted to
investigate the uptake and release of 5-HT in the ME. However,
this proved difficult and attention was focussed on in vivo studies.
1
CHAPTER 4
The Effects of Inhibition of Uptake of Serotonin
on the Concentration of Luteinizing Hormone and
Prolactin in Plasma in Various Animal Models
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4.1 INTRODUCTION
The role of 5-HT in the control of the release of LH and PRL
from the anterior pituitary gland has long been controversial
(Weiner and Ganong, 1978; Krulich, 1979; Meites and Sonntag, 1981).
The release of LH has been reported to be inhibited in castrated
male and ovariectomized female rats after peripheral or i.e.v.
injection of 5-HT (Kamberi, Mical and Porter, 1970; Schneider and
McCann, 1970; Pilotte and Porter, 1979) and both spontaneous
ovulation and that induced by pregnant mare serum gonadotrophin
(PMSG) have been reported to be blocked after peripheral injection
of 5-HT (O'Steen, 1965; Kordon and Glowinski, 1972; Labhetswar,
1972; Wilson and MacDonald, 1974). However, these findings
conflict with those of the numerous reports showing an inhibition of
LH release after injection of either a 5-HT synthesis inhibitor or a
5-HT neurotoxin in both pro-oestrous rats and ovariectomized rats
treated with exogenous steroids (Hery et a!., 1976; Wuttke, Hancke,
Hohn and Baumgarten, 1978; Coen and Mackinnon, 1980; Chen,
Sylvester, Heiri and Meites, 1981).
In contrast to the confusion in the literature concerning the
effect of 5-HT on LH release, there appears to be general agreement
that 5-HT stimulates the release of PRL under most circumstances.
The concentration of PRL in peripheral plasma is increased after
peripheral or i.e.v. injection of 5-HT or a 5-HT depletor (Kamberi,
Mical and Porter, 1971; Caligaris and Taleisnik, 1974; Becu and
Libertun, 1982; Van de Kar and Bethea, 1982) and also after
injection of 5-HTP (the immediate precursor of 5-HT) in combination
with a 5-HT reuptake blocker (Krulich, 1975; Clemens et al., 1977).
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Although there appear to be no reports of an inhibitory influence of
5-HT on PRL release, there have been a few studies wich have found
no change in the concentration of PRL in peripheral plasma after
experimental manipulations designed to alter 5-HT transmission
(Gallo et al., 1975; Krulich et al., 1980).
Much of the dispute concerning the effect of 5-HT on the release
of LH and PRL arises from the multiplicity of experimental animal
models studied. Although there is a naturally occurring model
suitable for the study of the release of LH and PRL and their
possible 5-HT components, namely the cyclic release of LH and PRL
during the oestrous cycle of the female rat (Butcher, Collins and
Fugo, 1974), most investigators have examined the role of 5-HT in
the release of LH and PRL using the ovariectomized female rat
treated with various combinations of exogenous steroids. The models
that have been used most commonly to study possible involvement of
5-HT have been i) the long-term ovariectomized rat, injected with
a priming dose of oestrogen followed at least 72h later by an
injection of progesterone (Caligaris, Astrada and Taleisnik, 1968;
Caligaris and Taleisnik, 1974) and ii) the long-term
ovariectomized rat exposed to a continuously elevated concentration
of oestrogen achieved by either daily injections of high doses of OB
(Caligaris et al., 1971), injection of a long-acting preparation of
oestrogen (Subramanian and Gala, 1976) or implantation of a silicone
elastomer capsule containing crystalline OE (Legan, Coon and Karsch,
1975; Henderson et al., 1977b). The first model shows an increase
in the concentration of both LH and PRL in peripheral plasma,
beginning 4—5h after the injection of progesterone and persisting
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for a few hours, before returning to baseline values. The second
model shows a circadian rhythm of LH and PRL with increases in
hormone concentration in peripheral plasma every day during the late
afternoon. It has been proposed (Legan et al., 1975; Freeman et
a!., 1976; Brown-Grant, 1977) that the mechanisms involved in the
massive release of hormones in these models, and specifically that
of LH, may be similar to those that subserve the surges of LH and
PRL that occur spontaneously on the afternoon of pro-oestrus.
However, this may not be strictly correct since, for example, while
the spontaneous surge of LH depends upon an increased release of
LHRH into hypophysial portal blood and an increase in the
responsiveness of the pituitary gland to LHRH, the LH surge in
animals treated with oestrogen followed by progesterone may be due
mainly to a massive increase in responsiveness to LHRH (Sarkar and
Fink, 1980).
The aim of the present study was to investigate the role of 5-HT
in the release of LH and PRL in a range of animal models, using two
drugs, alaproclate and zimelidine_,developed by Astra
Pharmaceuticals, and shown to be potent inhibitors of 5-HT reuptake
in vitro (Astra, unpublished data; Ross, Ogren and Renyi, 1976).
In preliminary studies alaproclate and zimelidine have been tested,
by Astra, for their effects on endocrine function in the male rat.
Alaproclate, injected i.p. at doses ranging from 3-30mg/kg, caused
increases in plasma LH and PRL at doses of 10-30mg/kg, and an
increase in plasma corticosterone at a dose of 30mg/kg. Z.imelidine,
tested at a similar range of doses, caused a small increase in
plasma PRL and had no significant effect on plasma LH. Unlike
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alaproclate, zimelidine caused a decrease in plasma corticosterone.
Theoretically an inhibitor of the uptake of 5-HT could affect
the release of LH and PRL by a number of different routes, for
instance:
i) by altering the release of releasing factors or
release-inhibiting factors
ii) by altering the responsiveness of the pituitary gland to
releasing factors or release-inhibiting factors
iii) by increasing the concentration of 5-HT in the immediate
vicinity of the anterior pituitary gland and so changing the
magnitude of a possible direct action of 5-HT on the gland
iv) by an effect on the ovary, either directly or indirectly, to
alter peripheral concentrations of steroid hormones.
There is evidence for the involvement of 5-HT in all of these
possible mechanisms of action.
4.1.1 Involvement of serotonin in the release of luteinizing hormone
It has been reported that incubation of hypothalamic tissue with
5-HT in vitro causes an inhibition of LH-releasing activity
(Moszkowska, 1965) and of LHRH release (Charli, Rotsztejn, Pattou
and Kordon, 1978). An increase in LHRH immunoreactivity in rat
brain after an i.e.v. injection of 5-HT has also been interpreted as
indicating an inhibitory action of 5-HT on the release of LHRH
(Leonardel1i, Dubois and Poulain, 1974). Other workers have failed
to demonstrate any effect of 5-HT on the release of LHRH from
hypothalamic synaptosomes (Bennett et al., 1975) or on the release
of LH from the medial basal hypothalamus/anterior pituitary complex
in vitro (Schneider and McCann, 1969).
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The change in pituitary responsiveness to LHRH leading to
increased LH release is a complex phenomenon involving a direct
effect of oestrogen and a 'priming' effect of LHRH on the
gonadotrophs of the anterior pituitary gland (Aiyer and Fink, 1974;
Aiyer et al., 1974). There has been an interaction proposed for
5-HT in the release of LH caused by LHRH. Martin, 'Engel and Klein
(1977) showed that 5-HT could cause a 40% decrease in the
concentration of LH released from neonatal rat pituitary glands in
response to LHRH in vitro. However, this effect was not specific
for 5-HT, since melatonin caused a 100% suppression of the release
of LH in response to LHRH stimulation.
An unconfirmed report by Kamberi et al. (1970) claimed that 5-HT
injected into a hypophysial portal vessel had no effect on
peripheral LH concentration, but that an i.e.v. injection of 5-HT
caused an inhibition of the release of LH, and concluded that 5-HT
did not have a direct effect on the pituitary gland to affect LH
release but did so instead by inhibiting the release of LHRH.
Schneider and McCann (1969) and Birge et al. (1970) found that 5-HT
had no effect on the release of LH from isolated pituitary glands in
vitro.
Both 5-HT and PCPA, an inhibitor of 5-HT synthesis, have been
shown to disrupt ovarian function and cause an inhibition of
ovulation by way of a decrease in peripheral steroid concentrations
(Wilson and Macdonald, 1974; Al Satli and Aron, 1981) caused by
vasoconstriction in the ovary (Wilson and Macdonald, 1974).
Although this may occur in the intact pro-oestrous animal it is
unlikely to be an important factor in the proposed studies since the
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effects of alaproclate in the male rat were of short duration, and a
change in peripheral steroid concentrations in the female rat is
unlikely to occur during this short period. Obviously, this effect
does not have to be considered when dealing with the experimental
models involving ovariectomized animals.
4.1.2 Involvement of serotonin in the release of prolactin
Although there is general agreement in the literature that 5-HT
stimulates the release of PRL, there is some dispute as to whether
this is due to the stimulation of the release of a PRF or to the
inhibition of the release of a PIF. There is evidence that 5-HT can
stimulate the release of an unspecified PRF (Clemens et a!., 1978;
Garthwaite and Hagen, 1979) and the release of TRH and VIP, both
proposed as possible PRFs, is stimulated by 5-HT (Chen and Ramirez,
1981; Shimatsu, Kato, Matsushita, Katakami, Yanaihara and Imura,
1982; Shimatsu et al., 1983). Dopamine, generally, but not
universally accepted as the major physiological PIF (Weiner and
Ganong, 1978; Leong et al., 1983), is decreased in portal plasma
after an i.e.v. injection of 5-HT (Pilotte and Porter, 1981) and PRL
in peripheral plasma is increased. However, although this result
indicates that 5-HT can inhibit the release of a presumed PIF, there
seems to be the additional involvement of a PRF since an
intra-atrial infusion of DA to give concentrations of DA equivalent
to those normally present in hypophysial portal plasma did not
prevent the 5-HT stimulated increase in the concentration of PRL in
peripheral plasma.
The mechanisms involved in the increase in PRL responsiveness of
the anterior pituitary gland are unknown. There does not appear to
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be a self-priming effect of a PRF, by analogy with LHRH, since
repeated administration of hypothalamic extracts to anterior
pituitary glands in short-term incubation in vitro did not increase
PRL responsiveness (Pickering and Fink, 1979). Although there are
suggestions of interactions between DA, oestrogen and a PRF to
increase PRL responsiveness (Leong et a!., 1983), there has so far
been no suggestion of a comparable interaction involving 5-HT.
Results from in vitro studies concerning a direct action of 5-HT
on the anterior pituitary gland have mainly been negative (Lamberts
and MacLeod, 1978; Delitala, Yeo, Stubbs, Jones and Besser, 1980)
but a very brief report by Fang (1976) claimed a stimulatory effect
of 5-HT on PRL release from anterior pituitary cells. The latter
report, must however, be accepted with caution, since the author
also claimed that 5-HIAA was more effective than 5-HT in the system
studied. It would seem unlikely that a neurotransmitter metabolite
would be more effective than the neurotransmitter itself on the
release of a hormone. A possible direct effect of 5-HT on the
release of PRL from the anterior pituitary gland has been shown in
vivo. Wehrenberg et al. (1980) found that 5-HT caused an increase
in the concentration of PRL in peripheral plasma in the
stalk-sectioned monkey and very recently Stobie and Shin (1983)
demonstrated that 5-HT could cause the release of PRL from an
ectopic pituitary gland implanted under the kidney capsule. It has
been suggested that the failure of 5-HT to cause any increase in PRL
secretion in vitro may be due to the presence of a very high release
of PRL upon which it is not possible to superimpose any further
stimulation. However in the in vivo studies quoted above(Wehrenberg
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et al. 1980; Stobie and Shin 1983), PRL release was high
and yet 5-HT caused further stimulation of release. An unconfirmed
report by Kamberi et al. (1971) stated that 5-HT injected directly
into a hypophysial portal vessel in an intact animal, had no effect
on peripheral PRL concentrations.
It has been claimed that 5-HT does not cross the blood-brain
barrier (Axelrod and Iscoe, 1963) and so studies showing an increase
in PRL concentrations in peripheral plasma after a systemic
injection of 5-HT (Lawson and Gala, 1975; Gala, Subramanian, Peters
and Pieper, 1977; Stevens and Lawson, 1977) could be interpreted as
a direct action of 5-HT acting directly on the anterior pituitary
gland. However, it does appear that 5-HT can cross the blood-brain
barrier (Bulat and Supek, 1968) and so these results must be
interpreted with care.
As was discussed for 5-HT and LH release, although steroids do
alter the release of PRL in response to 5-HT (Caligaris and
Taleisnik, 1974) it is unlikely that an alteration of steroid
concentrations caused by the vasoconstrictor action of 5-HT in the
ovary (Wilson and Macdonald, 1974) would be of significance in the
proposed studies.
4.1.3 Possible sites of action of serotonin
There is a large body of indirect evidence which is consistent
with an involvement of 5-HT in the release of LH and PRL from the
anterior pituitary gland. The uptake of 5-HT in hypothalamic slices
is significantly increased on the afternoon of pro-oestrus (Meyer
and Quay, 1976) and the number of 5-HT receptors in the basal
forebrain is decreased at a similar time .(Biegnon, Bercovitz and
-92-
Samuel, 1980). Recently it has been shown that tryptophan
hydroxylase activity in the dorsal raphe nuclei was decreased after
castration of adult male rats (Long and Youngblood, 1983). The ME
contains 5-HT (Baumgarten and Lachenmayer, 1974; Calas et al., 1974)
and in vitro can synthesize and release 5-HT (Hamon, Javoy, Kordon
and Glowinski, 1974). The anterior pituitary gland has been shown
to exhibit 5-HT immunofluorescence (Dahlstrom and Fuxe, 1965) and
5-HT has also been detected in pituitary tissue by a radioenzymatic
assay (Saavedra, Palkovits, Kizer, Brownstein and Zivin, 1975).
Cells of the anterior pituitary have the capacity to take up 5-HT
(Nunez, Gershon and Silverman 1981; Johns, Azmitia and Krieger
1982) and 5-HIAA has been reported to be present at a higher
concentration in hypophysial portal plasma than in peripheral plasma
(Johnston et al., 1983).
4.1.4 Proposed experimental studies
In addition to studies on the pro-oestrous rat and the two
experimental models described previously, studies were carried out
on the short-term ovariectomized rat treated with OB and P (Mann and
Barraclough, 1973; Fink and Henderson, 1977a,b) and the long-term
ovariectomized rat injected with OB followed by another injection of
OB 72h later (Brown-Grant, 1974). Very few studies have been
carried out on possible 5-HT involvement in the release of LH and
PRL in the short-term ovariectomized steroid-primed rat although
this is perhaps the model that most closely mimics the changes in
peripheral steroid concentration that occur in the intact animal
(Mann and Barraclough, 1973; Aiyer and Fink, 1974; Tapper, Grieg
and Brown-Grant, 1974; Sarkar and Fink, 1979). Studies were
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carried out on the long-term ovariectomized rat treated with 2
injections of OB 72h apart, because although there is an increase in
the release of LH and PRL after the second injection of OB, the LH
response has been reported to be of a smaller magnitude (Tapper et
al., 1974; Brown-Grant, 1974) and to involve different mechanisms
(Dyer and Mansfield, 1983) than the LH surges seen in long-term
ovariectomized animals, induced by an injection of OB followed by
P. The release of PRL in this model in response to a second
injection of either OB or P was also studied since this was not
measured in the studies of Tapper et al. (1974) or Brown-Grant
(1974).
4.2 MATERIALS AND METHODS
4.2.1 Animals
Animals used in this series of experiments were female Wistar
cobs (180-250g) maintained as described in section 2.1. Five
experimental models were studied,
i) the pro-oestrous rat (pro-oestrus was determined as in section
2.2.7).
ii) the short-term OVX female rat (2.2.9), injected with OB on the
day of OVX, dioestrus (day 1), and with P on the day of
presumptive pro-oestrus (day 2) "(Model 1).
iii) the long-term OVX female rat (2.2.9), injected with OB on day
1 and 72h later with P (day 4) (Model 2).
iv) the long-term OVX female rat (2.2.9), injected with two
injections of OB, one on day 1 and the next 72h later on day 4
(Model 3).
v) the long-term OVX female rat (2.2.9) injected with daily
injections of OB for 4 days (Model 4).
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4.2.2 Steroid treatments
Both steroids were kept as stock solutions in arachis oil, OB
at 100ug/ml and P at lOmg/ml and were injected s.c. (2.2.2.) into
the nape of the neck. Various combinations of surgery and steroid
treatment were studied;
i) Short term OVX rats were ovariectomized between 0630-0900h of
dioestrus (experimental day 1) and injected at 1200h with 20yg
OB. The next day (day 2), presumptive pro-oestrus, the
animals were injected at 1200h with 2mg P.
ii) Long term OVX rats were injected with 20yg OB at 1200h of
experimental day 1 and 72h later, (experimental day 4) either
with 2mg P, or 20yg OB.
iii) Long term OVX rats were injected daily with 20yg OB at 1200h
for 4 days.
4.2.3 Intra-atrial cannulation
Animals were cannulated (2.2.11) under halothane anaesthesia
between 0630-0900h either on day 1 of the experiment, (OVX animals),
or between 0630-0900h on the morning of pro-oestrus, and then caged
individually for the duration of the experiment.
4.2.4 Drug treatments and blood sampling
Alaproclate and zimelidine (2.2.3) were dissolved in 0.9% saline
immediately before use, and injected i.v. in a volume of 0.4-0.6ml
over a period of 2 min at doses and times stated in each
experiment. Control animals were injected with i.v. 0.4-0.6m1
saline.
Blood samples, 0.3ml, were taken using heparinized syringes at
times stated in each experiment and the plasma volume was maintained
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by replacing the withdrawn blood by an equal volume of 0.9% saline.
Samples were kept on ice until centrifuged at 2500g for 20 mins at
4°C. Plasma was removed and stored at -25°C until assayed for LH
and PRL.
4.2.5 Measurement of luteinizing hormone and prolactin
Concentrations of LH and PRL were measured using specific
RIAs (2.3).
4.2.6 Statistics
All data are presented as mean ± S.E.M. The significance of the
difference between two means was analysed using Students t-test.
The significance of differences between more than two means was
determined by analysis of variance and Duncan's multiple range test.
4.3 RESULTS
4.3.1 The effect of different doses and times of administration of
alaproclate on plasma luteinizing hormone and prolactin
concentrations in the pro-oestrous female rat
The i.v. injection of alaproclate at dosages of either 3mg/kg or
lOmg/kg at 1500h, had no effect on the plasma concentrations of
either LH or PRL in the pro-oestrous rat, but injection of 30mg
alaproclate/kg at this time caused a significant (p < 0.01), though
transient, decrease in PRL concentration 30 minutes after
administration (Table 4-1 and Fig. 4-1). The concentration of LH
was unaffected by any dose of alaproclate (Table 4-2 and Fig. 4-2).
t
When 30mg alaproclate/kg was injected i.v. into pro-oestrous
female rats at lOOOh there was no significant difference between
control and treated animals in either the morning low plasma
concentrations of PRL or in the higher (surge) afternoon








































































FIGURE 4-1 Mean (± S.E.M.) concentrations of prolactin in
peripheral plasma from pro-oestrous female rats at
various times after an i.v. injection of 30mg
alaproclate/kg at 1500h. Blood samples were removed
from conscious animals by way of an intra-atrial cannula
inserted between 0630-0830h on the morning of
pro-oestrus.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
alaproclate (n = 6)
**p < 0.01; level of significance of difference between
animals injected with alaproclate at 1500h
compared with animals injected with saline
at 1500h.


















































FIGURE 4-2 Mean (± S.E.M.) concentrations of luteinizing hormone
(LH) in peripheral plasma from pro-oestrous female rats
at various times after an i.v. injection of 30mg
alaproclate/kg at 1500h. Blood samples were removed
from conscious animals by way of an intra-atrial cannula
inserted between 0630-0830h on the morning of
pro-oestrus.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
alaproclate (n = 6)
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concentrations (Table 4-3). There were also no significant
differences in the morning or afternoon plasma LH concentrations
between control and treated animals (Table 4-4).
From these two studies it was decided that a dose of alaproclate
of 30mg/kg given at 1500h would be used in all other experiments.
4.3.2 The effect of alaproclate on plasma luteinizing hormone and
prolactin concentrations in the short-term ovariectomized rat
treated with oestradiol benzoate and progesterone (Model 1)
In'short term OVX rats treated with OB followed by P,
alaproclate, injected i.v. at a dose of 30mg/kg at 1500h on
experimental day 2 caused a significant decrease (p < 0.01) in the
concentration of plasma PRL 30 min later (Fig. 4-3). Figure 4-3
also shows that this difference between the control and experimental
animals although much smaller, was still significant (p < 0.05) at
1600h. The plasma concentrations of PRL in treated animals had
returned to control values by 1700h and there was no significant
difference between the maximum observed plasma concentrations of PRL.
The plasma concentration of LH at 1530h in alaproclate treated
animals was not significantly different from that in control animals
at 1530h (Fig. 4-4) but was significantly (p < 0.01) decreased
compared with that in control animals at 1600h. The decrease was
not sustained and there was no significant difference between the
maximum observed plasma concentrations of LH.
4.3.3 The effect of alaproclate on luteinizing hormone and
prolactin concentrations in the long-term ovariectomized rat
treated with oestradiol benzoate and progesterone (Model 2).
When alaproclate (30 mg/kg at 1500h on experimental day 4) was















































**p<0.01;levelofsignificancediffer ncbetweenanimalsnje t dithalaproclatet1500hcomparedwi animalsinjectedwithsalinet1500 .













































FIGURE 4-3 Mean (± S.E.M.) concentrations of prolactin in
peripheral plasma at various times after an i.v.
injection of 30mg alaproclate/kg at 1500h into
short-term ovariectomized rats treated with oestradiol
benzoate (OB) and progesterone (P). Animals were
injected s.c. with 20yg OB at 1200h on the day of
ovariectomy (dioestrus)and with 2mg P 24h later
(presumptive pro-oestrus). Alaproclate was injected at
1500h on presumptive pro-oestrus. Blood samples were
removed from conscious animals by way of an intra-atrial
cannula inserted at the time of ovariectomy (0630-0900h
on di oestrus).
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
alaproclate (n = 6)
*p < 0.05, **p < 0.01; levels of significance of
difference between animals injected with
alaproclate at 1500h compared with animals
injected with saline at 1500h.
 
FIGURE 4-4 Mean (± S.E.M.) concentrations of luteinzing hormone
(LH) in peripheral plasma at various times after an i.v.
injection of 30mg alaproclate/kg at 1500h into
short-term ovariectomized rats treated with oestradiol
benzoate (OB) and progesterone (P). Animals were
injected s.c. with 20pg OB at 1200h on the day of
ovariectomy and with 2mg P 24h later (presumptive
pro-oestrus). Alaproclate was injected at 1500h on
presumptive pro-oestrus. Blood samples were removed
from conscious animals by way of an intra-atrial cannula
inserted at the time of ovariectomy (0630-0900h on
dioestrus).
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
alaproclate (n = 6)
**p < 0.01; level of significance of
difference between animals injected with
alaproclate at 1500h compared with animals
injected with saline at 1500h.
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administered i.v. to long-term ovariectomized rats treated with OB
plus P, there were significant increases (p < 0.01) in plasma PRL
concentrations at 1700h and 1800h (Fig. 4-5). There was no
significant difference in the maximum observed PRL plasma
concentration between control and treated groups.
Alaproclate injection caused significant decreases (p < 0.01 and
< 0.05, respectively) in plasma LH concentrations in this model at
1600h and 1700h (Fig. 4-6). In this case there was also a
significant difference (p < 0.01) in the maximum concentration of
plasma LH measured.
4.3.4 The effect of alaproclate on plasma luteinizing hormone and
prolactin concentrations in the long-term ovariectomized
female rat treated with oestradiol benzoate (Model 3).
In long term OVX rats treated with OB and injected i.v. with 30
mg alaproclate/kg at 1500h on experimental day 4, there was a
significant (p < 0.02) decrease in the plasma concentration of PRL
30 min after injection, (Fig. 4-7). The decrease was not sustained
and there was no significant difference between the maximum observed
PRL concentrations.
There were no significant differences in either the plasma LH
concentrations compared with the control animals or in the maximum
observed plasma concentration of LH (Fig. 4-8).
4.3.5 The effect of alaproclate on plasma luteinizing hormone and
prolactin concentrations in long-term ovariectomized rats
injected with multiple doses of oestradiol benzoate (Model 4)
When 30mg alaproclate/kg was injected i.v. at 1500h into
long-term OVX rats that had been injected with daily doses of 20ug
^ 1500 1530 1600 1700 1800 1900
Alap. TIME ,hrs
Mean (± S.E.M.) concentrations of prolactin in
peripheral plasma at various times after an i.v.
injection of 30mg alaproclate/kg at 1500h into long-term
ovariectomized (OVX) rats treated with oestradiol
benzoate (OB) and progesterone (P). Long-term OVX
animals were injected s.c. with 20yg OB at 1200h on
experimental day 1 and 72h later (experimental day 4)
with 2mg P. Alaproclate was injected at 1500h on
experimental day 4. Blood samples were removed from
conscious animals by way of an intra-atrial cannula
inserted between 0900h - 1200h on experimental day 1.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
alaproclate (n = 6).
**p < 0.01; level of significance of difference between
animals injected with alaproclate at 1500h





FIGURE 4-6 Mean (± S.E.M.) concentrations of luteinizing hormone
(LH) in peripheral plasma at various times after an i.v.
injection of 30mg alaproclate/kg at 1500h into long-term
ovariectomized (OVX) rats treated with oestradiol
benzoate (OB) and progesterone (P). Long-term OVX
animals were injected s.c. with 20yg OB at 1200h on
experimental day 1 and 72h later (experimental day 4)
with 2mg P. Alaproclate was injected at 1500h on
experimental day 4. Blood samples were removed from
conscious animals by way of an intra-atrial cannula
inserted between 0900h - 1200h on experimental day 1.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
alaproclate (n = 6).
*p < 0.05, **p < 0.01; levels of significance of
difference between animals injected with
alaproclate at 1500h compared with animals
injected with saline at 1500h.
1500—
FIGURE 4-7 Mean (± S.E.M.) concentrations of prolactin in
peripheral plasma at various times after an i.v.
injection of 30mg alaproclate/kg at 1500h into long-term
ovariectomized (OVX) rats treated with oestradiol
benzoate (08) followed by another injection of OB.
Long-term OVX animals were injected s.c. with 20yg 08 at
1200h on experimental day 1 and 72h later (experimental
day 4) with another 20yg 08. Alaproclate was injected
at 1500h on experimental day 4. Blood samples were
removed from conscious animals by way of an intra-atrial
cannula inserted between 0900h - 1200h on experimental
day 1.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
alaproclate (n = 6).
FIGURE 4-8 Mean (± S.E.M.) concentrations of luteinizing hormone
(LH) in peripheral plasma at various times after an i.v.
injection of 30mg alaproclate/kg at 1500h into long-term
ovariectomized (OVX) rats treated with oestradiol
benzoate (08) followed by another injection of 08.
Long-term OVX animals were injected s.c. with 20yg 08 at
1200h on experimental day 1 and 72h later (experimental
day 4) with another 20yg 08. Alaproclate was injected
at 1500h on experimental day 4. Blood samples were
removed from conscious animals by way of an intra-atrial
cannula inserted between 0900h - 1200h on experimental
day 1.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
alaproclate (n = 6).
*p < 0.02; level of significance of difference between
animals injected with alaproclate at 1500h
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of OB for 4 days, there was a persistent significant decrease
(p < 0.01) in the concentration of PRL in plasma compared with
concentrations in rats that had been injected with saline at 1500h
(Fig. 4-9). There was no significant difference in the
concentration of LH in plasma from rats that had been injected with
alaproclate compared with animals that had been injected with saline
(Fig. 4-10).
4.3.6 Effect of zimelidine on plasma luteinizing hormone and
prolactin concentrations in the pro-oestrous rat and in
models 1 and 2
Zimelidine, injected i.v. at a dose of 20mg/kg at 1500h did not
cause any significant changes in the plasma concentrations of either
LH or PRL in either the pro-oestrous rat or experimental models 1
and 2 (Figs. 4-11 to 4-16). There was a trend towards a decreased
plasma PRL concentration in model 2 after zimelidine treatment (Fig.
4-15), but this was not significant.
4.4 DISCUSSION
The question as to whether 5-HT has a physiological role in the
control of the release of LH and PRL from the anterior pituitary
gland remains unanswered despite many years of intensive study
(Weiner and Ganong, 1978). Difficulties in interpretation of
results have arisen due to the large number of different animal
models studied (Fink, 1979), wide variation in the doses of 5-HT and
its precursors administered and the use of drugs which were thought
to act specifically on 5-HT systems but which on further study have
been found to have mixed actions (Douglas, 1975; Lamberts and
Macleod, 1978; Krulich, McCann and Mayfield, 1981).
FIGURE 4-9 Mean (± S.E.M.) concentrations of prolactin in
peripheral plasma at various times after an i.v.
injection of 30mg alaproclate/kg at 1500h, into
long-term ovariectomized (OVX) rats treated with
multiple injections of oestradiol benzoate (OB).
Long-term OVX animals were injected daily with 20yg OB
s.c. at 1200h for 4 days. Alaproclate was injected at
1500h on the 4th day of injection of OB.
Blood samples were removed from conscious animals by way
of an intra-atrial cannula inserted between 0900-1200h
on the first day of OB treatment.
Open bar = control group, animals injected with saline
(n = 6)
Closed bar = experimental group, animals injected with
alaproclate (n = 6)
*p < 0.05, **p < 0.01; levels of significance of
difference between animals injected with
alaproclate at 1500h compared with animals
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FIGURE 4-10 Mean (± S.E.M.) concentrations of luteinizing hormone
(LH) in peripheral plasma at various times after an i.v.
injection of 30mg alaproclate/kg at 1500h, into
long-term ovariectomized (OVX) rats treated with
multiple injections of oestradiol benzoate (OB).
Long-term OVX animals were injected daily with 20yg OB
s.c. at 1200h for 4 days. Alaproclate was injected at
1500h on the 4th day of injection of OB.
Blood samples were removed from conscious animals by way
of an intra-atrial cannula inserted between 0900-1200h
on the first day of OB treatment.
Open bar = control group, animals injected with saline
(n = 6)
Closed bar = experimental group, animals injected with


















FIGURE 4-11 Mean (± S.E.M.) concentrations of prolactin in
peripheral plasma from pro-oestrous female rats at
various times after an i.v. injection of 20mg
zimelidine/kg at 1500h. Blood samples were removed
from conscious animals by way of an intra-atrial cannula
inserted between 0630-0830h on the morning of
pro-oestrus.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
zimelidine (n = 6)
FIGURE 4-12 Mean (± S.E.M.) concentrations of luteinizing hormone
(LH) in peripheral plasma from pro-oestrous female rats
at various times after an i.v. injection of 20mg
zimelidine/kg at 1500h. Blood samples were removed
from conscious animals by way of an intra-atrial cannula
inserted between 0630-0830h on the morning of
pro-oestrus.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
zimelidine (n = 6)
FIGURE 4-13 Mean (± S.E.M.) concentrations of prolactin in
peripheral plasma at various times after an i.v.
injection of 20mg zimelidine/kg at 1500h into short-term
ovariectomized rats treated with oestradiol benzoate
(OB) and progesterone (P). Animals were injected s.c.
with 20ug OB at 1200h on the day of ovariectomy
(dioestrus) and with 2mg P 24h later (presumptive
pro-oestrus). Zimelidine was injected at 1500h on
presumptive pro-oestrus. Blood samples were removed
from conscious animals by way of an intra-atrial cannula,
inserted at the time of ovariectomy (0630-0900h on
dioestrus).
Open bar = control group, injected with saline (n = 6
Closed bar = experimental group, injected with
zimelidine (n = 6)
FIGURE 4-14 Mean (± S.E.M.) concentrations of luteinzing hormone
(LH) in peripheral plasma at various times after an iM.
injection of 20mg zimelidine/kg at 1500h into short-term
ovariectomized rats treated with oestradiol benzoate
(OB) and progesterone (P). Animals were injected s.c.
with 20yg OB at 1200h on the day of ovariectomy
(dioestrus) and with 2mg P 24h later (presumptive
pro-oestrus). Zimelidine was injected at 1500h on
presumptive pro-oestrus. Blood samples were removed
from conscious animals by way of an intra-atrial cannula,
inserted at the time of ovariectomy (0630-0900h on
dioestrus).
Open bar = control group, injected with saline (n = 6
Closed bar = experimental group, injected with
zimelidine (n = 6)
FIGURE 4-15 Mean (± S.E.M.) concentrations of prolactin in
peripheral plasma at various times after an i.v.
injection of 20mg zimelidine/kg at 1500h into long-term
ovariectomized (OVX) rats treated with oestradiol
benzoate (08) and progesterone (P). Long-term OVX
animals were injected s.c. with 20yg OB at 1200h on
experimental day 1 and 72h later (experimental day 4)
with 2mg P. Zimelidine was injected at 1500h on
experimental day 4. Blood samples were removed from
conscious animals by way of an intra-atrial cannula
inserted between 0900h - 1200h on experimental day 1.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
zimelidine (n = 6).
Zimel. TIME.hrs
FIGURE 4-16 Mean (± S.E.M.) concentrations of luteinizing hormone
(LH) in peripheral plasma at various times after an i.v.
injection of 20mg zimelidine/kg at 1500h into long-term
ovariectomized (OVX) rats treated with oestradiol
benzoate (08) and progesterone (P). Long-term OVX
animals were injected s.c. with 20ug OB at 1200h on
experimental day 1 and 72h later (experimental day 4)
with 2mg P. Zimelidine was injected at 1500h on
experimental day 4. Blood samples were removed from
conscious animals by way of an intra-atrial cannula
inserted between 0900h - 1200h on experimental day 1.
Open bar = control group, injected with saline (n = 6)
Closed bar = experimental group, injected with
zimelidine (n = 6).
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The present studies investigated the effect of two reportedly
specific inhibitors of 5-HT uptake, alaproclate and zimelidine (Ross
and Renyi, 1975a,b; Ross et al., 1975) on the concentrations of LH
and PRL in peripheral plasma in a number of different animal
models. It is known, particularly for LH, that the mechanisms
governing the concentrations of both of these hormones in peripheral
plasma are likely to differ in different experimental models
(Brown-Grant 1977; Henderson et al., 1977b; Fink, 1979b) and,
therefore, it was of interest to determine the effect of one
experimental manipulation, namely injection with an inhibitor of
5-HT uptake, on LH and PRL in a variety of animal models. It was
found that alaproclate, but not zimelidine, caused short-term
changes in the concentrations of both hormones, and that the changes
whether an increase or a decrease, were dependent upon the steroid
status of the animal (Figs. 4-1 to 4-15).
The supposition that alaproclate and zimelidine are selective
inhibitors of the uptake of 5-HT was based on studies carried out by
Astra in a number of in vivo and jji vitro systems. Slices of
hypothalamus removed from animals that had been injected in vivo
with alaproclate or zimelidine, had a significantly lower
3
accumulation of H-5-HT in vitro than slices of hypothalamus from
saline-injected control animals, and both drugs when added to
3
incubation media in vitro caused a significant decrease in H-5-HT
uptake into hypothalamic slices from untreated animals (Ross and
Renyi, 1975a,b). The effects of the two drugs on endocrine systems
have not been extensively studied. Male rats, injected i.p. with
doses of alaproclate ranging from 3-30mg/kg, showed increased
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concentrations of LH, PRL and corticosterone in peripheral plasma 2h
after injection (Astra, unpublished data). Similar effects were
seen after an injection of lOmg zimelidine/kg, although the
increases were apparent at 30 min after the injection (Fuxe, ftgren,
Everitt, Agnati, Eneroth, Gustafsson, Jonsson, Skett and Holm, 1977).
The animal models chosen for study in the present series of
experiments all show prominent surges of LH and PRL in peripheral
plasma as a consequence of increased peripheral concentrations of
oestrogen and/or progesterone (Fink, 1979a, b). The increases in
the plasma concentrations of LH are due to changes in the release of
LHRH and in pituitary responsiveness to LHRH (Aiyer, Fink and Greig,
1974; Aiyer et al., 1974; Aiyer et al., 1976; Sarkar, Chiappa,
Fink and Sherwood, 1976; Fink and Henderson, 1977a; Fink, 1979;
Sarkar and Fink, 1979). Although the PRL surge also involves
changes in the secretion of releasing and/or release-inhibiting
factors and changes in pituitary responsiveness to PRFs and PIFs
(Leong et al., 1983), the relative contribution of each of these
components is uncertain.
4.4.1 Changes in luteinizing hormone and prolactin caused by
inhibition of serotonin uptake
The initial experiments carried out on the intact pro-oestrous
rat indicated that the release of PRL could be inhibited by a high
dose of alaproclate (30mg/kg) injected at 1500h (a time near to the
initiation of the spontaneous surges of LH and PRL in the animals
used in these studies), but not at lOOOh (a time proposed as a
'critical period' for the activation of the release of LH; Coen and
Mackinnon, 1979), and that the release of LH was unaffected by an
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iinjection at either lOOOh or 1500h (Tables 4-1 to 4-4). These
results suggest that 5-HT is not involved in the spontaneous
pro-oestrous LH surge although there may be some involvement in the
release of PRL.
There was a significant decrease in the concentration of LH in
peripheral plasma after an i.v. injection of 30mg alaproclate/kg, in
model 1 (short-term OVX rat injected with OB and P), model 2
(long-term OVX rat injected with OB and P) and in model 4 (long-term
OVX rat injected daily with OB), although the decrease seen in model
4 was of a shorter duration than the decreases seen in models 1 and
2. It has been argued that the steroid status of model 1 mimics the
changes in steroid concentration occurring on dioestrus and
pro-oestrus and that similar mechanisms are involved in the
generation of the LH surge in these two systems (Fink, 1979a,b).
The results presented here are not consistent with this view, at
olafocloW ouc\<k vVs poss\V>W
least with respect to^ involvement 5-HT, since alaproclate
caused a decrease in the concentration of LH in peripheral plasma in
model 1 (Fig. 4-4) but had no effect on the plasma LH concentration
in the pro-oestrous animal.
It has been proposed that the mechanisms involved in the
generation of the LH surge in models 2 and 3 are only quantitatively
and not qualitatively different (Brown-Grant, 1974). The results of
the present studies indicate that this may not be so since
alaproclate caused a decrease in the concentration of LH in
peripheral plasma only in model 2 (OB + P) and not in model 3 (OB +
OB). A possible explanation for these differences may be the
finding of Franks, McElhone, Young, Kraulis and Ruf (1980) that the
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stimulatory effect of progesterone on LH in model 2 requires
activity of 5-HT systems. Unfortunately, these workers did not
investigate whether this was also true of the stimulatory effect of
a second injection of oestrogen in model 3. On the basis of
differences in the times at which stimulatory effects on LH can be
induced by OB and P in long-term ovariectomized rats, Dyer and
Mansfield (1983) have also postulated that the release of LH in
these two models is indeed controlled by different mechanisms.
Injection of alaproclate in model 4 had no effect on the
concentrations of LH in peripheral plasma (Fig. 4-10). It has been
claimed that 5-HT is stimulatory to LH in this model (He'ry et a!.,
1976) but this conclusion has been reached after interpretation of
results from experiments involving the injection of PCPA. This drug
has recently been shown to have mixed actions in vivo (Coen et al.,
1983) that may include the inhibition of the synthesis of
adrenaline, and it has been shown that this transmitter may be
involved in the generation of the LH surge, in addition to 5-HT
(Coen et al., 1983). This statement may be countered by the
observation than an injection of 5-HTP can restore the LH surge
(Hery et al., 1976; Coen and Mackinnon, 1979). However it has been
shown that catecholamine-containing terminals can take up 5-HTP
(Lichtensteiger, Muntzner and Langemann, 1967) and that 5-HTP can
displace catecholamines from nerve terminals (Ng, Chase, Colburn and
Copin 1972) and therefore, the restorative effects of exogenous
5-HTP, like the inhibitory effects of PCPA may not be specific for
5-HT containing neurons.
It is not possible to determine from the results of the present
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studies whether the uptake blocker is acting at the hypothalamic or
at the pituitary level since there was a decrease in LH
concentration in peripheral plasma in models which are thought to
involve different mechanisms to generate the LH surge . For
example, there was a decrease in the concentration of LH in
peripheral plasma in model 1 in which the LH surge is generated by
increases in both the release of LHRH and in pituitary
responsiveness, but there was also a decrease in model 2, in which
the LH surge is due primarily to an increase in pituitary
responsiveness (Fink, 1979b).
Although the results of the present studies tend to suggest that
the involvement of 5-HT in the generation of the LH surge is of a
minor degree, this conclusion must be reached tentatively since it
has been found in previous studies that uptake blockers when
injected alone have very little effect on LH release (Ruszas,
Limonta and Martini, 1982) and require additional injection of 5-HTP
before any effects are seen.
4.4.2 Changes in prolactin caused by inhibition of serotonin uptake
The surge of PRL occurring in these models has not been as
intensively studied as the surge of LH, and where it has been
examined, most workers have examined models 2 and 4. Results of the
majority of reported studies are consistent with 5-HT stimulating
the release of PRL (Weiner and Ganong, 1978). Injection of 30mg
alaproclate/kg caused a short-term decrease in the concentration of
PRL in peripheral plasma in all models studied except model 2 where
PRL concentrations were sustained above those in animals injected
with saline throughout the period of the experiment (Fig. 4-5). The
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latter result could be interpreted to mean that 5-HT stimulates PRL
release. However, on the assumption that the uptake blocker was
causing an increased stimulation by 5-HT of post-synaptic neurons
(Fuller, Perry and Molloy, 1974), the other results of the present
studies indicate that 5-HT may be inhibiting the release of PRL.
Although this is in direct opposition to the prevailing view in the
literature, it would appear that previous studies should be
re-examined, particularly as discussed previously, those involving
the use of PCPA and 5-HTP or 5-HT (Caligaris and Taleisnik, 1974;
Lawson and Gala, 1975).
Zimelidine, injected at a dose equipotent to alaproclate, did
not cause any significant changes in the concentrations of LH and
PRL in peripheral plasma in any of the animal models studied. This
was unexpected as zimelidine, and particularly its active metabolite
norzimelidine, has been found to be a more potent inhibitor of 5-HT
uptake in vitro than alaproclate (Fuxe et al., 1977). However,
underestimated, since it has been shown to be more potent than
zimelidine in behavioural studies (Fuxe et al., 1977). More
recently, it has been reported that zimelidine had no effect on
endocrine function in man (Syvlahti, Nagy and Van Praag, 1979;
Kletzky, St.Michel, Maschak and Coleman, 1983). Another possibility
may be that zimelidine is not as specific as has been thought
(Harms, 1983) and that the drug may have mixed actions on other
systems, particularly noradrenergic and cholinergic (Astra,
unpublished data), which may be in direct opposition to effects
that the potency of al
SosVen\S
there are indications ave been
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caused by inhibition of 5-HT uptake, causing no net changes to be
observed i_n_ vivo.
The results of the studies reported here, cannot be interpreted
fully without some knowledge as to the concentrations of 5-HT and
5-HIAA in the brain after the injection of the uptake blocker.
There is the possibility of both increased and decreased 5-HT
transmission occurring after injection of such a drug (Fuller et
al., 1974) and the next chapter details the changes in the
concentrations of 5-HT and 5-HIAA in the brains of a few of these
animal models after injection of alaproclate, in an attempt to
correlate these with the observed changes in hormone concentration
in peripheral plasma.
CHAPTER 5
The Effects of Inhibition of the Uptake of Serotonin
3
on the Concentration of Serotonin and 5-HydroxJndole Acetic Acid
in the Brains of Various Animal Models
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5.1 INTRODUCTION
The studies presented in Chapter 4 indicate that there may be
some involvement of 5-HT in the release of LH and PRL from the
anterior pituitary gland, and that the degree of involvement may
depend upon the steroid status of the animal. As was stated in
Chapter 4, it is difficult to interpret the results of the studies
reported therein without some knowledge of the degree of possible
changes in 5-HT function that could be induced by the steroid
treatments or any changes that may occur subsequent to the injection
of an inhibitor of 5-HT uptake.
Although studies concerning direct effects of steroids on 5-HT
metabolism in vivo have yielded conflicting results (Munaro, 1978;
Crowley, O'Donohue, Muth and Jacobowitz, 1979; Cone, Davis and Goy,
1981; Di Paolo, Daigle, Picard and Barden, 1983) there is
suggestive evidence from in vivo and in vitro studies that there are
interactions between ovarian steroids and 5-HT systems in the
brain. The uptake of 5-HT in brain is increased at times coincident
with the surge of LH on the afternoon of pro-oestrus (Quay, 1968;
Hery et al., 1972) and this effect has been localized to the
hypothalamus, particularly to the SCN (Meyer and Quay, 1976; Hery et
al., 1982; Hery, Dusticier and Calas, 1982), a site in which there
is a high density of 5-HT containing terminals (Saavedra et al.,
1974; Descarries and Beaudet, 1978; Steinbusch, 1981) and which is
thought to be important in the maintenance of circadian rhythms
(Moore, 1978). The decrease in the number of 5-HT receptors in the
basal forebrain on the afternoon of pro-oestrus (Biegnon et al.,
1980) may depend upon an increased peripheral concentration of
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oestrogen (Biegnon and McEwen, 1982). Studies in vitro have shown
3
that the accumulation of H-5-HT into hypothalamic slices can be
inhibited by incubation with physiologically relevant concentrations
of oestrogen and progesterone (Endersby and Wilson, 1974).
The experiments reported in this chapter were therefore carried
out to determine a) whether the different steroid status' of the
animal models studied induced any significant changes in the
concentration of 5-HT and its major metabolite, 5-HIAA, in brain,
and b) whether the different animal models showed any differences in
the concentrations of 5-HT and 5-HIAA in brain after injection of a
5-HT reuptake blocker at times during which changes in the
concentrations of LH and PRL in peripheral plasma had been observed
(Chapter 4).
Three types of animal model were studied in this series of
experiments; the pro-oestrous female rat, model 1 (see Chapter 4)
and model 2 (see Chapter 4). These three models were chosen since
there is increasing evidence for an interaction between 5-HT and
progesterone in the control of neuroendocrine function (Munaro,
1978; Franks et al., 1980; Walker, 1983; Walker and Wilson, 1983)
whereas evidence for a possible interaction between oestrogen and
5-HT is as yet less convincing (Crowley et al., 1979; Cone et al.,
1981).
The concentrations of 5-HT and 5-HIAA were measured
simultaneously in tissue from 5-HT terminal areas, AH and PH,
(Steinbusch, 1981) and an area containing 5-HT cell-bodies, R,
(Steinbusch, 1981) using an HPLC-LCED system described in detail in
section 2.4. The HPLC-LCED system used allowed the simultaneous
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determination of the concentrations of NA, OA and DOPAC in the same
samples and these are also reported.
5.2 MATERIALS AND METHODS
5.2.1 Animals and drugs
Animals used in this series of experiments were male and female
Wistar cobs (180-250g) maintained as described in section 2.1. The
experimental models studied are described in detail in section 4.1.2
and were:
i) the male rat
ii) the pro-oestrous female rat
iii) the short term OVX female rat (2.2.9) treated with OB and P
(Model 1)
iv) the long term OVX female rat (2.2.9) treated with OB and P
(Model 2)
Animals were cannulated (2.2.11) either on day 1 of the
experiment (male animals and ovariectomized animals) or on the
morning of pro-oestrus, and then caged individually for the duration
of the experiment.
Alaproclate and zimelidine were dissolved in 0.9% saline
immediately before use and injected i.v. as described in section
4.2.4. Parachlorophenylalanine was dissolved in 0.9% saline,
neutralized with 5M ^HPO^, and injected i.p. in a volume of
0.4ml of buffered saline. Control animals were injected i.v. with
0.4ml buffered saline or 0.4ml 0.9% saline at times appropriate for
each experiment.
5.2.2 Detection of monoamines and their metabolites
Animals were killed 30 min after injection of alaproclate or
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zimelidine, and brains rapidly removed and placed on ice. Anterior
(r\=ao)
hypothalamus (AH) (3.10 ± 0.15 mg) ,i posterior hypothalamus (PH)
(17.70 ± 0.28mg) and raphe nuclei (R) (17.24 ± 0.43mg) were
dissected out (2.2.5) and homogenized in 75 yl, 150yl and 150yl of
homogenization buffer (2.4.2.4) respectively. After the homogenates
had been centrifuged and filtered (2.4.2.4), supernatants were kept
on ice until injected into the HPLC-LCED system.
The concentrations of catechol- and indoleamines and their
metabolites in the supernatants were measured using the HPLC-LCED
system described in detail in section 2.4.
5.2.3 Statistics
All data are presented as mean ± S.E.M. The significance of the
difference between two means was measured using Students t-test.
The significance of differences between more than two means was
determined by analysis of variance and Duncan's multiple range test.
5.3 RESULTS
5.3.1 The concentrations of catecholamines and indoleamines and
their metabolites in the brain of the male rat after an
injection of alaproclate
When male rats were injected i.v. at llOOh with 30mg
alaproclate/kg and killed 30 min later, the concentration of 5-HT
was slightly increased and the concentration of 5-HIAA was slightly
decreased in the three areas of brain studied (Table 5-1) but these
differences were not significant when compared with control rats
which had been injected i.v. with saline. The ratio of 5-HIAA/5-HT
concentration was significantly decreased (p < 0.05) in all three
areas when compared with control values (Table 5-1).
TABLE 5-1
Mean (± S.E.M.) concentrations (ng/mg wet wt) of serotonin (5-HT),
5-hydroxyindoleacetic acid (5-HIAA) and the 5-HIAA/5-HT ratio in
anterior hypothalamus (AH), posterior hypothalamus (PH) and raphe
(R) in male rats injected i.p. with saline (Sal.) or
parachlorophenylalanine (PCPA) and 72h later injected i.v. with
saline or alaproclate (Alap.). Animals were cannulated between
0630-0900h on the morning of the day of the i.v. injection and were
killed 30 min after the i.v. injection of saline or Alap. (n = 3).
(N.O. = undetectable at a lower limit of sensitivity of 15pg).
Treatment Area 5-HT 5-HIAA 5-HIAA/5-HT
Sal. + Sal. AH 1.18 ± 0.24 0.33 ± 0.03 0.30 ± 0.04
Sal. + Alap. AH 1.55 ± 0.26 0.24 ± 0.014 0.16 ± 0.02*
Sal. + Sal. PH 1.42 ± 0.18 0.29 * 0.05 0.20 ± 0.01
Sal. + Alap. PH 1.43 ± 0.03 0.20 ± 0.017 0.14 ± 0.01*
Sal. + Sal. R 1.95,1.44 0.88,0.65 0.31,,0.,33
Sal. + Alap. R 2.60 ± 0.12 0.64 ± 0.04 0.26 ± 0.01*
PCPA + Sal. AH N.D.** N.D.**
PCPA + Al ap. AH N.D.** N.D.**
PCPA + Sal. PH 0.14 ± 0.01** 0.08 ± 0.01** 0.44 ± 0.20
PCPA + Alap. PH 0.17 ± 0.01** 0.06 ± 0.01 0.48 ± 0.20
PCPA + Sal. R 0.39 ± 0.02** 0.27 ± 0.04** 0.69 ± 0.10**
PCPA + Alap. R 0.38 ± 0.07** 0.27 ± 0.02** 0.71 ± 0.15**
* p < 0.05; level of significance of difference between animals
injected with saline and then 72h later with
alaproclate compared with animals injected with saline
and then 72h later with another injection of saline.
**p < 0.01; level of significance of difference between animals
injected 72h previously with saline compared with
animals injected 72h previously with PCPA.
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There were no significant differences between control animals
and animals injected with alaproclate in the concentrations of NA,
OA or DOPAC in any of the three areas (Table 5-2).
5.3.2 Depletion of 5-HT and 5-HIAA in the brain of the male rat
after an injection of parachlorophenylalanine and the effect
of a subsequent injection of alaproclate
When male rats were killed 72h after an i.p. injection of 300mg
PCPA/kg there was a total depletion of 5-HT and 5-HIAA in the AH and
marked reductions in the concentrations of both compounds in PH and
R when compared with control rats (Table 5-1) which had been
injected with buffered saline 72h previously. There was no
significant difference between control animals and animals that had
been injected with PCPA in the 5-HIAA/5-HT ratios in PH (Table 5-1),
but there was a significant increase (p < 0.01) in R.
Table 5-1 shows that when male rats injected 72h previously with
PCPA, were injected i.v. at HOOh (30 min before killing) with 30mg
alaproclate/kg there were no significant differences in either 5-HT
or 5-HIAA concentrations in or R compared
with control animals that had been injected with PCPA and saline.
There were also no significant differences in the 5-HIAA/5-HT ratios
in PH or R in animals that had been injected with
PCPA and alaproclate compared with the ratios either in animals that
had been injected with PCPA and saline or animals that had been
injected with saline alone (Table 5-1).
The concentrations of NA, DA and DOPAC in any of the three areas
were not significantly different in any of the four groups of
animals (Table 5-2).
TABLE 5-2
Mean (± S.E.M.) concentrations (ng/mg wet wt) of noradrenaline (NA),
dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) in anterior
hypothalamus (AH), posterior hypothalamus (PH) and raphe (R) in male
rats injected i.p. with either saline (Sal.) or
parachlorophenylalanine (PCPA) and then 72h later injected i.v. with
either saline or alaproclate (Alap.). Animals were implanted with
an intra-atrial cannula on the morning of the day of the injection
with alaproclate. Animals were decapitated 30 min after the
injection of alaproclate. (N.D. = undetectable at a lower limit of
sensitivity of 15pg).
Treatment Brain NA DA DOPAC
Area
Sal. + Sal. AH 1.53 ± 0.10 0.42 0.03 N.D.
Sal. + Alap. AH 1.47 ± 0.20 0.46 ± 0.03 N.D.
Sal. + Sal. PH 1.89 ± 0.08 0.74 ± 0.05 N.D.
Sal. + Alap. PH 1.94 ± 0.04 0.65 ± 0.03 N.D.
Sal. + Sal. R 0.74 ± 0.10 0.78 ± 0.07 0.16 ± 0.03
Sal. + Alap. R 0.63 ± 0.06 0.69 ± 0.09 0.16 ± 0.05
PCPA + Sal. AH , 1.60 ± 0.13 0.53 ± 0.05 N.D.
PCPA + Alap. AH 1.66 ± 0.08 0.51 ± 0.06 N.D.
PCPA + Sal. PH 2.34 ± 0.13 0.87 ± 0.04 N.D.
PCPA + Alap. PH 2.63 ± 0.22 0.78 ± 0.02 N.D.
PCPA + Sal. R 0.80 ± 0.03 0.80 ± 0.06 0.15 ± 0.005
PCPA + Al ap. R 0.72 ± 0.02 0.78 ± 0.04 0.16 ± 0.03
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5.3.3 The effect of alaproclate on the concentrations of
catecholamines and indoleamines and their metabolites in the
brains of various animal models
i) The pro-oestrous female rat
An i.v. injection of 30mg alaproclate/kg at 1500h on the
afternoon of pro-oestrus caused a small increase in the
concentration of 5-HT in PH and R, a small decrease in^5-HT
concentration in AH and a small decrease in the concentration of
5-HIAA in all three areas 30 min later (Table 5-3). These
differences were not significant when compared with control animals
in pro-oestrus that had been injected with saline. The 5-HIAA/5-HT
ratio was significantly decreased (p < 0.01) compared with control
animals in PH and R (Table 5-3).
There were no significant differences in the concentrations of
NA, DA or DOPAC in any of the three areas (Table 5-4) between
control animals and animals that had been injected with alaproclate.
ii) The short term ovariectomized female rat treated with
oestradiol benzoate and progesterone (model 1)
Table 5-5 shows that when short term ovariectomized female rats
(model 1) treated with OB and P were injected i.v. with 30mg
alaproclate/kg at 1500h on experimental day 2, the concentration of
5-HT was slightly decreased in AH and slightly increased in PH and
R, and the concentration of 5-HIAA was slightly decreased in all
three areas, but these differences were not significant when
compared with the values in rats that had been injected i.v. with
saline. There were significant decreases (p < 0.01) in the
5-HIAA/5-HT ratios in PH and R in animals injected with alaproclate
TABLE 5-3
Mean (± S.E.M.) concentrations (ng/mg wet wt) of serotonin (5-HT)
and 5-hydroxyindoleacetic acid (5-HIAA), and ratio of 5-HIAA/5-HT in
anterior hypothalamus (AH), posterior hypothalamus (PH) and
raphe (R), 30 min after an i.v. injection of 30mg alaproclate/kg
(Alap.) or saline at 1500h on the afternoon of pro-oestrus (n =9).
Alaproclate was injected i.v. into conscious animals by way of an
intra-atrial cannula inserted between 0630-0830h on the morning of
pro-oestrus and animals were decapitated 30 min after injection of
alaproclate.
Treatment Brain 5-HT 5-HIAA 5-HIAA/5-HT
Area
Saline AH 1.77 ± 0.22 0.45 ± 0.04 0.27 ± 0.02
Alap. AH 1.54 ± 0.44 0.38 ± 0.04 0.23 ± 0.02
Saline PH 1.54 ± 0.09 0.29 ± 0.02 0.18 ± 0.01
Alap. PH 1.79 ± 0.18 0.24 ± 0.03 0.13 ± 0.01**
Saline R 2.26 ± 0.11 0.73 ± 0.04 0.30 ± 0.01
Alap. R 2.48 ± 0.13 0.64 ± 0.06 0.25 ± 0.01**
** p < 0.01; level of significance of difference between animals
injected with alaproclate at 1500h compared with
animals injected with saline at 1500h.
TABLE 5-4
Mean (± S.E.M.) concentrations (ng/mg wet wt) of noradrenaline (NA),
dihydroxyphenylacetic acid (DOPAC) and dopamine (DA) in anterior
hypothalamus (AH), posterior hypothalamus (PH) and raphe (R) 30 min
after an i.v. injection of 30mg a!aproclate/kg (Alap.) or saline at
1500h on the afternoon of pro-oestrus.
Alaproclate was injected i.v. into conscious animals by way of an
intra-atrial cannula inserted between 0630-0830h on the morning of
pro-oestrus and animals were decapitated 30 min after the injection





Saline AH 2.62 ± 0.31 0.56 ± 0.09 N.D.
Alap. AH 2.13 ± 0.22 0.54 ± 0.07 N.D.
Saline PH 2.22 * 0.19 0.71 ± 0.04 0.09 * 0.01
Alap. PH 2.37 ± 0.13 0.67 ± 0.03 0.07 ± 0.01
Saline R 0.77 ± 0.04 0.64 ± 0.04 0.14 ± 0.01
Alap. R 0.74 ± 0.07 0.56 ± 0.03 0.16 ± 0.01
TABLE 5-5
Mean (± S.E.M.) concentrations (ng/mg wet wt.) of serotonin (5-HT)
and 5-hydroxyindoleacetic acid (5-HIAA), and the ratio of
5-HIAA/5-HT in anterior hypothalamus (AH), posterior hypothalamus
(PH) and raphe (R), 30 min after an i.v. injection of 30mg
alaproclate/kg (Alap.) or saline into short-term ovariectomized rats
treated with oestradiol benzoate (08) and progesterone (P) (n =
9). Animals were ovariectomized between 0630-0830h on dioestrus
(day 1), injected s.c. with 20ug OB at 1200h on day 1 and with 2mg P
at 1200h on day 2 (presumptive pro-oestrus). Alaproclate was
injected i.v. into conscious animals at 1500h on day 2 by way of an
intra-atrial cannula inserted on day 1, and animals were decapitated
30 min after the injection of alaproclate.
Treatment Brain 5-HT 5-HIAA 5HIAA/5-HT
Area
Saline AH 1.86 ± 0.36 0.45 0.09 0.27 0.03
Alap. AH 1.70 ± 0.12 0.42 ± 0.04 0.22 ± 0.02
Saline PH 1.68 ± 0.12 0.33 ± 0.04 0.20 ± 0.01
Alap. PH 1.86 ± 0.03 0.26 ± 0.007 0.14 ± 0.005**
Saline R 2.46 0.30 0.90 ± 0.12 0.37 ± 0.02
Alap. R 2.50 ± 0.10 0.82 ± 0.15 0.28 ± 0.01**
** p < 0.01; level of significance of difference between animals
injected with alaproclate at 1500h compared with
animals injected with saline at 1500h.
TABLE 5-6
Mean (± S.E.M.) concentrations (ng/mg wet wt) of noradrenaline (NA),
dopamine (DA) and dihydroxyphenyl acetic acid (DOPAC) in anterior
hypothalamus (AH), posterior hypothalamus (PH) and raphe (R) 30 min
after an i.v. injection of 30mg alaproclate/kg (Alap.) or saline
into short-term ovariectomized rats treated with oestradiol benzoate
(OB) and progesterone (P) (n = 9). Animals were ovariectomized
between 0630-0830h on dioestrus (day 1), and injected s.c. with 20yg
OB at 1200h on day 1 and with 2mg P at 1200h on day 2 (presumptive
pro-oestrus). Alaproclate was injected i.v. into conscious animals
at 1500h on day 2 by way of an intra-atrial cannula inserted on day
1, and animals were decapitated 30 min after the injection of
alaproclate. (N.D. - not detectable at lower limit of sensitivity
= 15pg).
Treatment Brain NA DA DOPAC
Area
Saline AH 1.61 ± 0.22 0.37 ± 0.06 N.D.
Al ap. AH 1.69 ± 0.13 0.32 ± 0.02 N.D.
Saline PH 1.92 ± 0.13 0.61 ± 0.04 N.D.
Alap. PH 1.80 ± 0.11 0.61 ± 0.08 N.D.
Saline R 0.62 ± 0.02 0.59 0.03 0.13 ± 0.01
Alap. R 0.55 ± 0.02 0.55 ± 0.03 0.16 ± 0.02
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when compared with control animals (Table 5-5). Noradrenaline, DA
and DOPAC concentrations in any of the three areas were not
significantly different between control animals and animals that had
been injected with alaproclate (Table 5-6).
iii) The long term ovariectomized female rat treated with
oestradiol benzoate and progesterone (model 2)
When long term ovariectomized rats treated with 08 and P were
injected i.v. with 30mg alaproclate/kg at 1500h on experimental day
4, there were small increases in 5-HT concentration in all three
areas studied and a small increase in AH and small decreases in PH
and R in 5-HIAA concentration (Table 5-7), but these changes were
not significant when compared with control rats. The 5-HIAA/5-HT
ratio was significantly decreased (p < 0.01) in the R 'Table 5-7).
There were no significant differences in NA, DA or DOPAC
concentrations in any of the three areas between control animals and
animals that had been injected with alaproclate (Table 5-8).
5.3.4 The effect of zimelidine on the concentrations of
catecholamines and indoleamines and their metabolites in the
brain of the long term ovariectomized female rat treated with
oestradiol benzoate and progesterone (model 2)
Table 5-9 shows that an i.v. injection of 20mg zimelidine/kg at
1500h on experimental day 4 into long term ovariectomized rats
treated with OB and P caused small increases in 5-HT concentrations
and small decreases in 5-HIAA concentrations in all three areas
studied, but that these differences were not significant when
compared with control animals. There was no significant difference
in the 5-HIAA/5-HT ratio in any of the three areas when animals
TABLE 5-7
Mean (± S.E.M.) concentrations (ng/mg wet wt) of serotonin (5-HT)
and 5-hydroxyindoleacetic acid (5-HIAA), and the ratio of
5-HIAA/5-HT in anterior hypothalamus (AH), posterior hypothalamus
(PH) and raphe (R) 30 min after an i.v. injection of 30mg
alaproclate/kg (Alap.) or saline into long-term ovariectomized rats
treated with oestradiol benzoate (OB) and progesterone (P) (n =
9). Long-term ovariectomized animals were injected s.c. with 20pg
OB at 1200h on day 1 and with 2mg P 72h later on day 4.
Alaproclate was injected i.v. into conscious animals by way of an
intra-atrial cannula, inserted on day 1, and animals were
decapitated 30 min after the injection of alaproclate.
Treatment Brain 5-HT 5-HIAA 5-HIAA/5-HT
Area
Saline AH 1.37 0.13 0.38 ± 0.04 0.31 £ 0.03
Alap. AH 1.90 ± 0;28 0.44 ± 0.08 0.23 ± 0.02
Saline PH 1.84 ± 0.12 0.27 ± 0.018 0.15 ± 0.01
Alap. PH 1.97 ± 0.16 0.25 ± 0.015 0.13 ± 0.006
Saline R 2.61 ± 0.22 0.78 ± 0.06 0.30 ± 0.017
Al ap. R 2.52 ± 0.20 0.60 ± 0.05 0.24 ± 0.007**
** p < 0.01; level of significance of difference between animals
injected with alaproclate at 1500h compared with animals
injected with saline at 1500h.
TABLE 5-8
Mean (± S.E.M.) concentrations (ng/mg wet wt) of noradrenaline (NA),
dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) in anterior
hypothalamus (AH), posterior hypothalamus (PH) and raphe (R) 30 min
after an i.v. injection of 30mg alaproclate/kg (Alap.) or saline
into long-term ovariectomized rats treated with oestradiol benzoate
(OB) and progesterone (P) (n = 9). Long-term ovariectomized
animals were injected s.c. with 20yg OB at 1200h on day 1 and with
2mg P 72h later on day 4. Alaproclate was injected i.v. into
conscious animals by way of an intra-atrial cannula, inserted on day
1, and animals were decapitated 30 min after the injection of
alaproclate. (N.D. - not detectable at a lower limit of
sensitivity = 15pg).
Treatment Brain NA DA DOPAC
Area
Saline AH 1.92 ± 0.12 0.37 ± 0.05 N.D.
Alap. AH 1.89 ± 0.24 0.51 ± 0.07 N.D.
Saline PH 1.97 ± 0.19 0.73 ± 0.04 N.D.
Alap. PH 2.03 ± 0.20 0.78 ± 0.06 N.D.
Saline R 0.62 ± 0.05 0.65 ± 0.03 0.11 ± 0.009
Alap. R 0.53 ± 0.05 0.60 ± 0.015 0.11 ± 0.01
TABLE 5-9
Mean (± S.E.M.) concentrations (ng/mg wet wt) of serotonin (5-HT)
and 5-hydroxyindoleacetic acid (5-HIAA) and the ratio of 5-HIAA/5-HT
in anterior hypothalamus (AH), posterior hypothalamus (PH) and raphe
(R) 30 min after an i.v. injection of 20mg zimelidine/kg (Zimel.) or
saline into long-term ovariectomized rats treated with oestradiol
benzoate (OB) and progesterone (P) (n = 9). Long-term
ovariectomized animals were injected s.c. with 20yg OB at 1200h on
day 1 and with 2mg P 72h later on day 4. Zimelidine was injected
i.v. into conscious animals by way of an intra-atrial cannula,
inserted on day 1, and animals were decapitated 30 min after the
injection of zimelidine.
Treatment Brain 5-HT 5-HIAA 5-HIAA/5-HT
Area
Saline AH 0.99 ± 0.20 0.58 0.06 0.61 0.08
Zimel. AH 1.05 ± 0.24 0.51 ± 0.08 0.57 ± 0.07
Saline PH 1.62 ± 0.07 0.57 ± 0.05 0.35 ± 0.02
Zimel. PH 1.70 ± 0.35 0.47 ± 0.05 0.31 ± 0.01
Saline R 1.92 ± 0.12 1.09 ± 0.10 0.58 ± 0.06
Zimel. R 2.11 ± 0.20 0.92 ± 0.08 0.44 ± 0.04
TABLE 5-10
Mean (± S.E.M.) concentrations (ng/mg wet wt) of noradrenaline (NA),
dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) in anterior
hypothalamus (AH), posterior hypothalamus (PH) and raphe (R) 30 min
after an i.v. injection of 20mg zimelidine/kg (Zimel.) or saline
into long-term ovariectomized rats treated with oestradiol benzoate
(OB) and progesterone (P) (n = 9). Long-term ovariectomized
animals were injected s.c. with 20vg OB at 1200h on day 1 and with
2mg P 72h later on day 4. Zimelidine was injected i.v. into
conscious animals by way of an intra-atrial cannula, inserted on day
1, and animals were decapitated 30 min after the injection of
zimelidine.






2.68 ± 0.21 0.41 ± 0.11 0.08 * 0.009





1.83 ± 0.16 0.59 ± 0.03 0.06 ± 0.007
1.84 ± 0.15 0.65 ± 0.05 0.08 ± 0.008
Saline R 0.69 ± 0.06 0.64 ± 0.10 0.10 ± 0.01
Zimel. R 0.72 ± 0.06 0.61 ± 0.09 0.11 ± 0.01
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injected with zimelidine were compared with control animals
(Table 5-9).
The concentrations of NA, DA and DOPAC in any of the three areas
were not significantly different in animals injected with zimelidine
when compared with control animals (Table 5-10).
5.4 DISCUSSION
The results of the present studies showed that 30 min after the
injection of an inhibitor of 5-HT uptake there were small but
significant decreases in the 5-HIAA/5-HT ratio in various regions of
the brain in the pro-oestrous animal, in animal model 1 and in
animal model 2 (Tables 5-3, 5-5 and 5-7). The greatest changes in
the concentration of LH and PRL in peripheral plasma had been seen,
in most cases, 30 min after the injection (see Chapter 4).
The concentration of 5-HT measured in the three areas of brain
in the present studies was comparable to that reported by Crowley et
al. (1979), Cone et al. (1981) and Di Paolo et al. (1983). The
concentration of 5-HIAA measured in the present studies was lower
than that reported by Di Paolo et al. (1983). This difference is
not due to differences in the detection systems, since both studies
used HPLC-LCED, but is likely to be due to differences in
dissection. Microdissection of hypothalamic and raphe nuclei, as
used by Di Paolo et al. (1983), is a more precise technique than the
gross dissection carried out in the present studies, since any
'dilution' of 5-HT and its metabolites by areas of brain devoid of
5-HT is avoided. In the studies cited (Crowley et al., 1979; Cone
et al., 1981; Di Paolo et al., 1983), the concentration of 5-HT and
5-HIAA was much higher in brain areas containing raphe nuclei than
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in hypothalamic areas and this was confirmed in the present
experiments.
Although there were also significant differences between AH, PH
and R in the concentrations of NA, DA and DOPAC (Tables 5-4, 5-6 and
5-8) there did not appear to be any significant differences between
the three different models in the concentrations of these
neurotransmitters in the three areas studied. This is perhaps not
surprising since it has frequently been argued that a static
measurement of neurotransmitter concentration gives very little
indication concerning its functional activity or the control of its
metabolism (Weiner, 1974).
It has been reported that^after blockade of 5-HT uptake j_n vivo,
the concentration of 5-HIAA is decreased (Fuller et al., 1974;
Hyttel, 1977) and this was confirmed in the experiments reported
here (Tables 5-3, 5-5 and 5-7). In contrast to reports stating that
there is no change in the concentration of 5-HT until some time
after the injection of a reuptake blocker (Fuller et al., 1974),
there was a trend towards an increase in the concentration of 5-HT
in the present studies. This observation is, however, in agreement
with a report by Halaris, Lovell and Freedman, (1973) which showed
an increase in the concentration of 5-HT Ih after injection of an
inhibitor of 5-HT uptake, followed some hours later by a decrease.
Unfortunately, it was not possible to study the effect of
alaproclate on the concentration of 5-HT in brain at later periods
after the injection.
The changes in the concentrations of 5-HIAA and 5-HT, although
not significant by themselves, accounted for significant decreases
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in the ratio of 5-HIAA/5-HT. This decrease would be expected after
the inhibition of 5-HT reuptake in vivo since 5-HIAA is formed
intraneuronally from 5-HT which has been released and taken back up
into the pre-synaptic neuron (Reinhard and Wurtman, 1977) and
therefore if reuptake is blocked, the concentrations of 5-HIAA and
5-HT would fall and rise respectively and this would be reflected in
a decreased 5-HIAA/5-HT ratio. It cannot be concluded from the
present results whether the net change in the ratio of 5-HIAA/5-HT
is due solely to the inhibition of 5-HT reuptake since there are
other compensatory mechanisms which may come into effect after the
inhibition of reuptake that may also cause changes in this ratio
(Tozer, Neff and Brodie, 1966). There is unlikely to have been any
alteration in the synthesis of 5-HT over the short time-period of
the experiment through changes in tryptophan hydroxylase, since this
enzyme has been shown to have a relatively long half-life (Meeks and
Nett, 1972), and to be resistant to short-term changes (Kizer,
Palkovits, Zivin, Brownstein, Saavedra and Kopin, 1974; Palkovits
et a!., 1976). There is however a possibility that a block of
reuptake could have caused a decrease in neuronal firing (Sheard,
Zolovick and Aghajanian, 1972; Clemens et al., 1977) by a direct
pre-synaptic effect of 5-HT (Gothert and Weinheimer, 1979) and hence
a decrease in the release of 5-HT and a consequential decrease in
the concentration of 5-HIAA. This idea is supported by the
observation that in the studies reported here, there were no
significant changes in the ratio of 5-HIAA/5-HT in the anterior
'tn (Wvcxle rabr
hypothalamic area^where it has been reported that there were no
changes in neuronal firing rate after injection of an inhibitor of
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5-HT uptake (Clemens et al., 1977) but there were significant
changes in R, where there were also changes in firing rate (Clemens
et al., 1977). However, there was no significant change in the
concentration of 5-HT in either of these areas. The observed
decreases in the 5-HIAA/5-HT ratio could also result from an
inhibition of MAO, but this is under the present
circumstances as alaproclate has not been reported to inhibit MAO.
As has already been stated, there were no significant
differences in the concentrations of 5-HT or 5-HIAA in the three
brain regions in any of the animal models, but there were
differences between the models in the areas in which there was a
significant change in the ratio of 5-HIAA/5-HT (Tables5-Wo). The
most obvious difference between the three models is the absence of
(-Vo-WS-l)
any change in the ratio of 5-HIAA/5-HT in the PH in model 2. Since
this was the only model not to show a decrease in the concentration
of PRL in peripheral plasma after alaproclate (Tables5-M0 and
Fig. 4-7) and to show in fact a PRL surge sustained above the values
seen in control animals, this may be a significant correlation. It
is difficult to explain why there was no change seen in the ratio of
5-HIAA/5-HT in the PH in model 2 after alaproclate. If there had
been no change in the 5-HIAA/5-HT ratio in R and no changes in PRL,
it could be suggested that this model is resistant to alaproclate.
However, PRL was raised significantly in this model at 1700h and
1800h which suggests that the neurons in this area show a delayed
response to alaproclate by way of a decrease in turnover so causing
the increase in PRL seen at later stages. Obviously this suggestion
requires verification by measuring the ratio of 5-HIAA/5-HT at these
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later times.
The AH region of the present study contains the SCN, an area of
brain that has been postulated to be important in the control of the
rhythmic release of LH and PRL (Dunn et al., 1980; Hery et al.,
1982) and to be modulated by input from the raphe nuclei (Van de Kar
and Lorens, 1979; Van de Kar and Bethea, 1982). The fact that there
_ Pe-i^vAe,
was no change in the 5-HIAA/5-HT ratio in AH in any^model after
alaproclate at a time at which there were changes in both PH and R
suggests that neurons in this area may respond differently to
alaproclate. It has recently been proposed (Long, Youngblood and
Kizer, 1983) that there are regional differences in the response of
5-HT neurons in the rat CNS to drugs affecting 5-HT function.
Since the changes seen in these models were so small, the
question was posed as to whether the effects of an inhibitor of 5-HT
reuptake could not be better distinguished against a much smaller
functional pool of 5-HT. To answer this question, male rats were
first injected with PCPA, and 72h later with alaproclate.
Surprisingly, while alaproclate caused small decreases in the ratio
of 5-HIAA/5-HT in the normal male rat (Table 5-1), in the male rat
injected with PCPA and in which the concentrations of 5-HT and
5-HIAA were severely depleted, there was no change in the ratio of
5-HIAA/5-HT (Table 5-1). This may indicate that the 'functional
pool1 of 5-HT (Shields and Eccleston, 1973; Morot-Gaundry, Bourgoin
and Hamon, 1981) in the animal treated with PCPA is so severely
depleted that 5-HT is released at such a slow rate that any effect
of a reuptake blocker is not seen.
-118-
Zimelidine, that had no effect on LH and PRL in any of the
animal models tested (Chapter 4) also had no effect on the
concentrations of 5-HT or 5-HIAA or the ratio of 5-HIAA/5-HT in the
three brain regions in model 2. These two results suggest that
although zimelidine is a potent inhibitor of the uptake of 5-HT in
vitro (Ross et al., 1976) it may require prolonged exposure before
any effects are observed jn_ vivo.
The results presented in this chapter and in Chapter 4 are
consistent with a possible involvement of 5-HT in the release of LH
and PRL as induced by steroid hormones but do not show clearly the
degree or direction of this involvement. This is also true of the
published work in this area, where much confusion has been
generated, particularly by the use of drugs whose specificity of
action can be questioned. Indeed, Krulich et al. (1981) reached
the conclusion that "because of the dual nature of the
PRL—inhibiting mechanism of methysergide and metergoline (two
supposed blockers of 5-HT receptors), combined possibly with other
actions, the serotonin receptor blockers have limited value in
studies concerning the role of the central serotonergic system in
the regulation of PRL secretion". This claim is probably also
applicable to many other drugs used in the study of 5-HT function
and so results of pharmacological studies must be accepted with some
caution.
Due to uncertainty regarding the effect of alaproclate on
systems other than 5-HT, it must be emphasised that the results
reported in Chapters 4 and 5 may be due to other actions of
alaproclate on neurotransmitter systems which were not measured.
CHAPTER 6
The Effects of Inhibition of the Synthesis of Serotonin
on the Concentration of Luteinizing Hormone and Prolactin
in Plasma in the Pro-oestrous Rat
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6.1 INTRODUCTION
The injection of animals with PCPA, an inhibitor of tryptophan
hydroxylase (Koe and Weissman, 1966) has been reported to block the
LH surge and ovulation in the pro-oestrous rat and the LH surge in
the long-term ovariectomized rat treated with exogenous steroids
(Hery et a!., 1976; Coen and Mackinnon, 1979, 1980), supposedly by
way of its action to deplete 5-HT in the brain (Miller and Cox,
1970; Sloviter, Drust and Connor, 1978). However, other treatments
designed to deplete 5-HT in the brain, such as i.e.v. injections of
serotonin neurotoxins had no effect on the pre-ovulatory surges of
LH and PRL (Wuttke et a!., 1978). Paradoxically it has also been
reported that increased peripheral concentrations of 5-HT, achieved
by injections of either 5-HT or 5-HTP, can block ovulation, but this
has been stated to be due to a peripheral vasoconstrictor action of
5-HT leading to decreased release of ovarian steroids (Wilson and
Macdonald, 1974). Recent work has implied that PCPA may have mixed
actions in vivo and that any effects of the drug may be due either
to unspecified actions on the ovary (A1 Sat 1i and Aron, 1981) or to
disruption of central or peripheral adrenergic activity (Coen et
al., 1983).
In contrast to the number of studies concerned with the
investigation of a possible 5-HT component of the pro-oestrous surge
of LH, there is a lack of information concerning the possible
involvement of this system in the surge of PRL on pro-oestrus. In
particular, the effect of PCPA on this surge does not appear to have
been investigated. Complementing the studies in Chapter 4 using
5-HT uptake blockers, the present study set out to determine whether
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the inhibition of the LH surge seen after treatment with PCPA (Coen
and Mackinnon, 1980) was accompanied by an inhibition of the PRL
surge and if there was any inhibition, whether this could be due to
a peripheral action of PCPA resulting in an altered secretion of
oestradiol-17s by the ovary.
6.2 MATERIALS AND METHODS
6.2.1 Animals
All animals used in this study were female Wistar cobs
(180-200g) maintained as in section 2.1.
Animals were cannulated (2.2.11) under halothane anaesthesia
between 0630-0900h on the morning of pro-oestrus. After recovery,
animals were caged singly for the duration of the experiment.
Parachlorophenylalanine was dissolved in 0.9% saline and brought
to pH 6.0 by the addition of 5M ^HPO^. It was administered at
a dose of 200mg/kg in 0.4ml buffered saline s.c. at 1200h on
dioestrus. Control animals were injected with 0.4ml of buffered
saline s.c. at 1200h of dioestrus.
Blood samples were taken as described in section 2.2.11 at times
stated in each experiment.
6.2.2 Luteinizing hormone, prolactin and oestradiol-17g measurements
0estradiol-17s was measured by RIA (2.3) in plasma remaining
from samples after LH and PRL had been assayed. Due to the small
amount of plasma left after assay for LH and PRL, all the plasma
remaining in a set of samples from each animal was pooled into one
aliquot and 0E measured in this aliquot.
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6.3- RESULTS
6.3.1 The effect of parachlorophenylalanine on prolactin
concentration in peripheral plasma in the pro-oestrous
female rat
Figure 6-1 shows that treatment with 200mg PCPA/kg at 1200h on
dioestrus markedly reduced (p < 0.001) the height of the afternoon
surge of PRL in the plasma of a group of pro-oestrous rats compared
with that in a control group of pro-oestrous rats injected with
saline. Another group of pro-oestrous rats, although also
simil arly treated with 200mg PCPA/kg showed surges of plasma PRL
that were not significantly different from those in the control rats
(Fig. 6-1).
There was no significant difference in the morning concentration
of PRL in plasma in any of the three groups.
6.3.2 The effect of parachlorophenylalanine on luteinizing hormone
concentration in peripheral plasma in the pro-oestrous female
rat
Figure 6-2 shows that the LH surge was blocked completely in the
PCPA-treated animals that had shown reduced surges of plasma PRL.
Plasma LH concentrations were also markedly reduced compared with
control animals in those PCPA-treated animals that had shown normal
surges of plasma PRL (Fig. 6-2).
6.3.3 The effect of parachlorophenylalanine on oestradiol-178
concentration in peripheral plasma in the pro-oestrous female
rat
CK
b basis of whether or not animals treated with PCPA showed surge of PRL, the animals were
A
ivided into three groups. In the PCPA-treated animals not showing a PRL surge,
FIGURE 6-1 Mean (± S.E.M.) concentrations (ng/ml) of prolactin in
peripheral plasma during the afternoon of pro-oestrus
from female rats injected s.c. with either saline or
200mg parachlorophenylalanine (PCPA)/kg at 1200h on
dioestrus. Blood samples were withdrawn from an
intra-atrial cannula inserted between 0630-0830h on the
morning of pro-oestrus.
Open bar = animals injected with saline at 1200h on
dioestrus, and with peripheral
oestradiol-17s (OE) concentration > 60pg/ml
piasma (n = 9).
Hatched bar = animals injected with PCPA at 1200h on
dioestrus, and with peripheral OE
concentration > 30pg/ml plasma but < 60pg/ml
piasma (n = 4).
Cross-hatched bar = animals injected with PCPA at 1200h
on dioestrus and with peripheral OE
concentration < 30pg/ml plasma (n = 6).
**p < 0.01; level of significance of difference between
animals injected with PCPA at 1200h on
dioestrus and with peripheral OE
concentration < 30pg/ml plasma compared both
with animals injected with saline (OE
concentration > 60pg/ml plasma) and with
animals injected with PCPA (OE concentration
> 30pg/ml plasma but < 60pg/ml plasma).
 
FIGURE 6-2 Mean (± S.E.M.) concentrations (ng/ml) of luteir^ing
hormone (LH) in peripheral plasma during the afternoon
of pro-oestrus from female rats injected s.c. with
either saline or 200mg parachlorophenylalanine (PCPA)/kg
at 1200h on dioestrus. Blood samples were withdrawn
from an intra-atrial cannula inserted between 0630-0830h
on the morning of pro-oestrus.
Open bar = animals injected with saline at 1200h on
dioestrus, and with peripheral
oestradiol-17& (OE) concentration > 60pg/ml
plasma (n = 9).
Hatched bar = animals injected with PCPA at 1200h on
dioestrus, and with peripheral OE
concentration > 30pg/ml plasma but < 60pg/ml
piasma (n = 4).
Cross-hatched bar = animals injected with PCPA at 1200h
on dioestrus and with peripheral OE
concentration < 30pg/ml plasma (n = 6) lower
limit of sensitivity of LH radioimmunoassay.
**p < 0.01; level of significance of difference between
animals injected with PCPA at 1200h on
dioestrus and with peripheral OE
concentration < 30pg/ml plasma compared both
with animals injected with saline (OE
concentration > 60pg/ml plasma) and with
animals injected with PCPA (OE concentration

























FIGURE 6-3 Mean (± S.E.M.) concentrations (pg/ml) of oestradiol-17g
(OE) in peripheral plasma on the afternoon of
pro-oestrus from female rats injected s.c. with 200mg
parachlorophenylalanine (PCPA)/kg at 1200h on
dioestrus. Plasma remaining in samples after
measurement of luteinizing hormone and prolactin was
pooled and OE measured in these pooled aliquots for each
animal.
Open bar = animals injected s.c. with saline at 1200h on
dioestrus and showing surges of both LH and
PRL (n =9).
Hatched bar = animals injected s.c. with PCPA at 1200h on
dioestrus and in which the LH surge but not
the PRL surge was abolished (n = 4).
Cross-Hatched bar = animals injected s.c. with PCPA at
1200h on dioestrus and in which both the LH
and PRL surges were abolished (n = 6).
*p < 0.02; level of significance of difference between
animals injected with PCPA at 1200h on
dioestrus and in which the LH and PRL surges
were abolished compared with animals
injected with saline.
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the OE values were significantly lower (p < 0.02) than those in
control animals. Plasma concentrations of OE in PCPA-treated
animals which did show a PRL surge fell in between the values of the
control group and the values in the PCPA-treated animals that did
not show a PRL surge. There was a significant correlation (r =
0.70, p < 0.01) between the peak concentration of PRL and the
concentration of OE in peripheral plasma (Figs. 6-1 and 6-3).
6.4 DISCUSSION
In the present study, and in agreement with other workers (Coen
and Mackinnon, 1980) it was found that an s.c. injection of PCPA
(Koe and Weissman, 1966) caused a complete abolition of the
pre-ovulatory surge of LH in the pro-oestrous female rat
(Fig. 6-2). In addition to this finding, it was also discovered
that the pre-ovulatory surge of PRL was inhibited, but not in all
animals injected with PCPA (Fig. 6-1). Subsequent analysis of the
concentration of OE in peripheral plasma revealed that the
concentrations of OE in animals in which the surge of PRL was
abolished by PCPA, were significantly lower (Fig. 6-3) than those in
animals injected wth buffered saline which showed a marked surge of
PRL.
This study reveals two new findings. Firstly, the pre-ovulatory
surge of PRL in peripheral plasma, like the pre-ovulatory LH surge
can be abolished by a s.c. injection of PCPA. It cannot be stated
from the present studies whether this is due solely to a depletion
of 5-HT in the brain since the concentration of 5-HT in brain after
the PCPA injection was not measured in this study. However, there
was likely to have been a significant reduction (Chapter 5). There
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was a significant decrease in the concentration of OE in peripheral
plasma from animals in which the PRL surge was absent, which may
have been due to peripheral effects of PCPA, and this indirect
effect may have resulted in the abolition of the surges of both LH
and PRL. It has been claimed that the effects of PCPA on the ovary
that lead to decreased peripheral concentrations of OE can be
avoided by administering the drug s.c. rather than i.p. (Coen and
Mackinnon, 1980), but the present study shows that these effects are
still present after an s.c. injection. It has been found that rats
*
exhibit massive abdominal lesions after both i.p. and s.c.
injections of PCPA (Watts, A.G. personal communication).
The concentration of P in peripheral plasma was not measured in
the present study, but it is likely that this was affected by the
injection of PCPA since some animals that had been injected with
PCPA but were not included in the hormonal study, showed vaginal
indications of pseudopregnancy after the injection of PCPA,
indicating that a disruption of ovarian activity had occurred. It
has been reported that PCPA can induce pseudopregnancy
(Gonzalez-Baron, Jimenez-Vargas and Marco, 1975), and in the study
of Coen and Mackinnon (1980) one animal that had been injected i.p.
with PCPA on dioestrus showed an increased peripheral concentration
of P 12h later, consistent with the induction of pseudopregnancy.
The second main finding of this study was the presence of a
difference in the threshold of the peripheral concentration of OE
required for expression of the surges of LH and PRL in the intact
pro-oestrous animal. In animals in which the concentration of OE
in peripheral plasma was < 30pg/ml both the LH and the PRL surges
*The gut wall of these animals showed gross oedema and haemorrhage.
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were abolished. However, in animals in which the concentration of
OE was > 35pg/ml, but < 60pg/ml only the LH and not the PRL surge
was abolished. Animals injected with buffered saline had OE
concentrations > 60pg/ml and exhibited surges of both LH and PRL.
Although it has been reported in the ovariectomized animal that
there is a threshold concentration of OE which must be reached
before LH secretion is increased (Henderson et al., 1977a; Krey and
Parsons, 1982), and that this threshold may be higher than that
required for the induction of the release of PRL (Caligaris et al.,
1971; Caligaris et al., 1974) there does not appear to be any
indication in the literature that this is also true of the intact
pro-oestrous animal.
The present results indicate that PCPA has severe effects on
peripheral organs, and the results of these effects may be
misinterpreted as being due to an inhibition of 5-HT transmission in
the CNS. As has been discussed previously, the drastic and mixed
actions of this compound (Coen et al., 1983) indicate that




The Effects of an Injection of Anti-TRH Serum on the Concentration
of Prolactin in Plasma in the Pro-oestrous Rat
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7.1 INTRODUCTION
The release of PRL from the anterior pituitary gland is thought
to be controlled by many different factors under different
physiological conditions (MacLeod, 1976; Vale et a!., 1980; Leong
et al., 1983). A bewildering array of substance have been reported
to cause release of PRL from the anterior pituitary gland by a
direct action on the gland itself, including TRH (Tashjian et al.,
1971), 5-HT (Wehrenberg et al., 1980), oestradiol (Zyzek et al.,
1981), LHRH (Denef, 1981), VP (Shin, 1982), somatostatin (Vale et
al., 1974) vasoactive intestinal polypeptide (Ruberg, Rotsztejn,
Arancibia, Besson and Enjalbert, 1978) and numerous other
neuropeptides and neurotransmitters (Lien, Fenichel, Garsky,
Sarantakis and Grant, 1976; Grandison and Guidotti, 1977; Vijayan
and McCann, 1979; Malarkey, O'Dorisio, Kennedy and Cataland, 1981).
Thyrotrophin-releasing hormone, besides its role in the
regulation of TSH secretion, has been shown to release PRL from the
anterior pituitary gland in a number of species (Jacobs, Snyder,
Wilber, Utiger, Utiger and Daughaday, 1971; Fell, Findlay, Cumming
and Goding, 1973; Kelly, Bedirian, Baker and Friesen, 1973) under
circumstances in which TSH release is unchanged (Gautvik, Tashjian,
Kourides, Weintraub, Graeber, Maloof, Suzuki, Zuckerman, 1974) but
its role in PRL secretion in the rat is controversial. While there
is some evidence for the involvement of TRH in the suckling-induced
rise in plasma PRL in the rat (Blake, 1974; de Greef and Visser,
1981; Fink, Koch and Ben Aroya, 1983) its role in the release of
PRL under other conditions is not clear. It has been reported that
TRH can release PRL in a number of experimental models (Mueller,
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Chen and Meites, 1973; D'Angelo, Wall, Bowers and Rosa, 1975;
Lawson, Gala, Chin and Haislender, 1980) and that the concentration
of TRH in hypophysial plasma is increased on the afternoon of
pro-oestrus (Fink et al., 1983), a time at which the concentration
of PRL, but not of TSH, in peripheral plasma is increased (Smith,
Freeman and Neill, 1975; Fukuda, Greer, Roberts, Allen, Critchlow
and Wilson, 1975). It has been claimed that differences in the
response of TSH and PRL to TRH may be due to differences in the
responsiveness of mammotrophs and thyrotrophs (DeLean et al., 1977;
Leong et al., 1983). However, the changes in pituitary
responsiveness to TRH do not appear to be mediated by TRH itself (De
Lean et al., 1977; Pickering and Fink, 1979). Thyrotrophin
releasing hormone can release PRL from rat pituitary
tumour cells in vitro (Tashjian et al., 1971) but appears to have
rather a minor effect on PRL release from normal rat pituitary cells
both in vitro and in vivo (Lu, Shaar, Kortright and Meites, 1972;
Vale, Blackwell, Grant and Guillemin, 1973; Hill —Samli and MacLeod,
1974; Rivier and Vale, 1974).
In the study reported here, the technique of passive
immunization (injection of an animal with antiserum, raised in
another species, against an antigen from the antiserum recipient)
has been used to investigate the involvement of TRH in the PRL surge
occurring on the afternoon of pro-oestrus in the female rat. This
technique has been used to identify the main physiological action of
various hormones including those released by the hypothalamus
(Shani, Goldhaber and Sulman, 1975; Arimura, Smith and Schally,
1976; McCormack, Plant, Hess and Knobil, 1977; Robinson and
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Parsons, 1981) but experiments designed using this technique to
elucidate the involvement of TRH in the release of PRL into plasma
have yielded contradictory results (Koch, Goldhaber, Fireman, Zor,
Shani and Tal, 1977; Harris, Christianson, Smith, Fang, Braverman
and Vagenakis, 1978).
7.2 MATERIALS AND METHODS
7.2.1 Animals
Animals used in these studies were female Wistar cobs,
(200-300g) maintained as described in section 2.11. Only those
animals that had shown at least 2 consecutive 4 day oestrous cycles
were used. Animals were cannulated (2.2.11) under halothane
anaesthesia between 0630-0830h on the morning of pro-oestrus, and,
after recovery, were placed in individual cages for the duration of
the experiment.
Experimental animals were injected i.p. with 1ml of undiluted
anti-TRH serum at 1300h. Control animals were injected with 1ml
of undiluted normal sheep serum (NSS) i.p. at 1300h.
Anti-TRH serum (donated by Dr. H. Fraser, MRC Reproductive
Biology Unit; Edinburgh) was raised by immunizing sheep with TRH
conjugated with BSA. Sheep were injected at 4 s.c. sites with 1ml
of a solution containing 6mg TRH/BSA conjugate in 10ml of saline,
emulsified in 16ml Freund's complete adjuvant. Booster injections
were given at 3-monthly intervals (Fraser and McNeilly, 1982). The
particular antiserum used in these experiments showed a sensitivity
of 0.3pg/tube when used in an RIA for TRH. Specificity of the
antiserum is shown in Table 7-1.
TABLE 7-1
Cross reactivity of thyrotrophin-releasing hormone(TRH)
and its analogues with anti-TRH serum used in these studies.


















Substance P < 0.005
8-endorphin < 0.005
Reprinted by kind permission of Dr. H. Fraser, MRC Reproductive
Biology Unit, Edinburgh.
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7.2.2 Collection of blood samples and assaying of hormones
Blood samples, (0.4ml), were taken (2.2.11) using heparinized
syringes, 3h and 5 min before administration of sera, and every hour
after administration of sera, until 1900h. Plasma volume was
maintained by replacing the volume of blood removed with an equal
volume of heparinized (100IU/ml) 0.9% saline solution after each
sampling.
Samples were kept on ice until centrifuged at 2500g for 20 min
at 4°C. Plasma was removed and stored at -25°C until assayed for
PRL, LH and thyroid stimulating hormone (TSH).
Due to the small amount of plasma left after assay for LH and
PRL, TSH estimates were carried out on pooled plasma samples,
designated as:
i) Pre-treatment - plasma obtained before administration of sera:
lOOOh and 1255h samples pooled,
ii) Post-treatment(l) - plasma obtained after administration of
sera: 1400h, 1500h and 1600h samples
pooled.
iii) Post-treatment (2) - plasma obtained after administration of
sera: 1700h, 1800h and 1900h samples
pooled.
PRL, LH and TSH concentrations were all determined by
double-antibody radioimmunoassay (RIA) as described in Chapter 2
7.2.3 Statistics
Concentrations of PRL, LH and TSH were expressed as mean - SEM.
Student's t-test was used to determine significance of difference
between two means. In cases where the values for LH and PRL
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concentrations were below the lower limit of detection of the RIA, a
value equal to the lower limit of detection of the assay was
assigned and the difference between groups determined by
non-parametric statistics, using either the Mann-Whitney or Kruskal
Wall is tests.
7.3 RESULTS
7.3.1 Effect of anti-TRH serum on plasma concentrations of
prolactin in the pro-oestrous female rat.
Administration of 1ml of anti-TRH serum at 1300h to pro-oestrous
female rats caused a delay in the onset of the PRL surge. The
concentrations of PRL in plasma from animals injected with anti-TRH
serum at 1300h were significantly lower at 1400h and 1500h (p < 0.01
and p < 0.05, respectively) than those in pro-oestrous animals
injected with 1.0ml NSS (Fig. 7-1). There was no difference in the
maximum concentration of PRL.
7.3.2 Effect of anti-TRH serum on plasma concentrations of
luteinizing hormone in the pro-oestrous female rat
There were no significant differences in plasma LH
concentrations between the two groups of animals at any time nor was
there any significant difference between the maximum concentration
of plasma LH or the time at which the maximum concentration was
reached (Fig. 7-2).
7.3.3 Effect of anti-TRH serum on plasma concentrations of thyroid
stimulating hormone in the pro-oestrous female rat
In animals injected with anti-TRH serum, plasma TSH
concentrations were significantly decreased at 1400-1600h and at
1700-1900h compared with the concentrations before the anti-TRH
2500—1
2000—
FIGURE 7-1 Mean (± S.E.M.) concentrations (ng/ml) of prolactin in
peripheral plasma during the afternoon of pro-oestrus
from animals injected i.p. either with normal sheep
serum (NSS) or anti-TRH serum at 1300h on pro-oestrus.
Blood samples were removed by way of an intra-atrial
cannula inserted between 0630-0830h on the morning of
pro-oestrus.
Open bar = animals injected i.p. with NSS (n = 6)
Closed bar = animals injected i.p. with anti-TRH serum
(n = 6)
(AS = antiserum)
*p < 0.05, **p < 0.01; level of significance of
difference between animals injected with
anti-TRH serum at 1300h compared with
animals injected with NSS at 1300h.
40—
FIGURE 7-2 Mean (±S.E.M.) concentrations (ng/ml) of luteinizing
hormone (LH) in peripheral plasma during the afternoon
of pro-oestrus from animals injected i.p. either with
normal sheep serum (NSS) or anti-TRH serum at 1300h on
pro-oestrus. Blood samples were removed by way of an
intra-atrial cannula inserted between 0630-0830h on the
morning of pro-oestrus.
Open bar = animals injected i.p. with NSS (n = 6)




serum was injected, and the concentrations in the plasma of animals
treated with NSS (Table 7-2).
Plasma concentrations of TSH in the afternoon in animals
injected with NSS were not significantly different from the values
in the morning (Table 7-2).
7.4 DISCUSSION
There is considerable evidence that TRH, in addition to its role
in mediating the neural control of TSH, can release PRL from the
anterior pituitary gland. The results of the present study showed
that an i.p. injection of anti-TRH serum at 1300h caused a delay in
the onset of the PRL surge in a group of pro-oestrous rats compared
with the time of onset in a group of rats injected with NSS
(Fig. 7-1). The delay was manifested as a significant decrease (p
< 0.01) in the plasma PRL concentration at 1400h and 1500h in the
animals injected with anti-TRH serum compared with those injected
with NSS. By 1600h, the plasma concentration of PRL in the animals
injected with anti-TRH serum had reached the same value as those
injected with NSS, and this was probably not due to degradation of
(Fctxser
the antiserum as the half-life in plasma is approximately 10 days.
\
Other studies carried out on concentrations of TSH and PRL in plasma
after passive-immunization have yielded conflicting results. Koch
et al. (1977), reported a decrease in the concentrations of both TSH
and PRL at 1500h in plasma from pro-oestrous animals that had been
injected i.p. with 1.0ml of an anti-TRH serum. However, in a more
complete study, Harris et al. (1978), found a decrease-in plasma TSH
concentration, without any accompanying change in plasma PRL
concentration, at 1300h, 1500h and 1700h on pro-oestrus after an
TABLE 7-2
Mean (± S.E.M.) concentrationNof thyroid stimulating
hormone (TSH) after i.p. injection of normal sheep
serum (NSS) or anti-TRH serum
(n) Pre-treatment Post-treatment(1) Post-treatment(2)
Anti-TRH (6) 1.08 ± 0.13(A) 0.59 ± 0.15(B) 0.53 ± 0.09(C)
serum
NSS (4) 0.91 ± 0.30(D) 1.46 ± 0.15(E) 1.07 ± 0.08(F)
(A) vs (B), 0.025 < p < 0.0125,
(A) vs (C), "
(B) vs (E), 0.005 < p < 0.0025





Pre-treatment = plasma obtained before administration of sera:
lOOOh and 1255h samples pooled.
Post-treatment (1) = plasma obtained after administration of sera:
1400h, 1500h and 1600h samples pooled.
Post-treatment (2) = plasma obtained after administration of sera:
1700h, 1800h and 1900h samples pooled.
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i.v. injection of 0.1ml of an anti-TRH serum at 1230h. The
discrepancy between the results of the present study and those of
Harris et al. (1978) could be due to a number of factors. The most
obvious are differences between the two antisera used. Harris et
al. (1978) used a much smaller volume of antiserum (0.1ml, against
1.0ml used in the present study) which when used in a RIA had a
lower limit of detection of 2pg (Vagenakis, Roti, Mannix and
Braverman, 1975). The antiserum used in the study reported here
showed a lower limit of detection of 0.3pg when used in a RIA
(Fraser and McNeilly, 1982). The smaller volume of antiserum of
lower affinity may not have been sufficient to remove all of the TRH
present in hypophysial portal blood (Wilber and Porter, 1970;
Eskay, Oliver, Ben-Jonathan and Porter, 1978; Fink et al., 1983)
allowing enough TRH to reach the lactotrophs of the anterior
pituitary gland and cause release of PRL. It is also possible that
any changes occurring in PRL concentrations in plasma after the
injection of anti-TRH serum in the study of Harris et al. (1978)
were not seen due to infrequent sampling of blood. Prolactin
secretion has been shown to be pulsatile (Leighton, McNeilly and
Chard, 1976; Saunders, Terry, Audet, Brazeau and Martin, 1976;
Shin and Reifel, 1981) and any short-term changes occurring in
plasma PRL concentration after the suppression of releasing or
release-inhibiting factors may be masked by this pulsatile release
>
and so, not be apparent during infrequent blood sampling.
Plasma TSH concentrations were significantly lower after an
injection of anti-TRH serum than after an injection of NSS and
remained low after PRL concentrations had returned to the control
-132-
range (Table 7-2). This agrees with the studies of Koch et al.
(1977) and Harris et al. (1978) and confirms the role of TRH in the
neural control of TSH secretion (Reichlin, Martin, Mitnick, Boshans,
Grimm, Bollinger, Gordon and Malacara, 1972). However, TSH release
was not completely suppressed as shown by the fact that the
concentration of TSH in plasma after the injection of anti-TRH serum
was still 40% of the value of the concentration of TSH in plasma
from animals injected with NSS. This is in agreement with the
previous studies of Koch et al. (1977) and Harris et al. (1978) who
both found that the plasma TSH concentration in animals injected
with immune serum was approximately 40% of that in animals injected
with non-immune serum. The incomplete suppression of TSH release
may again have been due to insufficient antiserum being present to
neutralize all of the TRH in hypophysial portal blood. In the
present studies, it was not possible to inject animals with more
than 1ml of either anti-TRH serum or NSS due to a severe
anaphylactic response of the animals to larger volumes of sera.
The fact that plasma TSH concentrations remained low after PRL
concentrations had returned to control values further suggests a
dissociation between TRH-stimulated TSH release and TRH-stimulated
PRL release on the afternoon of pro-oestrus. This is in contrast to
a suggestion by Brown-Grant, Button and ter Haar (1977) that
increases in the plasma concentrations of both PRL and TSH (not seen
*
in the present study) on the afternoon of pro-oestrus are mediated
by TRH.
There was no significant difference in the concentration of LH
in plasma at any time between animals injected with anti-TRH serum
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and those injected with non-immune serum, indicating that the
decreases in the concentrations of TSH and PRL in plasma were not
due to a non-specific action of the anti-TRH serum on the release of
hormones from the anterior pituitary gland. These results indicate
that the involvement of TRH in the pro-oestrous PRL surge is
probably of importance only at the beginning of the surge and is
transient and rapidly overtaken by other factors (Valverde, Chieffo
and Reichlin, 1972; Blake, 1974; Grosvenor and Mena, 1980; de Greef
and Visser, 1981). Fraser and McNeilly (1982) have shown that major
physiological changes in PRL release can still occur when TRH is
inhibited long-term even although responses to some stimuli such as
heat stress, suckling or injection of TRH, which generally cause
significant increases in plasma PRL concentrations, are blunted.
Fink, Fraser and Sheward (1983) have also recently shown that
electrically-stimulated release of PRL cannot be inhibited by an
injection of anti-TRH serum. Therefore, in summary, the role of TRH
in PRL secretion, which may be important during suckling, is not so




Vasopressin and Oxytocin in Hypophysial Portal Blood
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8.1 INTRODUCTION
There are an increasing number of substances thought to be
involved in the regulation of the release of hormones from the
anterior pituitary gland (Weiner and Ganong, 1978; McCann, 1980;
Vale et al., 1980). Vasopressin and oxytocin, for many years
thought to be exclusively located in the posterior pituitary gland
(Lederis, 1974) and concerned primarily with osmoregulation (Moses
and Miller, 1974) and milk ejection (Tindal, 1974) respectively,
have recently been discovered in a fibre system terminating in the
EL of the ME (Zimmerman, Stillman, Recht, Antunes and Carmel, 1977)
and have been implicated in the control of ACTH release (Burlet,
Chateau and Czernichow, 1978; Beny and Baertschi, 1980; Gillies
and Lowry, 1979, 1982) and PRL release (Vaughan et al., 1979;
Salisbury, Kreig and Seibel, 1980; Shin, 1982). This fibre system
has been identified immunohistochemically in numerous species
including amphibia, birds, and mammals (Parry and Livett, 1973;
Silverman, 1976; Dierickx and Vandesande, 1977; Zimmerman et al.,
1977) and using Gomori staining has been identified in birds
(Oksche, Kirscht, Hartwig, Oemke and Farner, 1974). The VP
component, but not the OT component is absent in the homozygous
Brattleboro rat (Vandesande and Dierickx, 1976) genetically
deficient in VP (Valtin, Sawyer and Sokol, 1965).
It has been reported that VP can be released from the isolated
ME in vitro (Beny and Baertschi, 1981) at concentrations higher than
would be expected if all the VP measured was being released from cut
axons of the SOHT (Lesnik, Guzek and Traczyk, 1969) and there are a
few reports showing the presence of high concentrations of VP in
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hypophysial portal plasma from both rats and monkeys (Zimmerman,
Carmel, Husain, Ferin, Tannenbaum, Frantz and Robinson, 1973;
Oliver et al., 1976; Recht, Hoffman, Haldar, Silverman and
Zimmerman, 1981). However, the high concentrations of VP in
hypophysial portal plasma may be derived, in addition to the
proposed VP-containing terminals in the EL of the ME, from a number
of other areas; for example, from the PN, and carried to the portal
vessels by backflow of blood (Oliver et al., 1976; Page and
Bergland, 1977), from cut axons of the SOHT (Lesnik et al., 1969) or
from CSF (Dogterom, van Wimersma Griedanus and de Wied, 1978).
There are no reports of the VP or OT in the ME system being
involved in either osmoregulation or milk-ejection but there is
evidence that VP has a functional role in the release of ACTH from
the anterior pituitary gland (Gillies and Lowry, 1982).
Vasopressin has been shown to alter the release of ACTH both in vivo
and in vitro (Hedge, Yates, Marcus and Yates, 1966; Portanova and
Sayers, 1973; Lutz-Bucher, Koch and Mialhe, 1977; Aizawa, Yasuda,
Greer and Sawyer, 1982) but this appears to be due to a synergistic
action with corticotrophin-releasing hormone (CRH) (Vale, Speiss,
Rivier and Rivier, 1981; Gillies and Lowry 1982; Gillies, Linton
and Lowry, 1982; Yasuda et al., 1982) since CRH activity is still
present in the hypothalamus and ME of the homozygous Brattleboro
rat, in which VP is absent (Pearlmutter, Dokas, Kong, Miller and
Saffran, 1980; Buckingham, 1981; Pearlmutter, Dokas, Loeser, Kong,
Saffran and Simmons, 1982).
An isolated report by Shin (1982) claimed that VP could also
release PRL from the anterior pituitary gland in vitro by a direct
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action on the lactotrophs.
There have, as yet, been no reports of the presence of OT in
hypophysial portal blood but there is increasing speculation as to a
functional role for OT, or fragments of OT, in the release of
hormones from both the intermediate and anterior lobes of the
pituitary gland. Two different fragments of OT have been isolated
from hypothalamic tissue and have been proposed as a
melanocyte-stimulating hormone (MSH) inhibitory factor
(NH^-Gly-Leu-Pro) (Kastin, Viosca and Schally, 1974; Kastin,
Schally and Kostrzewa, 1980) and as an MSH releasing factor
(SH-Cys-Tyr-Ile-Gln-Asn-OH) (Cell's, Taleisnik and Walter, 1971) and
OT itself has been shown to cause release of PRL both in vivo and in
vitro (Forsling et al., 1974; Vaughan et al., 1979; Lumpkin et
al., 1983).
The studies presented in this chapter were designed to
investigate:
i) whether VP and OT could be measured in pituitary stalk plasma
ii) the possible sources of these peptides in pituitary stalk
plasma
iii) whether the increased VP immunoreactivity seen after
adrenalectomy was reflected in increased release of VP into
pituitary stalk plasma.
8.2 MATERIALS AND METHODS
8.2.1 Animals and surgery
Animals used in this series of experiments, unless otherwise
stated, were male Wistar cob rats (200-300g). In some experiments
the animals used were male heterozygous and homozygous Brattleboro
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rats (200-250g) maintained as described in section 2.1. Homozygous
and heterozygous Brattleboro rats were caged singly in metabolic
cages to allow measurement of urine output. A homozygous
Brattleboro rat was defined as an animal which passed urine equal to
or greater than 75% of body weight (150ml for a 200g rat) during a
241V collection period. Brattleboro rats passing less than this
volume during the 24h collection period were designated
heterozygous. These definitions were tested at the end of the
experiment when the pituitary gland was removed and assayed for VP
and 0T.
Adrenalectomy, collection of peripheral blood, collection of
hypophysial portal blood and CSF, electrothermal lesioning, and
electrical stimulation of the hypothalamus anc| ME were all carried
out under urethane anaesthesia as described 'in Chapter 2.
Hypophysial portal blood was collected (2.2.15) during two
consecutive periods of 30 min each and electrical stimulation, when
applied, was applied during the second 30 min period.
Electrothermal lesions (2.2.14) of the SOHT were made using
co-ordinates, lateral 0.0mm, anterior + 6.0mm, ventral + 1.2mm,
described by de Groot (1959). The correct placement of the lesion
was determined by monitoring urine output of lesioned animals in the
first few post-operative days. Only those animals which continued
to show an increase in urine output 5 days after placement of the
lesion were used. Animals in which lesion placement was correct
(verified histologically) showed a typical phasic pattern of urine
output consisting of an initial increase (days 1-2 post-lesioning)
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fo1 lowed by a decrease (days 2-3) and a subsequent sustained
increase (days 4-12) (Table 8-1). The position and extent of
lesions were checked histologically and a representative lesion is
shown in Figure 8-1. Bipolar electrodes were implanted long-term
(2.2.13) into the PVN and SCN and unipolar electrodes were implanted
long-term into the SON. Co-ordinates for implantation used for
rats weighing 200g (based on de Groot, 1959) were
Hypothalamic area Lateral Anterior Ventral
PVN 0.0mm +5.3mm +3.4mm
SCN 0.0mm +7.4mm +1.6mm
SON +2.0mm +7.0mm +2.3mm
Lateral co-ordinates given for PVN and SCN indicate the position
of the exact mid-point between the 2 electrode tips of the bipolar
electrode assembly (electrodes were 1mm apart).
8.2.2 Drugs used and measurement of peptides
Alaproclate and zimelidine were dissolved in 0.9% saline
immediately before use. Parachlorophenylalanine was dissolved in
0.9% buffered saline before use. Dexamethasone stock solution
(2.2.2) was diluted in 0.9% saline immediately before use. All
drugs were injected i.p. at times stated in results.
Vasopressin, 0T and LHRH in peripheral and hypophysial portal
plasma and VP and 0T in the pituitary gland of Brattleboro rats were
measured by specific RIAs described in section 2.4.
8.2.3 Statistics
All data are presented as mean ± S.E.M. The significance of the
difference between two means was measured using Student's t-test.
The significance of difference between more than two means was
TABLE 8-1
Urine output (ml/24h) in male rats after placement of an
electrothermal lesion in the supraopticohypophysial tract. Lesions
were placed on day 0.
Animal Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7
1 13 2 5 70 120 105 95
2 41 15 14 32 36 60 70
3 31 14 10 24 35 46 54
4 24 9 12 16 35 42 61
5 40 35 20 36 46 50 58
6 16 9 6 16 33 53 60
FIGURE 8-1 Representative photomicrograph of a lesion in the
supraopticohypophysial tract.
EL = intact external layer of median eminence
L = lesion
V = third ventricle
F = fornix
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measured by analysis of variance and Duncan's multiple range test.
8.3 RESULTS
8.3.1 Vasopressin and oxytocin in peripheral and hypophysial portal
plasma
The concentrations of OT and VP in hypophysial portal plasma
were significantly greater (p < 0.001) than the concentrations in
peripheral plasma (Fig. 8-2). When the pituitary gland was removed
at the time of pituitary stalk section, and hypophysial portal blood
collected as before, there were no significant differences in the
concentrations of either peptide in either peripheral or hypophysial
portal plasma compared with the concentrations in plasma from
animals sampled with the pituitary gland in situ (Figs. 8-3 and 8-4).
8.3.2 The effect of a lesion in the supraopticohypophysial tract on
vasopressin and oxytocin concentrations in hypophysial portal
and peripheral plasma
Hypophysial portal blood was sampled from animals 8-10 days
after placement of a lesion in the SOHT. There were significant
increases (p < 0.01) in the concentrations of both VP and 0T in
hypophysial portal plasma from animals that had a lesion in the SOHT
compared with concentrations in hypophysial portal plasma from
unlesioned animals (Figs. 8-3 and 8-4). There were no significant
differences in the concentrations of either VP or OT in peripheral
plasma from lesioned animals when compared with peripheral plasma
concentrations from unlesioned animals.
8.3.3 Vasopressin and oxytocin in peripheral and hypophysial portal
plasma from heterozygous and homozygous Brattleboro rats












































FIGURE 8-2 Mean (± S.E.M.) concentrations (ng/ml) of vasopressin
(VP) and oxytocin (OT) in peripheral plasma (open bar,
n = 9) and hypophysial portal plasma (closed bar, n = 9)
from male rats.
Peripheral blood samples were removed from anaesthetized
animals from the external jugular vein after exposure
but before cutting of pituitary stalk (1), and, (2)
after the completion of the collection of hypophysial
portal blood.
Hypophysial portal blood was collected during 2
half-hour periods (1 and 2).
**p < 0.001; level of significance of difference between
the concentration of VP and OT in
hypophysial portal plasma compared with the
concentration of VP and OT in peripheral
piasma.
FIGURE 8-3 Mean (± S.E.M.) concentrations (ng/ml) of vasopressin
(VP) in hypophysial portal plasma and peripheral plasma
from intact male rats (pituitary in situ), male rats
with the pituitary gland removed at the time of stalk
section (pituitary removed) or with a lesion placed in
the supraopticohypophysial tract 7-8 days before
sampling of blood (SOHT lesion), (n = 8 in each group).
Peripheral blood samples were removed from anaesthetized
animals from the external jugular vein after exposure
but before cutting of pituitary stalk (1) and (2) after
the completion of the collection of hypophysial portal
blood.
Hypophysial portal blood was collected during 2
half-hour periods (1 and 2).
*p < 0.01; level of significance of difference between
the concentration of VP in hypophysial
portal plasma from animals with a lesion in
the SOHT compared with the concentration of























in situ removed lesion
FIGURE 8-4 Mean (± S.E.M.) concentrations (ng/ml) oxytocin (OT) in
hypophysial portal plasma and peripheral plasma from
intact male rats (pituitary in situ), male rats with the
pituitary gland removed at the time of stalk section
(pituitary removed) or with a lesion placed in the
supraopticohypophysial tract 7-8 days before sampling of
blood (SOHT lesion), (n = 8 in each group).
Peripheral blood samples were removed from anaesthetized
animals from the external jugular vein after exposure
but before cutting of pituitary stalk (1) and (2) after
the completion of the collection of hypophysial portal
blood.
Hypophysial portal blood was collected during 2
half-hour periods (1 and 2).
*p < 0.01; level of significance of difference between
the concentration of OT in hypophysial
portal plasma from animals with a lesion in
the SOHT compared with the concentration of







































and homozygous Brattleboro rats was undetectable (Fig. 8-5). The
concentration of VP in hypophysial portal plasma from heterozygous
Brattleboro rats collected during the first 30 min collection period
was slightly but not significantly lower than that in Wistar rats
(Fig. 8-5). Vasopressin was undetectable in hypophysial portal
plasma from homozygous Brattleboro rats (Fig. 8-5).
There were no differences between Wistar and
heterozygous and homozygous Brattleboro rats in the concentration of
0T in peripheral plasma but there was a significant increase (p <
0.01) in the concentration of OT in hypophysial portal plasma from
both heterozygous and homozygous Brattleboro rats compared with the
concentration in hypophysial portal plasma from Wistar rats
(Fig. 8-6).
8.3.4 Vasopressin and oxytocin concentrations in cerebrospinal fluid
Cerebrospinal fluid was removed from ^animals that had been
implanted 10 days previously with a cannula in the third cerebral
ventricle. Concentrations of VP were lower than those in
hypophysial portal blood, and ranged from < 0.02 - 0.5ng/ml (mean ±
S.E.M. = 0.24 ± 0.10, n = 8). On the basis of the concentrations of OT, the
Is could bedivided into two groups, those with high concentrations of OT, mean
± 1.33 ng/ml (n=4), and those with low concentrations of 0T,mean = 0.04 ± 0.01 nq/ml
(n = 4). There was no correlation between VP and OT concentrations
in CSF.
8.3.5 The effect of electrical stimulation of the hypothalamus and
median eminence on the concentrations of vasopressin and
oxytocin in peripheral and hypophysial portal plasma
To determine the effects of ME stimulation on the release of VP
FIGURE 8-5 Mean (± S.E.M.) concentrations (ng/ml) of vasopressin
(VP) in peripheral plasma and hypophysial portal plasma
from Wistar male rats (Wistar), heterozygous Brattleboro
rats (Hetero. Bratt'b's) and homozygous Brattleboro rats
(Homo. Bratt'b's) (n = 6, in each group).
(N.D. = not detectable at a lower limit of assay
sensitivity of lpg/tube).
Peripheral blood samples were removed from anaesthetized
animals from the external jugular vein after exposure
but before cutting of pituitary stalk (1), and, (2)
after the completion of the collection of hypophysial
portal blood.
Hypophysial portal blood was collected during 2
half-hour periods (1 and 2).
*p < 0.01; level of significance of difference between
the concentration of VP in hypophysial
portal plasma from heterozygous and
homozygous Brattleboro rats compared with
the concentration of VP in hypophysial
portal plasma from Wistar rats.





















FIGURE 8-6 Mean (± S.E.M.) concentrations (ng/ml) of oxytocin (OT)
in peripheral plasma and hypophysial portal plasma from
Wistar male rats (Wistar), heterozygous Brattleboro rats
(Hetero. Bratt'b's) and homozygous Brattleboro rats
(Homo. Bratt'b's) (n = 6, in each group).
Peripheral blood samples were removed from anaesthetized
animals from the external jugular vein after exposure
but before cutting of pituitary stalk (1), and, (2)
after the completion of the collection of hypophysial
portal blood.
Hypophysial portal blood was collected during 2
half-hour periods (1 and 2).
*p < 0.01; level of significance of difference between
the concentration of OT in hypophysial
portal plasma from heterozygous and
homozygous Brattleboro rats compared with
the concentration of OT in hypophysial











































and OT into peripheral blood, the ME and pituitary stalk were
exposed but the stalk was not cut. A unipolar electrode was placed
onto the ME and a stimulus applied. The stimulus consisted of
accurately balanced biphasic rectangular waves, 1mA peak-peak,
lm sec duration at 50Hz, applied in trains of 30 sec on and 30 sec
off for 30 min. Peripheral blood samples were removed from the
external jugular vein at 15 and 30 min during application of the
stimulus. Figures 8-7 and 8-8 show that ME stimulation was
accompanied by significant increases (p < 0.01) in the
concentrations of VP and OT in peripheral plasma. Application of
the same stimulus to the ME during the second 30 min collection of
portal blood from animals in which the pituitary stalk had been cut
produced no significant change in the concentrations of VP and OT
compared either with the concentrations in hypophysial portal plasma
collected from the same animals during the first 1pre-stimulation1
30 min collection period or with concentrations in hypophysial
portal plasma from control animals that were not electrically
stimulated, (Table 8-2). This stimulus did however cause increased
release of LHRH into hypophysial portal plasma in another group of
animals (Table 8-3). In another group of animals, however, the
same electrical stimulus applied to the ME in trains of 10 sec on
and 110 sec off, for 30 min had no effect on the concentration of
either VP or OT in either peripheral or hypophysial portal plasma
(Table 8-2).
Electrical stimulation of the PVN, SON or SON with the same
stimulus used for stimulating the ME and intact pituitary stalk, had
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FIGURE 8-7 Mean (± S.E.M.) concentrations of vasopressin (VP) in
peripheral plasma from intact male rats after electrical
stimulation of the posterior pituitary gland by way of a
unipolar electrode on the median eminence (n = 6).
Blood samples were removed from the external jugular
vein at 15 min intervals before, during and after the
period of stimulation (shown by the black bar).
Stimulation parameters are shown in the upper right of
the figure.
*p < 0.01; level of significance of difference between
concentrations of VP in peripheral plasma
during and after stimulation compared with
concentrations present before stimulation.
— 2msec —
T1ME,min.
FIGURE 8-8 Mean (± S.E.M.) concentrations of oxytocin (OT) in
peripheral plasma from intact male rats after electrical
stimulation of the posterior pituitary gland by way of a
unipolar electrode on the median eminence (n = 6).
Blood samples were removed from the external jugular
vein at 15 min intervals before, during and after the
period of stimulation (shown by the black bar).
Stimulation parameters are shown in the upper right of
the figure.
*p < 0.01; level of significance of difference between
concentrations of OT in peripheral plasma
during and after stimulation compared with
concentrations present before stimulation.
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TABLE 8-3
The concentration (pg/ml) and content (pg/30 min) of luteinizing
hormone-releasing hormone (LHRH) in hypophysial portal plasma from
male rats after electrical stimulation of the median eminence during
the second half-hour collection of hypophysial portal blood
(Portal 2).
LHRH content LHRH concentration
Animal Portal (1) Portal (2) Portal (1) Portal
1 30 276 301 1840
2 35 106 468 708
3 272 466 906 465
4 95 255 315 424
5 81 244 266 417
99 + 49 269 + 57* 451 + 119 771 + 272*
*p < 0.05; level of significance of difference between the
concentration or content of LHRH present in hypophysial
portal plasma before stimulation of the median eminence
(Portal 1) compared with the concentration or content of
LHRH present after stimulation of the median eminence
(Portal 2).
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portal plasma or peripheral plasma compared with concentrations
before the start of the stimulation (Table 8-2).
There were significant decreases, (p < 0.01) compared with
control animals, in the concentrations of both peptides in
hypophysial portal plasma collected during both 'stimulated' and
'unstimulated' collection periods from animals implanted long term
with electrodes in PVN (Table 8-2).
8.3.6 The effect of adrenalectomy on the concentrations of
vasopressin and oxytocin in peripheral and hypophysial portal
piasma.
When hypophysial portal blood was collected from animals that
had been bilaterally adrenalectomized either 3, 7 or 10 days
previously, there were no differences in the concentrations of
either VP or 0T in hypophysial portal plasma or peripheral plasma
when compared with the concentrations in hypophysial portal plasma
or peripheral plasma from animals that had undergone
sham-adrenalectomy 7 days previously (Table 8-4). Injection of
animals that had been adrenalectomized 7 days previously with 0.5mg
dexamethasone/kg lh before the start of the collection of
hypophysial portal blood had no effect on the concentration of
either peptide in hypophysial portal plasma or peripheral plasma
when compared either with plasma concentrations from animals that
had been adrenalectomized 7d previously and injected with injection
vehicle,or with sham-adrenalectomized animals.
8.3.7 Serotonergic involvement in the release of vasopressin and
oxytocin into hypophysial portal blood
Injection of 200mg PCPA/kg i.p. 72h before the start of the






























































Portal(1)=concentrationfpeptideihypo hysialport llasmac llecteddu ingfirst30min. Portal(2)=concentrationfpeptideihy o hysialport lplasmacollectedduring second30mi . *Dexamethasonew sinjected.p.lb forths artfollectionfypophysial portalblood. ConcentrationsofVPandOTiperipheralpl smwe el<0.02ng/mlisa plesk nbotheforeandftercuttingfthpi u tarys alk.
-143-
experiment had no significant effect on either the OT or VP
concentrations in either peripheral or hypophysial portal plasma
compared with the plasma concentrations in control animals
(Table 8-5). Zimelidine and alaproclate, injected i.p. at doses of
20mg/kg and 30mg/kg, respectively, lh before the start of the
collection of hypophysial portal blood, had no significant effect on
either VP or OT concentrations in either peripheral or hypophysial
portal plasma (Table 8-5).
8.4 DISCUSSION
The results reported in this chapter show the presence of high
concentrations of both VP and OT in pituitary stalk plasma. There
have so far been no reports concerning the presence of OT in
hypophysial portal plasma and only a few reports concerning the
presence of VP. Early work, using a relatively insensitive bioassay
for VP (Dekanski, 1952) claimed that there was no VP activity
detectable in hypophysial portal blood (Rumfeld and Porter, 1959;
Fink, Smith and Tibballs, 1971). However, with the development of
sensitive RIAs for VP, high concentrations of VP have been found in
hypophysial portal plasma from monkeys (Zimmerman et al., 1973) and
rats (Oliver et al., 1977; Recht et al., 1981). It has been argued
that the high concentrations of VP seen in hypophysial portal plasma
are due either to the presence of VP in blood arising from backflow
from the posterior pituitary gland to the hypophysial portal vessels
*
(Bergland and Page, 1977; Oliver et al., 1977) or to the presence of
VP in CSF (Dogterom et al., 1977) or to the leakage of VP from cut
axons of the SOHT (Lesnik et al., 1969). It is unlikely that a
significant amount of either VP or OT is arising in hypophysial
TABLE8-5
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portal plasma due to backflow of blood from the posterior pituitary
g1 and, since the present studies showed that there was no
significant change in the concentration of either peptide in
hypophysial portal plasma from animals in which the pituitary gland
had been removed at the time of pituitary stalk section compared
with concentrations in hypophysial portal plasma from animals with
the pituitary gland left in situ (Figs. 8-3 and 8-4). These results
agree with those of Recht et al. (1981) who also found no
significant change in the concentration of VP in hypophysial portal
plasma after removal of the posterior pituitary gland compared with
concentrations present when the gland was left in situ. However,
the results found here do not agree with those of Oliver et al.
(1977) who found significant decreases in the concentrations of a
number of anterior and posterior pituitary hormones, including VP,
in hypophysial portal plasma after removal of the pituitary gland,
and concluded that all of the VP in hypophysial portal plasma
originated from the posterior pituitary gland. The vasculature that
was originally proposed to be involved in the backflow of blood from
the pituitary gland to the hypophysial portal vessels (Bergland and
Page, 1978) has recently been shown to be part of a different system
which does not after all flow from the posterior pituitary gland to
the hypophysial portal vessels in the ME (Page, 1983). The
differences between the studies of Oliver et al (1977) and those of
Recht et al. (1981) and the present studies cannot be attributed to
differences in the method of collection of hypophysial portal blood
or to the method used for determination of VP concentrations since
both Oliver et al. (1977) and Recht et al. (1981) used the portal
i
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vessel cannulation method of Porter and Smith (1967) and all three
studies measured the concentration of VP by RIA.
There is evidence for the presence of VP and OT in CSF (Robinson
and Zimmerman, 1973; Dogterom et al. 1978; Jackson, 1980) and in the
tanycytes lining the floor of the third ventricle (Robinson and
Zimmerman, 1973), but concentrations found in CSF in the present
studies are similar to those in peripheral plasma (20-50pg/ml) and
so are not high enough to be contributing significantly to the
concentrations seen in hypophysial portal plasma.
The outflow of VP from cut axons of the SOHT has been estimated
to be 80pg/h (Lesnik et al., 1969) and this is clearly not
sufficient to account for the measurement of approximately 1.25ng
VP/h in hypophysial portal plasma. It also seems unlikely that
axons of the SOHT contribute significantly to the high
concentrations of VP and OT in hypophysial portal blood since, after
lesioning of these axons, there is a significant increase in the
concentrations of VP and OT in hypophysial portal plasma compared
with concentrations in hypophysial portal plasma from unlesioned
animals (Figs. 8-3 and 8-4). The increased concentrations could be
due to a build-up of both peptides behind the lesion (Moll, 1957;
Beck and Daniel, 1961) which are released upon subsequent section of
the pituitary stalk (histological examination of the brains of these
animals showed some intact perikarya in the SON and PVN and a lesion
in the internal layer of the ME). Another possible explanation for
the increased concentrations could be the presence of axon branches
from axons in the SOHT, terminating in the EL of the ME, and
containing increased concentrations of peptides after lesioning of
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the main axon. There is electrophysiological (Blume, Pittman and
Renaud, 1978; Pittman, Blume and Renaud, 1978; Hatton, Ho and Mason,
1983) and neuroanatomical (Hayward, 1974; Lu Qui and Fox, 1976;
Sofroniew and Glasmann, 1981) evidence for the existence of axon
collaterals on neurons of the SON, but so far evidence is sparse for
these collaterals being present at distances of more than a few
hundred microns outside the nucleus (Hayward, 1974; Lu Qui and Fox,
1976). Even if these collaterals did not show 'classical' terminals
in the EL of the ME there is evidence for the presence of
varicosities, usually associated with neurotransmitter release, in
axons of both the peripheral (Richardson, 1958; Burnstock and
Holman, 1961) and central (Anden, Dahlstrom, Fuxe, Larsson, Olson
and Ungerstedt, 1969) nervous systems which may also be present in
this VP and OT containing system. Evidence against the VP and OT
containing fibres in the EL of the ME arising from the same neurons
in the SON as those projecting to the neurohypophysial system comes
from anatomical studies. Wiegand and Price (1980) and Swanson,
Sawchenko, Wiegand and Price, (1980) have shown differences in both
the size and distribution of the VP and OT containing cells that
project to the EL of the ME compared with those that project to the
posterior pituitary gland. In addition to these differences, the
neurosecretory granules in the terminals on the portal vessels are
smaller (lOOnm) than those found in the posterior pituitary gland
(120-180nm) (Silverman and Zimmerman, 1975). These differences
would indicate that the neurons of these two systems are different
and that the ME system is not composed solely of axon collaterals
from the neurons of the SOHT.
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The destruction of the internal layer of the ME by the SOHT
lesion probably causes changes in many other peptide and
neurotransmitter systems present in this area. In an immuno-
histochemical study by Seybold, Elde and Hokfelt (1981) it was shown
that VP immunoreactivity in the EL of the ME was depleted 24h after
an injection of reserpine. This result was interpreted as
indicating the presence of a tonic inhibitory catecholamine system
involved in the control of the release of VP in the EL of the ME,
and it is possible that the destruction of this, or some other
neuroactive system, by the SOHT lesion, is causing the observed
increased release of VP and OT into hypophysial portal blood.
It has been reported that the vasopressinergic component of the
VP and OT system in the ME is absent in the homozygous Brattleboro
rat, genetically deficient in VP (Sokol, Zimmerman, Sawyer and
Robinson, 1976; Vandesande and Dierickx, 1977). This was confirmed
in the present studies where VP was undetectable in hypophysial
portal plasma from homozygous Brattleboro rats and slightly but not
significantly lower in hypophysial portal plasma from heterozygous
Brattleboro rats compared with concentrations in hypophysial portal
plasma from Wistar rats (Fig. 8-5). The concentration of OT was
significantly higher in hypophysial portal plasma from both
heterozygous and homozygous Brattleboro rats compared with
concentrations in hypophysial portal plasma from Wistar rats
(Fig. 8-6). This may have been due to the chronic dehydration of
the Brattleboro rats, which has been shown to cause increased
concentration of OT in peripheral plasma when compared with
Long-Evans rats (Valtin et al., 1965; Dogterom et al., 1978).
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However, the present studies did not show any differences in the
concentration of OT in peripheral plasma from either Wistar or
Brattleboro rats (Fig. 8-6) and others (Balment, Brimble and
Forsling 1980) have found no differences between rats of the
Long-Evans and Brattleboro strains.
The involvement of VP in the hypothalamo-hypophysial-adrenal
axis has long been controversial (Martini, 1964) with claims for VP
being an ACTH inhibitory factor (Itoh and Arimura, 1954) an ACTH
releasing factor (McCann, 1957) or having no effect on ACTH release
(Barondes, Johnson and Field, 1961). More recently, the discovery
of a 41-residue peptide with potent CRF-activity (Vale et al, 1981)
has shown that while VP may not be the CRH it has synergistic
properties with CRH (Gillies et al, 1982) and in some cases is as
potent (on an equimolar basis) as CRH (Rivier and Vale, 1983), to a
degree sufficient to allow it to be called a corticotrophin-
releasing factor (CRF). Vasopressin immunoreactivity in the EL of
the ME has been reported to increase after adrenalectomy (Zimmerman
et al., 1977; Burlet et al., 1978) but not after dehydration
(Seybold et al., 1981). Oxytocin immunoreactivity does not change
after adrenalectomy or dehydration (Zimmerman et al., 1977; Seybold
et al. 1981). There was no change in the concentration of either VP
or OT in hypophysial portal plasma from animals which had been
bilaterally adrenalectomized 3, 7 or 10 days previously compared
with concentrations in hypophysial portal plasma from
sham-adrenalectomized animals (Table 8-4). Treatment of
adrenalectomized animals with dexamethasone, which has been reported
to inhibit the increase in VP-immunoreactivity (Sti1Iman,Recht,
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Rosario, Seif, Robinson and Zimmerman, 1977; Silverman, Hoffman,
Gadde, Krey and Zimmerman, 1981) had no effect on either VP or OT
concentrations in hypophysial portal plasma (Table 8-4). It may be
that the increased VP immunoreactivity seen in the EL of the ME
after adrenalectomy is due to decreased release of VP from these
terminals rather than to increased synthesis. This is supported by
the present studies which showed no change in the concentration of
VP and OT in hypophysial portal plasma from adrenalectomized
animals. However, it has been reported that there is an increase in
3
the incorporation of H-cytidine into RNA in neurons of the PVN
(Silverman, Gadde and Zimmerman, 1980), and in the production of a
VP precursor (Russel1,Brownstein and Gainer, 1980) after
adrenalectomy, which is consistent with adrenalectomy causing
increased synthesis of VP.
There have been claims that OT may also function as a CRF, with
reports of a CRF extracted from the hypothalamus of Brattleboro rats
being identified as OT (Beny and Baertschi, 1981) and OT
concentrations in peripheral plasma being increased after stress
(Lang, Heil, Granten, Hermann, linger and Rascher, 1983). However,
there was no significant change in the concentrations of OT in
hypophysial portal plasma from adrenalectomized animals (Table 8-4)
in the present study.
High densities of VP and OT immunoreactivity have been shown to
be present in PVN, SCN and SON and in scattered fibres throughout
the brain (Sofroniew and Weindl, 1981). Most evidence indicates
that the VP and OT system of the ME arises from the PVN (Parry and
Livett, 1973; Vandesande et al., 1977; Zimmerman et al., 1977;
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Swanson and Sawchenko, 1983). However, when an electrical
stimulus, that had already been shown to cause release of VP and OT
into peripheral plasma (Figs. 8-7 and 8-8) and also to be effective
in releasing LHRH into hypophysial portal blood (Table 8-3), was
applied to any of these three areas there was no change in the
concentrations of VP and OT in hypophysial portal plasma
(Table 8-2). The stimulus was also ineffective when applied
directly to the ME (Table 8-2). The decrease in the concentration
of both peptides in hypophysial portal plasma from animals implanted
with an electrode in the PVN was not due to lesioning of this
nucleus itself. However, histological examination of the brains of
these animals revealed damage to an area approximately 200ym
anterior to the PVN. This may represent an important area of
afferent input to the nucleus (Swanson and Sawchenko, 1983),
lesioning of which causes decreased neuronal activity and so,
decreased peptide release. Note, however, that electrical
stimulation still caused no change in these lower concentrations
(Table 8-2). The lack of effect of electrical stimulation on the
release of these peptides into hypophysial portal blood is puzzling
since the stimulus used has been shown both in the present and
previous studies to cause release of other peptides into hypophysial
portal blood (Fink and Jamieson, 1976; Sherwood, Chiappa, Sarkar and
Fink, 1980; Millar, Sheward, Wegener and Fink, 1983; Sheward,
Benoit and Fink, 1984). There are several possible explanations
for the lack of effect of hypothalamic stimulation on VP and OT
release. First, the frequency of the stimulation pulses may have
been too high, but this frequency caused a significant release of VP
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and OT in intact animals (Figs. 8-7 and 8-8) and a similar frequency
was found to cause milk ejection in the rabbit (Harris, Manabe and
Ruf, 1969). Secondly, the neurons may have been fatigued by the
frequency of stimulation or the length of the trains of pulses
(Boer, Cransberg and Dogterom, 1980; Bicknell and Leng, 1981) but
again, Figures 8-7 and 8-8 makei this seem unlikely. The third, and
most likely explanation, is that exposure and subsequent cutting of
the pituitary stalk somehow leads to maximum activity of the VP and
OT neurons so that release of the peptides cannot be further
increased by electrical stimulation.
Although there is evidence for the involvement of Ach, DA and NA
in the release of VP and OT from terminals in the posterior
pituitary gland (Bhargava, Kulshrestha and Srivastava, 1972;
Bridges, Hillhouse and Jones, 1976; Hoffman, Phillips and Schmid,
1977; Moos and Richard, 1979; SIadek and Joynt, 1979; Kimura,
Share, Wang and Crofton, 1981), the neurotransmitters involved in
the control of the VP and OT system of the ME have yet to be
elucidated. Those that have been studied have been concerned with
the possible adrenocorticotrophic function of this system. There is
a large body of evidence concerning the involvement of 5-HT in the
hypothalamo-pituitary-adrenal axis (Fuller, 1981). Serotonin has
been shown to cause release of ACTH from the pituitary gland (Bruni,
Hawkins and Yen, 1982; Spinedi and Negro-Vilar, 1983) and of a CRF
from the hypothalamus (Jones, Gill ham and Hi 11 house, 1977;
Buckingham and Hodges, 1979; Fehm, Voigt, Lang and Pfeiffer, 1980;
Holmes, Direnzo, Beckford, Gill ham and Jones, 1982) and there is
evidence that adrenocortical hormones can alter tryptophan
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hydroxylase activity (Azmitia and McEwen, 1974) and change the
firing rate of 5-HT containing neurons (Foote, Liels, Martz and
Gordon, 1972). Vasopressin can also change the release and
synthesis of 5-HT in hippocampal slices (Auerbach and Lipton,
1982). However, 5-HT has been reported to have no effect on
electrical activity of the PVN (Moss, Urban and Cross, 1972),
although there is evidence for serotonergic input into this nucleus
(Kent and Sladek, 1978).
The studies reported in this chapter show that injection of
animals with either a 5-HT synthesis inhibitor or with a 5-HT
reuptake blocker, treatments designed to decrease and increase,
respectively, 5-HT concentrations at synapses, had no effect on the
concentrations of VP or OT in hypophysial portal plasma (Table
8-5). However, although 5-HT may not be involved in the release of
VP and OT from ME terminals, there is evidence for an interaction
between VP and 5-HT to affect ACTH release from the anterior
pituitary gland. Spinedi and Negro-Vilar (1983) recently reported a
synergistic effect of 5-HT both with synthetic VP and with an ME
extract to increase ACTH release from pituitary cells in vitro.
That this may occur in vivo is given support by recent work by
Johnston et al. (1983) who found significantly higher concentrations
of 5-HIAA in hypophysial portal plasma than in peripheral plasma.
The studies reported here are consistent with the existence of a
separate VP and OT containing fibre system, terminating on the EL of
the ME. In addition to the long proposed involvement of VP in ACTH
release (Hedge et al., 1966; Gillies and Lowry, 1982; Rivier and
Vale, 1983) there is increasing evidence for the involvement of both
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peptides in the release of other anterior pituitary hormones such as
PRL (Salisbury et a!., 1980; Shin, 1982; Lumpkin et al., 1983) and
LH (Cheesman, Osland and Forsham, 1977; Salisbury et al., 1980).
Evidence is also accumulating for the involvement of both of these
peptides in many other functions such as memory (de Wied, 1977; de
Wied and Versteeg, 1979) and maternal behaviour (Pedersen and
Prange, 1979) and it has been shown that both peptides can affect
neuronal firing (Morris, Salt, Sofroniew, 1980) and neurotransmitter
metabolism (Tanaka, de Kloet, de Wied and Versteeg, 1977; Auerbach
and Lipton, 1982).
Further studies, particularly concerning electrical stimulation
of areas thought to contain the cell bodies of this fibre system,






The studies in this thesis were carried out to investigate
possible interactions between hormones, hypothalamic peptides and
monoamines in the hypothalamic-PD system.
3
The release of H-DA from the superfused ME in vitro was
investigated and studies carried out to determine whether this was a
suitable system for the investigation of TIDA function. The uptake
of DA into the ME was determined to be of low affinity and to be
inhibited by the DA uptake blocker, nomifensine. After an initial
3
wash-out period, the release of previously accumulated H-DA from
the ME reached a steady baseline upon which it was possible to
superimpose an electrically-stimulated release. The electrically-
+ 2+
stimulated release was dependent on both Na and Ca ,
indicating that release was probably from neurons. Nomifensine
caused a significant increase in the electrically-stimulated release
3
of H-DA but had no effect on the basal release. This result
suggests that the DA uptake system in the ME, although of low
affinity, may be important during times of increased TIDA activity.
There was no difference in either the basal or the electrically-
3stimulated release of H-DA at any stage throughout the oestrous
cycle nor was there any difference in the release when LHRH, TRH or
PRL were added to the superfusion buffer. To determine whether
there was any evidence for the presence of presynaptic DA receptors
on the terminals of the TIDA neurons in the ME, the release of
3
H-DA was measured after the addition of various DA agonists and
antagonists to the superfusion buffer. None of the drugs tested
caused any changes in the basal or in the electrically-stimulated
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release of H-DA suggesting that there are unlikely to be any
presynaptic DA receptors on the terminals of the TIDA neurons.
It had been hoped that this in vitro system could be adapted to
investigate the uptake and release of 5-HT in the ME. However,
this proved difficult and attention was focussed on in vivo
studies. The involvement of 5-HT in the control of the release of
LH and PRL into peripheral blood was studied using two 5-HT reuptake
blockers, alaproclate and zimelidine, in a number of different
animal models in which the release of LH and PRL induced by gonadal
steroids are thought to be controlled by different mechanisms. The
models studied were:
i) the pro-oestrous female rat
ii) the short-term OVX rat treated with OB followed by P (model 1)
iii) the long-term OVX rat treated with OB followed by P (model 2)
iv) the long-term OVX rat treated with OB followed by OB (model 3)
v) the long-term OVX rat exposed to a continuously elevated
concentration of OB (model 4).
Injection of 30mg alaproclate/kg at 1500h caused a short-term
significant decrease in the concentration of PRL in the pro-oestrous
rat and in models 1, 3 and 4. In model 2, after a similar injection
of alaproclate, the plasma PRL concentration was sustained when the
concentration of PRL in animals injected with saline had decreased.
Alaproclate had no effect on the concentration of LH in peripheral
plasma in the pro-oestrous rat or in models 3 and 4 but did cause a
significant decrease in the concentration of LH in models 1 and 2
when compared with control animals injected with saline. Zimelidine
had no effect on either LH or PRL in any of the models tested.
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These results^ that the blockade of 5-HT uptake affects the
release of LH and PRL in several types of endocrine preparations and
that the direction of change is dependent upon the steroid
environment of the preparation. The lack of effect of zimelidine
may be due to the mixed actions of this compound (Harms, 1983) that
may cause changes in the activity of systems other than 5-HT: these
changes may be in direct opposition to those induced by alterations
in 5-HT activity and hence lead to no net effect on hormone release.
To determine whether the hormonal changes were due to changes
in 5-HT activity, the concentration of 5-HT and its major
metabolite, 5-HIAA, were measured in three areas of the brain (AH,
PH and R) in some of these animal models at the time of maximal
"7
changes in hormone concentration. The three models studied, the
pro-oestrous rat and models 1 and 2, were chosen because there is
more convincing evidence for interactions between 5-HT systems and
progesterone than there is for interactions between 5-HT systems and
oestrogen. There were no changes in the concentration of either
5-HT or 5-HIAA or in the 5-HIAA/5-HT ratio in the AH in any of the
three models after an injection of alaproclate. There were small
but not significant increases in the concentration of 5-HT and
decreases in the concentration of 5-HIAA in PH and R in the pro-
oestrous rat and in model 1, which accounted for significant
decreases in the 5-HIAA/5-HT ratio. Model 2 only showed changes in
5-HT, 5-HIAA and in the 5-HIAA/5-HT ratio in R. It was proposed
that the changes in 5-HT and 5-HIAA caused by the reuptake blocker
might be more easily seen if they were superimposed upon a smaller
functional pool of 5-HT. However, in male animals treated with a
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5-HT synthesis inhibitor and in which the concentrations of 5-HT and
5-HIAA were markedly reduced, there were no significant differences
in the concentration of 5-HT or 5-HIAA, or in the 5-HIAA/5-HT
ratio. While this may indicate that the 'functional pool' of 5-HT
in animals treated with a synthesis inhibitor is so severely
depleted that 5-HT is released at such a low rate that the effect of
a reuptake blocker is not seen, there is also the possibility that
the reuptake blocker may only be effective on the release of
newly-synthesized 5-HT and may have no effect on the release of
previously-synthesized and stored transmitter.
The studies carried out in Chapter 6 were designed to determine
whether the PRL surge that accompanies the LH surge on the afternoon
of pro-oestrus is inhibited by treatment of animals with an
inhibitor of 5-HT synthesis, and if so, whether this could be due to
a peripheral action of the inhibitor on the ovary. The LH surge was
abolished in all animals treated with the synthesis inhibitor but
although the PRL surge was also abolished after treatment with the
synthesis inhibitor in most animals, a few animals still exhibited
normal PRL surges despite the treatment. Subsequent measurement of
the peripheral plasma concentration of OE revealed that the effect
of the synthesis inhibitor to block the surges of LH and PRL was
probably due to an action on the ovary since OE concentrations were
decreased in the treated group of animals. The treated group of
animals could be divided into two groups: firstly, animals in which
both the LH and PRL surges had been abolished and in which the
plasma OE concentration was <30pg/ml and secondly, animals in which
the LH but not the PRL surge had been abolished and in which the
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plasma OE concentration was >30pg/ml but <60pg/ml. (There are also
likely to have been changes in the peripheral concentration of
progesterone, although this was not measured, since certain animals
treated with the synthesis inhibitor but not included in the
hormonal study showed vaginal indications of pseudopregnancy.) This
study revealed the existence of a possible difference in the
peripheral threshold concentration of OE required to induce the LH
and PRL surges. This hypothesis requires further investigation
using OVX animals treated with different doses of oestrogen and
progesterone before it can be more than a tentative proposal.
The release of PRL during the afternoon of pro-oestrus is
dependent upon a complex series of interactions between gonadal
steroids, PIFs and PRFs. The contribution of a proposed PRF, TRH,
to the pro-oestrous PRL surge was studied in Chapter 7. Injection
of female rats with a specific anti-TRH serum at 1300h on the
afternoon of pro-oestrus caused a delay in the onset of the PRL
surge but had no effect on the maximum concentration of PRL in
peripheral plasma. This result suggests that if TRH has a
functional role in the control of the pro-oestrous surge of PRL, it
is unlikely to be of major importance and is probably transient.
In common with TRH, originally proposed solely as a releasing
factor for TSH but subsequently ascribed additional actions, other
hypothalamic peptides originally proposed as having only one action
have been suggested to have many other effects. Vasopressin and
oxytocin were studied in this thesis with respect to their release
into hypophysial portal blood and possible function as releasing
factors, rather than with respect to their more classical actions in
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the PN. The two peptides were present in hypophysial portal blood
at concentrations significantly higher than those in peripheral
blood. The source of the two peptides was probably specific VP- and
0T- containing terminals in the EL of the ME since neither the PN,
axons of the SOHT or CSF contributed significantly to the
concentrations present in hypophysial portal blood. Vasopressin was
undetectable in hypophysial portal blood from the homozygous
Brattleboro rat, genetically deficient in VP, but OT was
significantly higher in hypophysial portal plasma from both
heterozygous and homozygous Brattleboro rats compared with
concentrations in Wistar rats. Electrical stimulation of the ME or
of areas known to contain VP and OT cell bodies (PVN, SON and SCN)
failed to cause any change in the concentrations of the two peptides
in hypophysial portal blood. It has been proposed that the VP in
the EL of the ME may act as a CRF. This proposal was examined by
measuring the concentrations of VP and OT in hypophysial portal
blood at various times after adrenalectomy. However, there was no
change in the concentration of either of the two peptides at 3, 7 or
10 days after adrenalectomy. As suggested in Chapter 8, the lack of
effect of electrical stimulation and of adrenalectomy on the
concentrations of VP and OT in hypophysial portal blood suggests
that the surgical procedure of exposure and subsequent cutting of
the pituitary stalk may lead to trauma and non-specific damage to
the VP- and OT- containing terminals in the EL of the ME, causing
them to release the two peptides at a maximal rate upon which it is
not possible to superimpose any further increase in release.
This thesis serves to demonstrate the increasing complexity of
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the control of the release of LH and PRL by hypothalamic peptides
and monoamines at both the hypothalamic and pituitary level. The
differences between the effects of 5-HT uptake blockers in the
various systems studied in this thesis makes it almost impossible to
present one unifying hypothesis concerning interactions between 5-HT
and peptides in the control of the release of LH and PRL from the
PD. This applies equally to the monoamines, NA, DA and ADR.
Further work on interactions between aminergic and peptidergic
neurons in the hypothalamus and ME is confounded by the biological
complexities of the interactions and the fact that there are few, if
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Appendix II Composition of Krebs-Heinsleit (K-H) buffer
Substance Weight, g/litre Final Concentration









Ascorbic acid 0.030 130 wm
EDTA 0.010 27ym
Buffer saturated with 95% 02/5% CO2
pH =7.4
+
In Na -free buffer, NaHCO^ and NaCl are replaced
with 50mM Tris (hydroxymethyl) ami no-methane
hydrochloride buffer (pH 7.4) and 0.25M isotonic
sucrose, respectively.
2+
In Ca -free buffer, CaC^ is replaced with 5mM
ethyleneglycol-bis-(s-amino-ethyl ether) -
N.N-tetra-acetic acid (EGTA).
Appendix III Radioimmunoassays for prolactin (PRL) and luteinizing
hormone (LH): based on the methods of Greenwood et
al (1963); Niswender et al (1968)
III.l Stock solutions





per litre distilled H20, pH to 7.6
Antiserum (AS) buffer
500ml 0.01M PBS
9.306g EDTA (ethylenediamine tetra-acetic acid disodium salt)
I.7ml normal rabbit serum (NRS)
pH to 7.6
Assay buffer (0.01M PBS/1% BSA)
1000ml 0.01M PBS
lOg bovine serum albumin (BSA)
Q.01M Borate buffer (for PRL iodination)
0.618g boric acid
O.lg Na methiolate
II.8ml 0.1M NaOH (4g/100ml distilled H20)
per litre distilled H20, pH to 8.6
0.Q5M Phosphate buffer (PB)
12.5g NaH2P04.2H20
59.65g Na2HP04 (anhydrous)
per litre distilled H20
Rinse for PRL iodination:
O.lg KI
0.8g sucrose
per 10ml distilled H20
0.01M PBS/5% egg white
5g egg albumin
per 100ml 0.01M PBS, centrifuged at 2000 x g for 5 min before
use
0.01M PBS/4.5% human albumin
4.5g human albumin
per 100ml 0.01M PBS
0.01M NaHC03
1.14g NaHC03










For LH - 12 x 1cm Biogel P60, coated with
1.5 ml 0.01M PBS/5% egg white, eluted with
0.01M PBS/1% BSA.
For PRL - 25 x 1cm Sephadex G50, coated with
200yl human albumin, eluted with 0.01M
borate buffer.
Ovine-LH (LER-1056-C2; NIADDK) - 500yg/ml
0.01M PBS; 20y1 aliquots stored at -40°C.
Rat-PRL (rat-PRL-I-S; NIADDK) - 100yg/400yl
0.01M NaHC03; 20yl aliquots stored at
-40°C.
lmCi in 10yl for each assay.
For LH: 5.0mg/ml 0.01M PBS; 10yl used.
For PRL: l.Omg/ml 0.05M PB; 15yl used.
Made up fresh before use.
For LH: 5.0mg/ml 0.01M PBS; 25yl used.
For PRL: 2.4mg/ml 0.05M PB; 50yl used.
Made up fresh before use.
Protocol:
i) Defrost hormone aliquot.
ii) Add lmCi Na I and mix gently,
iii) Add Chloramine T and mix gently,
iv) Reaction times: LH iodination = 2 min.
PRL iodination = 20 sec.
v) Add Na2S20g solution and mix gently,
vi) Transfer to column: PRL - after transfer of reaction
mixture onto the column, rinse reaction vial
with 2 x lOOul of rinse solution and
transfer these onto the column; elute with
0.1M borate buffer. LH - elute with 0.01M
PBS.
vii) Collect fractions: for LH collect 0.5 ml fractions into
tubes containing 0.5ml 0.01M PBS/5% egg
white; for PRL, collect 0.5ml fractions into
0.5ml PBS/1% BSA.
viii) Estimate radioactivity in fractions; retain fractions
with peaks of radioactivity.
N.B. LH iodination: two peaks of radioactivity found to elute;
125 12 5
I labelled hormone eluted in the first peak and free I in
125
the second. I-ovine- LH could be used for up to 10 days
without further purification. It could still be used for up to
another 14 days following re-chromatography on another Biogel P60
column.
125
PRL iodination: two peaks of radioactivity found to elute; I
125
labelled hormone eluted in the first peak and free I in the
125
second. I-PRL was routinely only used in the RIA on the day of
iodination.
III.3 Standards
Ovine LH (NIH-LH-S18; NIADDK) - 0.25, 0.5, 0.75, 1.2, 2.0, 4.0, 8.0
and 16.0ng/ml 0.01M PBS/1% BSA; 200ul aliquots stored at -40°C.
Rat PRL (rat-PRL-RP-1; NIADDK) - 0.5, 1.2, 2.0, 4.0, 8.0, 16.0,
32.0 and 64.0ng/ml 0.01M PBS/1% BSA; 200yl aliquots stored at -40°C.
III.4 Assay protocol











(~ 10,000 cpm) diluted in
0.01M PBS/1% BSA)
200y1 ARGG diluted in
0.01M PBS
Centrifuge tubes for









(~ 10,000 cpm) diluted in
0.01 M PBS/1% BSA
200y1 ARGG diluted in
0.01M PBS
Centrifuge tubes for
45 min at 2000 x g at 4°C
aspirate supernatant and
count pellet.
Appendix IV Radioimmunoassay for luteinizing hormone releasing
hormone (LHRH): based on the methods of Nett et al
(1973); Pickering (1978)
IV.1 Stock Solutions
0.01M PBS see Appendix III.l
Antiserum buffer see Appendix III.l
Assay buffer (0.01 M PBS/ 0.1% gelatine)
lg gelatine












20 x 0.75cm Sephadex G25 coated with 0.01M
PBS/1% gelatine
Synthetic LHRH (ICI Pharmaceuticals Ltd.,
Macclesfield) - Img/lOml 0.01M PBS; diluted
to 2pg/20nl in distilled H2O, stored at
-40°C.
lmCi in 10yl
2mg/ml 0.01M PBS; 20ul used
made up fresh before use
2mg/ml 0.01M PBS; 20yl used
made up fresh before use
i) Defrost LHRH aliquot.
125ii) Add lmCi I and mix gently,
iii) Add Chloramine T and mix gently,
iv) Reaction time = 15 sec
v) Add Na2S20g and mix gently,
vi) Transfer to column: elute with 0.01M PBS/0.1% gelatine
vii) Collect fractions - collect first 10ml fraction as a
pool, then 1ml fractions until total volume eluted is
22ml.
viii) Estimate radioactivity in fractions; retain fractions
with peaks of radioactivity.
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N.B. Two peaks of radioactivity found to elute; free I eluted
in the first 11-14 ml and ^I-LHRH eluted in the 15-19 ml
fractions. The labelled hormone could be used for up to 10 weeks
without further purification.
IV.3 Standards
Synthetic LHRH (ICI Pharmaceuticals Ltd., Macclesfield) -
7.8, 15.5, 31.0, 62.0, 125.0, 250.0, 500.0pg/ml 0.01M
PBS/0.1% gelatine; 200ul aliquots stored at -40°C.
IV.4 Assay protocol
Day 1 200 p1 standards/samples
200^1 assay buffer
200yl antiserum diluted in AS buffer
1?5
200yl I-LHRH (~ 5,000 cpm) diluted in assay
buffer
Day 2 200vl ARGG diluted in 0.01M PBS
Day 3 1ml 0.01M PBS, then centrifuge at 2000 x g for 45
min at 4°C; aspirate supernatant and count
pellet.
Appendix V Radioimmunoassays for vasopressin (VP) and oxytecin
(OT): based on the method of Robinson (1980)
Stock solutionsV.l
0.1M Tris buffer
12.114g tris-(hydroxy-methyl)-methylamine per litre
distilled H^O, adjusted to pH 7.4 with 5M HC1.
Assay buffer (0.1M Tris buffer/3% BSA)
1000ml 0.1M Tris buffer
3g BSA
0.2M Phosphate buffer (PB)
50g NaH2P04.2H20









For both VP and OT - 20 x 1cm Sephadex A-25,
eluted with 0.1M Tris/3% BSA
Oxytocin (440IU/mg; Dr. H. Vilhardt,
Ferring, Sweden) - 250pg/ml 0.2M PB; 20yl
aliquots stored at -20°C.
Vasopressin (400IU/mg; Batch no. 770110;
Ferring Sweden) - 250ug/ml 0.2M PB buffer;
20pl aliquots stored at -20°C.
lmCi in 10yl for each assay
2.5vg, deposited in a small glass tube.
i) Defrost hormone aliquot.
IOC
ii) Add hormone and Na I in lOOyl PB to tube containing
iodogen.
iii) Reaction time = 20 min.
iv) Transfer to column, elute with assay buffer.
v) Collect fractions - iodinated peptide appears as a
single broad peak. This peak is rechromatographed on
a smaller column (1 x 10cm, Sephadex A—25) under the
same conditions and the fractions tested for binding to
excess antibody.
vi) Fraction showing the best immunoreactivity is divided
into lyCi aliquots and stored at -20°C.
V.3 Standards
Oxytocin (IVth International Standard for OT; NIBSC) 1.0, 2.0, 4.0,
8.0, 16.0, 32.0, 64.0, 128.0, 256.0pg/tube. Made up immediately
before use by doubling dilutions in cleared dog plasma from a stock
solution of 5ng/ml assay buffer, stored at -20°C.
Vasopressin (1st International Standard for VP; NIBSC) 1.0, 2.0,
4.0, 8.0, 16.0, 32.0, 64.0, 128.0. 256.0pg/tube. Made up
immediately before use by doubling dilutions in cleared dog plasma
from a stock solution of 5ng/ml assay buffer, stored at -20°C.
V.4 Assay protocol
All incubations at 4°C.
Day VP OT
1 25yl standards/samples 50ul standards/samples





(~ 3,000 cpm) and specific (~ 3,000 cpm) and




4 900vi 1 absolute alcohol 900pl absolute alcohol
Centrifuge at 3000 x g
for 10 min at 4°C.
Centrifuge at 3000 x g
for 10 min at 4°C.
Aspirate supernatant Aspirate supernatant
and count pellet. and count pellet.
Appendix VI Radioimmunoassay for oestradiol-17g, based on the
method of Dick et al. (1978)
VI.1 Recovery solution
3
500 cpm H-OE blown to dryness, taken up in 50m1 assay
buffer (0.01M PBS/1% gelatine) and added to each 0.5ml
plasma sample.
VI.2 Sample extraction
0.5ml plasma + 2 x 5ml diethyl ether/petroleum ether at
50°C. Ether extracts combined, blown to dryness and taken
up in 300yl 0.01M PBS/1% gelatine. 2 x lOOul aliquots
taken for assay.
50vil counted for % recovery.
VI.3 Standards
4.5, 9.0, 18.0, 36.0, 72.0, 144.Opg OE/tube.
VI.4 Assay protocol
IOOmI standard/sample
lOOul 0.01M PBS/1% gelatine
500yl antiserum (1:300,000) in 0.01M PBS/1% gelatine
lOOul - 5000 cpm 3H-0E
Mixed and incubated at 4°C for 24h
500ul dextran coated charcoal solution
Incubated for 15 min on ice.
Centrifuge at 2000 x g for 30 min at 4°C.
500ul of supernatant removed for counting.
